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Summary 
 CD4+Foxp3+ regulatory T cells (Tregs) are the main regulators of 
peripheral tolerance and prevent the development of fatal autoimmune 
disease in humans and mice. Furthermore, Tregs have also been implicated 
in suppressing anti-tumour immune responses and are often enriched at 
sites of primary and metastatic tumours. While studies have shown the effect 
of Treg ablation on the control of primary tumours, few studies have 
examined their contribution to metastasis progression. 
 In this thesis I hypothesised that the depletion of Tregs could promote 
control over metastasis. To address this, a highly metastatic murine 
mammary carcinoma cell line 4T1 was injected into transgenic mice 
expressing the diphtheria toxin receptor in Foxp3+ cells. Foxp3+ cells were 
depleted by administration of diphtheria toxin and the impact of this on 
growth of primary tumours and metastases was assessed and measured in 
in vitro clonogenic assays. Results of these experiments indicated that Treg-
depletion led to control of primary tumour growth and in some mice to control 
of metastases. Control of metastases was linked to control of primary tumour 
growth.  
 In order to measure metastasis in vivo, a PET/CT imaging technique 
was optimized. Primary tumours and large metastatic nodules were 
successfully imaged in mice using F18 FDG as a radiotracer. However, the 
studies described herein revealed that micrometastases in mouse lungs 
were too small to be reliably identified using PET data parameters. CT 
imaging did however enable detection of increases in tissue density within 
the lungs, which was suggestive of micrometastases. Data obtained in this 
way also indicated that Treg-depletion promotes control of metastasis in 
some mice. 
 Collectively, the findings described in this thesis indicate that Treg-
depletion can contribute to control of metastatic disease and should 
therefore represent an important component of novel immunotherapies. 
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Chapter One 
1. Introduction 
1.1 Cancer 	 Cancer is a leading cause of mortality in humans with the number of 
people developing cancer increasing to every one in two (World Health 
Organization: Cancer Research UK). There are over 200 types of cancer 
that may affect each tissue within the body.  
 
1.1.1 Development of cancer 
Accumulation of genetic mutations through spontaneous DNA 
damage during proliferation of healthy cells or through inheritance of a 
genetic disorder leads to the uncontrolled proliferation of cells and the 
development of malignant tumours (Vogelstein et al. 2013). Further growth 
and invasion of malignant cells leads to distant-site metastasis, which is the 
main cause of fatality amongst cancer patients. 
 In 2000 Hanahan and Weinberg described the hallmarks of cancer 
detailing the traits obtained by neoplastic cells during the formation of a 
malignant tumour in a review which was later updated (Hanahan and 
Weinberg 2000; Hanahan and Weinberg 2011). Cancer cells must acquire 
the characteristic of chronic proliferation and resistance to anti-growth 
factors. Along with resistance to programmed cell death and acquisition of 
replicative immortality, this promotes healthy cells to create a large mass 
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(Hanahan and Weinberg 2000). The next important characteristic is the 
process of angiogenesis. In order for rapidly growing tumours to obtain all 
the nutrients and oxygen required for tissue growth, tumours must have an 
adequate blood supply (Hanahan and Weinberg 2000). Due the rapid growth 
of a tumour and unusual angiogenic structures, the developing vasculature 
often displays excessive branching and undifferentiated blood vessels 
leading to erratic blood flow, leakiness and hypoxia (Ten Hagen et al. 2008). 
Another hallmark is the invasion of the surrounding healthy stroma by cancer 
cells, which ultimately culminates in the dissemination of cancer cells and 
metastasis to distant sites (discussed further in Section 1.2). In 2011, 
Hanahan and Weinberg described a further two hallmarks of cancer, which 
are often seen as the most important traits of cancer cells. Firstly, the ability 
of cancer cells to deregulate cellular energetics allows chronic proliferation, 
survival and therefore tumour growth. The final hallmark acquired by cancer 
cells is the ability to evade the immune system and avoid destruction 
allowing propagation of tumours (Hanahan and Weinberg 2011).  
 
1.1.2 Immune surveillance and immune evasion 
1.1.2.1 History of immune surveillance 
 Immune surveillance refers to the continuous monitoring of host 
tissues by the immune system (Burnet 1957). This mechanism allows the 
detection of nascent cancer cells and initiates their destruction before 
development of a tumour. Therefore, cancer cells that have progressed into 
developing tumours have somehow evaded immune destruction. Paul 
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Ehrlich first postulated this idea in the early 1900s, hypothesizing that the 
frequency of genetic mutations occurring during DNA replication would 
naturally lead to an “overwhelming frequency” of tumour development 
without the presence of immune surveillance (Dunn et al. 2002; Ehrlich 
1909).  
 Interestingly, immunocompromised patients have an increased 
frequency of certain cancers, however this observation has been made with 
mainly virus- induced carcinomas (Vajdic and van Leeuwen 2009). The 
development of transgenic mice propelled the investigation of immune 
evasion, and gave further strength to the hypothesis of anti-tumour immune 
responses. Mice deficient for IFN-γ or perforin, therefore lacking the function 
of CTLs, NK cells or Th1 helper cells, displayed increased tumour incidence 
(Smyth et al. 2000a; Street et al. 2001; Street et al. 2002; van den Broek et 
al. 1996). Further more, transplantable tumours from immunodeficient mice 
were unable to initiate secondary tumour growth in syngeneic 
immunocompetent equivalents, whereas tumours developed in 
immunocompetent mice and subsequently transplanted were able to grow in 
a secondary immunocompetent host (Smyth et al. 2000b).  These studies 
sprouted the hypothesis of immune editing whereby highly immunogenic 
cancer cells are detected and destroyed by the surveying immune system 
and remaining weakly immunogenic cancer cells fail to elicit an immune 
response and are allowed to propagate. Conversely, in immunodeficient 
hosts there is no selective depletion of highly immunogenic cancer cells 
therefore when transplanted into an immunocompetent host these cells are 
recognised and destroyed (Smyth et al. 2006a).  
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 Clinical epidemiology supports the hypothesis of immune surveillance 
and immune editing in humans (Bindea et al. 2010; Ferrone and Dranoff 
2010; Nelson 2008). In cancer such as colorectal and ovarian, patients with 
a higher tumour infiltration of NK cells and CTLs have a better overall 
prognosis and survival (Nelson 2008; Pages et al. 2009). Interestingly, 
immunodeficient transplant recipients have an increased incidence of donor-
derived cancers, suggesting that dormant tumours in donor patients kept in 
check by immune surveillance are able to grow in recipients due to a lack of 
anti-tumour immune response (Birkeland et al. 1995; Morath et al. 2004; 
Myron Kauffman et al. 2002; Pham et al. 1995).  
 
1.1.2.2 Immune editing in cancer 
 The process of cancer immune editing is 3-fold: firstly, highly 
immunogenic tumour cells are eliminated by the immune system during 
immune surveillance. Secondly, tumour cells that avoid immune destruction 
undergo editing by the adaptive immune response in the process of 
equilibrium. Finally, tumour cells are able to escape the immune system and 
propagate to form solid tumours (Mittal et al. 2014; Schreiber et al. 2011).    
 In the phase of equilibrium tumour cells are kept in a state of 
dormancy, validated by Koebel in 2007 where a role for the adaptive 
immune system was demonstrated in dormancy in a methylcholanthrene 
(MCA)-induced tumour and further corroborated by other preclinical models 
(Eyles et al. 2010; Koebel et al. 2007; Loeser et al. 2007). In humans, this 
phase has also been demonstrated as described above whereby recipients 
of transplants develop tumours arising from donor organs (Strauss and 
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Thomas 2010). The state of dormancy requires a balance of cytokines, such 
as interleukin (IL)-23 involved in tumour promotion and IL-2 involved in 
tumour clearance, and regulatory (Treg and MDSCs) and effector immune 
cells (CTLs and NK cells) (Teng et al. 2012; Wu et al. 2013). The transition 
from equilibrium to escape involves the shifting of the balance in favour of 
immune escape rather than elimination. Many immunotherapies are 
designed to target this phase of immune editing, with the aim of tipping the 
balance in favour of tumour cell destruction (Quezada et al. 2011). 
 In the final escape phase of cancer immune editing, loss of Tumour 
Associated Antigens (TAAs), an establishment of an immunosuppressive 
microenvironment, and resistance to cytotoxic destruction are some of the 
key mechanisms that allow escape from immune-mediated tumour cell 
clearance (Mittal et al. 2014; Schreiber et al. 2011). Further mutations 
arising within an immune suppressive tumour microenvironment can result in 
the development of neoantigens (Schumacher and Schreiber 2015). The 
recognition of these neoantigens by T cells can be unleashed through 
checkpoint blockade as discussed in section 1.1.4 (Figure 1.1).  
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Figure 1.1| Exploiting neoantigen development. The loss of TAAs, recruitment of 
suppressive immune cells and secretion of TGF-β by tumour cells creates an 
immunosuppressive microenvironment within the tumour preventing immune clearance. 
Within the suppressive microenvironment further mutations within tumour cells lead to the 
generation of neoantigens. Checkpoint blockade such as anti-CTLA-4 or anti-PD-1 
antibodies reverse immunosuppression creating the opportunity for neoantigen recognition 
and immune-mediated tumour clearance.  
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Exome sequencing and MHC epitope prediction algorithm software 
has recently shed light on elusive neoantigens. Investigation of an MCA-
derived tumour from a RAG2 knockout mouse highlighted a neoantigen 
arising from the mutation in the gene encoding Spectrin-β2, which normally 
functioned as an immunodominant rejection antigen (Matsushita et al. 2012). 
Tumour cells lacking the Spectrin-β2 mutation were able to avoid immune 
clearance and were selected for growth when transplanted with clones 
expressing the functional Spectrin-β2, solidifying the notion of TAAs and 
neoantigens in the process of immune-mediated tumour cell clearance 
(Matsushita et al. 2012). Interestingly, this phenomenon has also been 
demonstrated in a clinical setting, where expansion of tumour cells lacking 
neoantigens is observed in patients after immunotherapy treatment 
(Nicholaou et al. 2011; von Boehmer et al. 2013). Therefore, when using 
neoantigens and TAAs as targets during immunotherapy, more than one 
must be taken into account to avoid selection of weakly immunogenic 
tumour cells (Mittal et al. 2014).  
 
1.1.3 Inflammation in cancer 
 It has been widely accepted that inflammation plays a role in 
tumorigenesis and was incorporated into Hanahan and Weinberg’s revised 
hallmarks of cancer in 2011 (Hanahan and Weinberg 2011; Raposo et al. 
2015). There are four main types of inflammation that can contribute to 
tumorigenesis. Firstly, inflammation arising in response to an infectious 
agent such a Helicobacter pylori can result in the development of mucosa-
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associated lymphoid tissue (MALT) lymphoma or gastric carcinoma in 
humans (De Falco et al. 2015). Secondly, patients with immune-mediated 
diseases have increased incidence of related cancers, for example 
inflammatory bowel disease (IBD) and colon cancer (Francescone et al. 
2015). Other subclinical inflammatory diseases leave patients with a 
predisposition to cancers, for example obese patients have a higher risk of 
liver cancer (Calle and Kaaks 2004). Finally, inflammation occurring as a 
result of environmental carcinogens such as smoke pollution is also notably 
correlated with increased cancer incidence (Cohen and Pope 1995). 
There are a variety of different mechanisms by which inflammation 
can initiate tumour growth, with many arising from the transition from acute 
inflammation to chronic inflammation (reviewed by Coussens and Werb 
2002). This results in the upregulation of reactive oxygen species (ROS) and 
reactive nitrogen intermediates (RNI) that ultimately lead to DNA mutations 
and inhibit intrinsic mismatch-repair mechanisms (Waris and Ahsan 2006). 
This genomic instability can initiate tumorigenesis, while the presence of 
DNA mutations further drives inflammation supporting tumour progression 
(Ohnishi et al. 2013). Inflammation at the site of a growing tumour supports 
angiogenesis and the epithelial to mesenchymal transition (EMT), a process 
necessary for the metastasis of cancer cells (discussed in section 1.2) 
(Raposo et al. 2015).  
 The overlapping intrinsic and extrinsic pathways of inflammation and 
cancer share transcription factors, cytokines and chemokines involved in the 
recruitment of leukocytes to the tumour (Mantovani et al. 2008). 
Furthermore, the production of immunosuppressive cytokines in the tumour 
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microenvironment supports immune evasion and recruits other suppress 
immune cell subsets such as Tregs, myeloid derived suppressor cells 
(MDSCs) and tumour promoting macrophages (Balkwill et al. 2005).  
 
1.1.3.1 The role of NF-κB and IL-6 in tumour promoting inflammation 
 The transcription factor NF-κB and the cytokine IL-6 have both been 
heavily implicated in the switch from acute wound-healing inflammation to 
tumour-promoting chronic inflammation (Raposo et al. 2015). The 
constitutive expression of NF-κB is a hallmark of chronic inflammation and is 
also documented in many cancer types (Chaturvedi et al. 2011; Karin 2008). 
Haematological malignancies and lymphomas, such as non-Hodgkin’s 
Lymphoma (NHL), display dysregulation and chronic activation of the NF-κB 
signaling pathway, resulting in the upregulation of anti-apoptotic proteins 
such as Bcl-2 promoting tumour cell survival and other chromosomal 
mutations (Brien et al. 2007; Escarcega et al. 2007; Hiscott et al. 2001; Karin 
2006). The constitutive expression of NF-κB has been highlighted as a main 
mechanism of resistance against chemotherapeutic agents, with some p53-
targeted therapies causing the activation of the NF-κB pathway (Brien et al. 
2007; Das and White 1997). NF-κB could be used as a target for anti-cancer 
therapies as inhibition of the transcription factor has been shown to improve 
the efficacy of and reduce resistance to anti-cancer agents both in vivo and 
in vitro (Nakanishi and Toi 2005). However, as NF-κB plays an essential role 
in many different signaling pathways, possible off-target effects might cause 
toxicity (Hoesel and Schmid 2013).     
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 IL-6 has both anti- and pro-inflammatory roles depending on the 
signaling pathways it induces (Yao et al. 2014). IL-6 can be described as an 
inflammation amplifier due to its interaction with NF-κB in a positive 
amplifying loop (Atsumi et al. 2014). Phosphatase and tensin homologue 
(PTEN) and p53 knockdown induces IL-6-mediate STAT3 and NF-κB 
signaling in a triple negative model of breast cancer, which can initiate EMT 
in cancer stem cells (Kim et al. 2015). IL-6 has also been shown to be 
involved in the maturation of DCs and other APCs and can promote the 
expression of MHC (Hsiao et al. 2008). However, IL-6-mediated small Rho 
GTPase and STAT3 signaling pathways can induce the differentiation of 
DCs into regulatory DCs (DCregs) (Zhong et al. 2014). 
 
1.1.3.2 Macrophages, inflammation, and cancer progression 
  Tumour associated macrophages (TAMs) are accepted to be involved 
in angiogenesis, tumour cell proliferation and metastasis (discussed further 
in Section 1.2) (Raposo et al. 2015). The phenotype of TAMs determines 
whether they have a pro- or anti-tumour response. While macrophages have 
a wide phenotypic spectrum with varying functions, their classification can be 
simplified to “M1” and “M2”. The classical M1 phenotype, induced by 
microbial products or IFN-γ, exhibits anti-tumour effects. However in most 
human cancers, the macrophage phenotype is weighted towards an M2 
phenotype (Sica et al. 2006). 
 An M2 phenotype is induced by Treg or tumour derived cytokines, 
such as colony stimulating factor 1 (CSF-1), IL-10, IL-4, IL-6, TGF-β and 
prostaglandin E2 (PGE2) (Mantovani et al. 2002; Sica et al. 2006). These 
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macrophages promote angiogenesis through the secretion of pro-angiogenic 
factors (such as VEGF, angiopoietins and prostaglandin E2 (PGE2)), 
stimulate proliferation of tumour cells through production of epidermal growth 
factor (EGF), platelet derived growth factor (PDGF), hepatocyte growth 
factor (HGF), and basic fibroblastic growth factor (bFGF) (Klimp et al. 2001; 
Lewis and Murdoch 2005; Sunderkötter et al. 1991). Furthermore, M2 
macrophages have increased production of PGE2, nitric oxide and H2O2 
resulting in direct cytotoxic and suppressive activity on T cells (Klimp et al. 
2001; Sica et al. 2006).  
  
1.1.4 Cancer immunotherapy 
 There is a vast array of different immunological mechanisms involved 
in tumorigenesis and tumour clearance, and while we are still investigating 
the events underpinning immune-mediated tolerance to self-antigens, a 
plethora of mechanisms can be targeted for cancer therapies.  
 A highly personalized immunotherapy involves the ex vivo expansion 
of patient tumour infiltrating anti-tumour lymphocytes that are subsequently 
re-infused in a process known as adoptive cell therapy (ACT) (Rosenberg 
and Restifo 2015). Additionally, the isolated infiltrating lymphocytes can be 
engineered to express T cell receptors (TCRs) or chimeric antigen receptors 
(CARs) specific to TAAs (Rosenberg and Restifo 2015). In clinical trials, this 
therapy has proven most successful in melanoma patients whereby 50% of 
patients exhibited a response with 22% eliciting complete responses 
(Hinrichs and Rosenberg 2014). In a study using genetically engineered 
	 22	
TCR expressing lymphocytes specific to the melanoma-melanocyte antigen 
Melan-A, tumour regression was observed in patients (Morgan et al. 2006). 
CAR therapy has also been trialed in patients with B cell lymphoma. T cells 
expressing a CAR against CD19 lead to remission in patients with the 
disease, with 67% of patients being in sustained remission (Kochenderfer et 
al. 2010; Maude et al. 2014). However, difficulties arise when targeting self-
antigens as on-target off-tumour toxicities are observed (Johnson et al. 
2009).  
 The existence of TAAs has also given rise to the use of cancer 
vaccines and was originally demonstrated in 1991 by the recognition of a 
melanoma antigen MAGE-A1 by T cells (van der Bruggen et al. 1991). While 
many TAAs have since been identified, the majority of antigens used for 
cancer vaccination are derivatives of male testis antigens (Vigneron et al. 
2013). The expression of these antigens is restricted to the male germ line, 
however many of them appear to be overexpressed in tumours. While some 
of these vaccines appear to have limited efficacy most likely due to the 
difficulty in overcoming self-tolerance, the addition of immune adjuvants 
such as IL-2 has seen some improvement (Makkouk and Weiner 2015). 
GVAX is a whole tumour cell cancer vaccine that consists of two irradiated 
prostates cancer cell lines that express Granulocyte-Macrophage Colony 
Stimulating Factor (GM-CSF). While whole cell tumour vaccines give rise to 
the opportunity of eliciting immune responses to many different TAAs 
present on the cancer cells, little change to overall survival was observed in 
a GVAX clinical trial (Makkouk and Weiner 2015).  
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 The use of DCs pulsed with TAAs as a cancer vaccine has also been 
explored and has shown the most promise. In 2010, the US Food and Drug 
Administration (FDA) approved an antigen-pulsed DC cancer vaccine called 
Provenge for the treatment of metastatic prostate cancer. This vaccine 
consists of DCs pulsed with a prostatic acid phosphatase fusion protein and 
GM-CSF, which demonstrated increased survival in three separate Phase III 
clinical trials (Higano et al. 2009; Kantoff et al. 2010; Kissick and Sanda 
2015; Small et al. 2006). While chronic antigen exposure can cause T cell 
exhaustion in response to a cancer vaccine thereby decreasing its efficacy, 
the combination of cancer vaccines with therapies to bypass T cell 
exhaustion show promise (Kissick and Sanda 2015).  
 Co-stimulatory molecules are used in conjunction with tumour-antigen 
MHC complexes to stimulate naïve T cells and initiate an anti-tumour 
immune response. While engagement of these co-stimulatory molecules 
initially leads to increased proliferation and expansion of specific T cells, 
negative feedback loops kick-in to prevent the uncontrolled and harmful T 
cell responses (Quezada and Peggs 2013; Salomon and Bluestone 2001; 
Sharma and Allison 2015). Checkpoint inhibition therapy aims to target the 
co-stimulatory molecules in order to prevent inhibition of T cell responses 
and circumvent T cell exhaustion. Cytotoxic T Lymphocyte Antigen 4 (CTLA-
4) is an inhibitory molecule that interacts with CD80 and CD86 on APCs. 
The co-stimulatory molecule CD28 on T cells that normally interacts with 
CD80 and CD86 is outcompeted by CTLA-4 in order to downregulate T cell 
responses (Krummel and Allison 2011; Walunas et al. 1994). Mouse studies 
also indicated that CTLA-4 was implicated in dampening an anti-tumour 
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immune response, and CTLA-4 blockade resulted in tumour rejection 
(Krummel and Allison 1996; Leach et al. 1996). In humans, the CTLA-4 
blocking antibody Ipilimumab was approved for use by the FDA after 
successful clinical trials in melanoma patients (Hodi et al. 2010; Robert et al. 
2011). However, while 20% patients treated with Ipilimumab had increased 
survival, approximately 60% patients observed immune related adverse 
events (irAE) (Hodi et al. 2010; Schadendorf et al. 2015).  
 It was initially hypothesised that Ipilimumab targeted CTLA-4 
expression on T cells, however CTLA-4 is also constitutively expressed on 
Tregs in both humans and in mice (Krummel et al. 1996; Read et al. 2000; 
Takahashi et al. 2000; Walunas et al. 1994; Wing et al. 2008). Therefore, 
anti-CTLA-4 could act by depleting Tregs thereby removing anti-tumour 
immune suppression (Read et al. 2006). Further investigations found that 
inhibition of CTLA-4 on both T cells and Tregs was required for tumour 
rejection, and while CTLA-4 blockade results in expansion of both T 
lymphocyte subsets, the ratio of Treg: T cell was ultimately increased in the 
tumour (Curran and Allison 2009; Liakou et al. 2008; Quezada et al. 2006; 
Schmidt et al. 2008; Shrikant et al. 1999; Waitz et al. 2012). Quezada and 
colleagues also demonstrated that CTLA-4 blockade-mediated Treg 
depletion was dependent on the presence of Fc receptor expressing 
macrophages within the tumour (Simpson et al. 2013).   
 A second checkpoint molecule was described in 2000 called 
Programmed cell Death receptor 1 (PD-1) (Freeman et al. 2000). While PD-
1 is expressed on activated T cells, it is mainly expressed on Tregs, B cells, 
NKT cells and monocytes (Greenwald et al. 2004). PD-1 is activated on 
	 25	
these cells when interacting with one of its two ligands PD-L1 and PD-L2 
and interferes with TCR signaling (reviewed in (Greenwald et al. 2004). 
While PD-L2 is mainly expressed on activated macrophages and DCs, PD-
L1 is expressed on T cells and B cells as well as DCs and macrophages. 
PD-L1 expression has also been shown in some human tumours in 
response to T cell derived IFN-γ (Dong et al. 2002; Zou and Chen 2008). 
Mouse models revealed that PD-1 blockade resulted in increased T cell-
mediated anti-tumour immunity, and the FDA approved a humanized anti-
PD-1 antibody in 2014 known as Pembroluzimab (Dong et al. 2002; Fife et 
al. 2009; Hamid et al. 2013; Iwai et al. 2002; Robert et al. 2014b; Topalian et 
al. 2012; Topalian et al. 2014). Pembroluzimab was correlated with good 
responses in melanoma patients, however like CTLA-4 also had high irAE 
(approximately 79%) with some patients developing autoimmune diabetes 
(Hamid et al. 2013; Martin-Liberal et al. 2015). Following from this, a second 
anti-PD-1 antibody called Nivolumab was approved by the FDA for the 
treatment of metastatic melanoma and non-small cell lung carcinoma 
(NSCLC) (Robert et al. 2014a). Interestingly the combination of anti-CTLA-4 
and anti-PD-1 therapies has demonstrated better outcome than either single 
therapy in preclinical studies (Curran et al. 2010). A phase I clinical trial 
observed over 80% regression of metastatic melanoma in around 50% of 
patients treated (Wolchok et al. 2013). A study by Zelenay et al in 2015 
demonstrated the use of a COX2 inhibitor with PD-1 blockade (Zelenay et al. 
2015). COX1 and COX2 are important for the production of PGE2, a growth 
factor involved in the survival, growth, migration, metastasis and 
immunosuppressive activities of cancer cells (Wang and DuBois 2010) and 
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are often overexpressed in many different cancer types such as colorectal 
cancer (CRC), breast, gastric, pancreatic and lung (Dannenberg and 
Subbaramaiah 2003; Wang and DuBois 2010). Zelenay and colleagues 
found that loss of COX2 expression in a murine melanoma cell line BrafV600E 
shifted the inflammatory profile, leading to a decrease in IL-6 and CXCL1 
and an increase in anti-tumour immune mediators IFN-γ, T-bet, CXCL10 and 
IL-12. The subsequent inhibition of COX by aspirin in combination with anti-
PD-1 antibody greatly increased BrafV600E tumour rejection, even when the 
inoculum of tumour cells was too great for anti-PD-1 alone to cause 
regression (Zelenay et al. 2015). Not only does this study solidify the impact 
of inflammation on tumour progression, but also suggests a use for COX 
inhibitors to amplify the effects of checkpoint blockade.   
 
1.2 Metastasis 
While there have been great advances in the treatment of primary 
cancers in patients, the development of metastasis is still responsible for 
around 90% of patient deaths (Chaffer and Weinberg 2011; Seyfried and 
Huysentruyt 2013). The term metastasis is used to describe the spread of 
cancer cells originating from a primary tumour to distant sites, leading to 
seeding and new metastatic lesion growth (Seyfried and Huysentruyt 2013). 
 
1.2.1 Metastatic Cascade 
 In order for metastasis to occur, cells from a primary tumour must 
detach and complete the steps dictated in the metastatic cascade 
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(Chambers et al. 2002; Duffy et al. 2008; Seyfried and Huysentruyt 2013). 
Primary tumours must undergo the process of angiogenesis not only to 
support the tumours metabolic needs but also to allow intravasation of 
tissue-invading tumour cells into circulation (Chambers et al. 2002; Wyckoff 
et al. 2000). Once the circulating tumour cells have reached their destined 
organ, extravasation occurs depositing cells into the surrounding tissue. 
From here, cells undergo proliferation and initiate angiogenesis, creating a 
niche for metastatic cell survival (Chambers et al. 2002; Scully et al. 2012). 
An overview of the metastatic cascade is demonstrated in Figure 1.2. 
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Figure 1.2| The metastatic cascade. The metastatic cascade describes all the steps a 
metastasizing cell has to complete to form distant site metastases. First, cells must undergo 
the epithelial to mesenchymal transition and then pass through the basement membrane. 
Once the basement membrane has been breached, the metastatic cells invade the ECM 
and intravasate into blood vessels (pictured) or lymphatic vessels. Metastatic cells then 
migrate through circulation, aggregating with platelets until cell arrest at the endothelial wall. 
Cells then extravasate the blood vessel and invade the ECM of the secondary organ before 
seeding and proliferating to form a secondary tumour. Finally, the new metastatic site 
induces angiogenesis.   
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1.2.1.1 Invasion 
The first stage of the metastatic cascade is the invasion of tumour 
cells into the surrounding tissue. This is achieved through alterations in cell-
cell interactions and between cells and the Extracellular Matrix (ECM) 
(Scully et al. 2012).  The cadherin family plays a vital role in the initial 
invasion step of metastasis (Bacac and Stamenkovic 2008). E-cadherin, 
important in the maintenance of adherens junctions in epithelial cells, acts as 
a tumour suppressor and prevents the detachment of tumour cells (Wendt et 
al. 2011). Experiments have shown that inhibition of E-cadherin through the 
use of mAbs can promote an invasive phenotype in epithelial cells, whereas 
the addition of E-cadherin into invasive carcinoma cells reversed this 
(Vleminckx et al. 1991). In breast cancer patients, the loss of E-cadherin has 
been associated with progression, metastasis, and a poor prognosis 
(Kowalski et al. 2003; Scully et al. 2012). During EMT cells can undergo a 
cadherin switch from E-cadherin to N-cadherin, which promotes a more 
motile and invasive phenotype in epithelial cells (Bacac and Stamenkovic 
2008; Scully et al. 2012; Wheelock and Johnson 2003). In mice, Kotb et al 
showed that the switch of E-cadherin for N-cadherin on breast epithelial cells 
leads to the formation of fibrosis in the mammary glands and eventually to 
the development of malignant breast tumours (Kotb et al. 2011).  
 While the EMT is an important step in the metastatic cascade, the 
ECM must be degraded in order for tumour cells to complete invasion into 
the surrounding tissue. Integrins are transmembrane adhesion receptors that 
can be found on components of the ECM and mediate the adherence of 
tumour cells to the ECM (Li and Feng 2011; Mego et al. 2010). It has been 
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shown that some integrins, such as αvβ1 and α3β1, play a role in degrading 
the ECM by upregulating certain matrix metalloproteinases (MMPs) allowing 
the invasion of tumour cells into the surrounding tissues (Mitchell et al. 2010; 
Rolli et al. 2003). Other MMPs work independently of integrins to 
enzymatically degrade the ECM, further promoting tissue invasion. Once 
epithelial carcinoma cells have undergone EMT to resemble long 
fibroblastic-like cells they are able to move through pores within the 
degraded ECM following a low resistance route (Provenzano et al. 2008; 
Rösel et al. 2008; Scully et al. 2012). From here, these cells can begin the 
intravasation stage of metastasis either through the vasculature or 
lymphatics.  
 
1.2.1.2 Intravasation 
 The process of angiogenesis within the primary tumour not only 
supplies the tumour with oxygen and glucose but also provides an 
opportunity for intravasation of invading tumour cells (Chambers et al. 2002; 
Scully et al. 2012). While intravasation can also occur within the lymphatics, 
the main route is through haematogenous intravasation (Bacac and 
Stamenkovic 2008; Chiang et al. 2016). Each tumour type has varying 
methods of intravasation, and can occur via a passive or active mechanism. 
Ultimately tumours that intravasate into the lymphatics eventually drain into 
the circulatory system but during this process come into contact with 
different lymph nodes, which in some cancers are the first point of 
metastasis (Bacac and Stamenkovic 2008; Chiang et al. 2016). The route of 
intravasation of tumour cells is dictated by various factors, namely the 
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availability of blood or lymphatic vessels. Blood vessels have tight 
endothelial junctions proving difficult to pass through, and once tumour cells 
are inside the blood vessel they are exposed to high blood flow and 
pressure. Lymphatics are easier to intravasate as they are designed for the 
passage of cells in and out of the vessels. The limiting factor for this method 
of intravasation is the ability of tumour cells to move through the ECM and 
reach the lymphatic vessels (Chiang et al. 2016).  
 There are a number of different in vivo models for the investigation of 
tumour cell intravasation. Transparent fluorescent transgenic Zebrafish can 
successfully be used to visualise intravasation through high-resolution 
imaging (Moore and Langenau 2012). Murine models can also be used to 
directly visualise intravasation through the use of intravital multiphoton 
imaging of fluorescently labeled tumour cells (Chiang et al. 2016).  
 
1.2.1.3 Circulation and extravasation 
 Once tumour cells have undergone intravasation they must survive in 
circulation until the point of extravasation is reached. This involves resisting 
stress-induced destruction from fast blood flow and escaping immune 
clearance. Tumour cells express oligosaccharides that correspond to various 
selectins (Bacac and Stamenkovic 2008). These lectins can be found on 
platelets and endothelial cells, such as P-selectin and E-selectin, and on the 
surface of leukocytes, such as L-selectin (Rosen 2004; Sackstein 2005). The 
expression of these selectin ligands on tumour cells allows aggregation of 
platelets and leukocytes to the tumour cells and can also promote 
adherence of tumour cells to activated endothelium (Mannori et al. 1995; 
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Rosen 2004). Integrins have also been shown to play a part in the adhesion 
of tumour cells to the endothelium. A study by Taichman et al showed that 
tumour cells expressing α4β1 integrin were able to adhere to VCAM-1 on 
activated endothelial cells (Taichman et al. 1991). Once tumour cells have 
arrested on the endothelium, they proliferate and disrupt the capillary wall 
(Chambers et al. 2002). From here it is then possible to infiltrate the 
surrounding tissues.  
 
1.2.2 Differing hypotheses of specific-site metastasis 
1.2.2.1 Seed and soil hypothesis 
 In 1889, Stephen Paget first proposed the seed and soil hypothesis of 
metastasis after analysis of over 900 autopsies of patients with primary and 
secondary tumours. It was noticed that there was a pattern to the location of 
organs that developed secondary tumours, which led him to develop the 
hypothesis that the seed (metastasizing cells) must be compatible with the 
soil (site of metastatic tumour growth) (Paget 1889). This was further 
evidenced through the review of clinical data by Sugarbaker and, later, 
Weiss (Sugarbaker 1979; Weiss 2000).   
 This hypothesis has come under scrutiny after intravital microscopy 
showed tumour cells aggregated to platelets and leukocytes can block 
capillaries and arrest against the endothelial walls. Tumour cells can then 
proliferate and disrupt the capillary wall and invade the local parenchyma 
(Bacac and Stamenkovic 2008; Chambers et al. 2002; Chambers et al. 
1998-1999). This is due to the size restrictions of capillaries. While white 
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blood cells can pass through small capillaries and arrest using cadherins 
and integrins, tumour cells arrest in the capillaries as a result of their large 
size. It is possible to speculate therefore that the site-specific metastases 
development is not due to homing of tumour cells but rather the suitability of 
the secondary site for metastases proliferation and angiogenesis.  
 
1.2.2.2 Chemokine-mediated hypothesis 
 Chemokines and their respective receptors are heavily involved in 
homing of lymphocytes to different organs and also tumours (discussed in 
Section 1.3.4.2) and have recently been shown to play a potential role in 
metastasis (Bacac and Stamenkovic 2008; Chambers et al. 2002). In breast 
cancer, tumour cells were found to express CXCR4 and CCR7 chemokine 
receptors with their ligands expressed at key sites of metastasis, such as the 
lungs, liver, lymph nodes and spleen (Muller et al. 2001). Further analysis of 
the human breast cancer cell line MDA-MB-231 injected into SCID mice 
along with human CXCR4 blocking antibody revealed fewer lung metastases 
after 28 days (Muller et al. 2001). Interactions of chemokines with their 
receptors initiates intracellular signaling resulting in actin polymerization and 
development of pseudopodia, as well as activation of the RAS/MAPK 
pathway (Chambers et al. 2002). In many human cancers, RAS genes are 
often mutated or activated through other mechanisms and influence the 
proliferation-apoptosis balance in favour of cell growth (Clark and Der 1995). 
Recent studies have shown that liver micrometastases induced with RAS-
transformed cells survived and maintained metastatic growth better than 
their control counterparts (Koop et al. 1996; Varghese et al. 2002). 
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 While studies suggest a key role for chemokines in metastasis, 
ultimately the size and shape of metastasizing cancer cells limits their ability 
to recirculate once they have arrested in a capillary and therefore raises 
doubts about their importance in tumour cell homing. However, chemokine 
interactions could be an important determining factor of tumour cells 
extravasation, proliferation and survival at specific organ sites (Chambers et 
al. 2002).  
 
1.2.2.3 Genetically determined metastatic homing 
 Another postulated hypothesis regarding organ-specific metastasis is 
that homing to new metastatic sites is, in part, genetically determined (Bacac 
and Stamenkovic 2008). Investigation of lung-colonizing B16 melanoma cell 
gene expression revealed the upregulation of RhoC, a protein in the Rho-
GTPase family normally associated with cell proliferation and cytoskeletal 
remodeling (Clark et al. 2000; Van Aelst and D’Souza-Schorey 1997). In the 
human breast cancer cell line MDA-MB-231, repeated intravenous injection 
led to the isolation of daughter cell lines exhibiting a pattern of gene 
expression specific not only to generalized metastasis, but also to the 
particular organs within which they had seeded and grown (Minn et al. 
2005). Another study demonstrated that overexpressed genes in cell lines 
able to metastasize to bone were associated with membrane-bound and 
secreted molecules within the bone microenvironment (Kang et al. 2003). 
While the induced expression of a single one of these overexpressed genes 
in MDA.MD-231 failed to initiate bone metastasis, the combination of three 
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or more bone metastasis-associated genes in this cell line successfully 
promoted metastasis to bone (Kang et al. 2003).  
 Each of these hypotheses has some merit in the context of 
metastasis. It is widely accepted that Stephen Paget’s idea of site-specific 
metastasis holds true whereby the site at which metastases develop must 
have the correct microenvironment, however the idea of chemokine-
dependent homing of metastasizing cells to distant organs remains unclear. 
While it is evident that chemokines play a role in metastasis, it is not known 
whether the expression of chemokine receptors by tumour cells aids cells 
extravasation after cell arrest within the capillaries. Evidence exists to 
support each of the three hypotheses, suggesting a combination of all 3 
must occur for successful metastasis.  
 
1.2.3 The metastatic niche 
 The notion of site-specific metastasis is supported by the 
development of distant-site metastatic niches. Similar to stem cell niches, 
metastatic niches provide the optimal environment for the seeding, 
proliferation and ultimate survival of metastasizing cells, however they lack 
structural organization observed in stem cell niches (Descot and Oskarsson 
2013).  
 The pre-metastatic niche is formed at distant sites ahead of cancer 
cell colonization under the influence of growth factors, cytokines, exosomes 
and enzymes secreted by the primary tumour (Psaila and Lyden 2009). The 
subsequent remodeling of ECM, vasculature and lymphatics create an 
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environment conducive to cancer cell extravasation and seeding (Descot 
and Oskarsson 2013; Psaila and Lyden 2009). Matrix metalloproteinases 
(MMPs) and other enzymes are able to remodel the ECM leading to an 
increase in stromal fibronectin and retention of recruited vascular endothelial 
growth factor (VEGF)R1+ bone marrow derived cells (BMDCs) (Kaplan et al. 
2005).  
 Studies have also shown metastasizing cells are able to take 
advantage of already established stem cell niches. For example, cancer 
cells have been shown to colonize the osteoblastic niche of hematopoietic 
stem cells in the metastasis of prostate cancer cells to bone (Shiozawa et al. 
2011). With the overlap of signaling pathways involved in both pluripotency 
and cancer cell propagation, such as Wnt, Notch, PI3K and JAK-STAT, the 
stem cell niche provides many benefits to metastasizing cells (Dreesen and 
Brivanlou 2007). Interestingly, endothelial cells have also been implicated in 
maintaining cancer stem cell phenotype in CRC through the induction of the 
Notch signaling pathway (Lu et al. 2013). Further evidence for the 
involvement of endothelial cells in metastasis was revealed in a xenograft 
mouse model of breast and melanoma cell metastasis to brain, which 
showed maintenance of cancer cell-endothelial cell contact long after 
extravasation (Carbonell et al. 2009; Kienast et al. 2010). While it is clear 
that the utilization of stem cell niches and involvement of endothelial cells 
play a role in the development of metastases, the precise mechanisms are 
yet to be described (Descot and Oskarsson 2013).  
 Upon formation of the metastatic niche, mechanisms of disease 
progression begin to unfold. The invasive front of the metastatic niche is the 
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site at which the newly formed secondary tumour meets the stroma, and is 
constantly moving (Friedl et al. 2012). Tumour cells at the invasive front 
undergo EMT as described in Section 1.2.1.1 allowing invasion of 
surrounding stroma and progression of metastatic disease (Thiery et al. 
2009). While the invasive front is highly vascularized, newly formed blood 
vessels are underdeveloped and leaky, preventing oxygen delivery to certain 
parts of the tumour (Vaupel et al. 2001). This leads to the formation of 
hypoxic pockets, an environment that promotes cancer stem cell phenotypes 
(Lu and Kang 2010). 
 
1.2.3.1 The niche ECM 
 The ECM in the metastatic niche develops an optimal structure for the 
progression and outgrowth of metastases (Descot and Oskarsson 2013). 
While investigation into the specific components of the niche ECM is 
ongoing, its general overall structure appears much different to ECM in 
homeostatic conditions (Descot and Oskarsson 2013; Sleeman 2012). The 
composition of the ECM undergoes both changes in constitution and 
deposition of new ECM components. The recruitment of fibroblasts and 
fibroblast-like cells plus the deposition by primary tumour cells leads to the 
accumulation of fibronectin, which is required for the attachment of cancer 
cells and BMDCs (Kaplan et al. 2005). Other ECM components, such as 
periostin and tenascin-c, are also key factors in the reconstitution of the 
niche ECM. Periostin is involved in retention of tenascin-c in the ECM 
through binding this factor along with fibronectin and collagen type I (Kii et 
al. 2010; Vogelstein et al. 2013). Both periostin and tenascin-c are strong 
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promoters of Notch and Wnt signaling pathways promoting stem cell like 
properties and remodeling, and have also been shown to promote 
metastasis to the lung (Oskarsson et al. 2011).  
Matrix proteins, heparin and heparin sulfate within the ECM are able 
to bind and retain growth factors and cytokines such as GM-CSF, HGF, 
interleukins, TGF-β, and EGFs (Taipale and Keski-Oja 1997). Furthermore, 
the structure of the ECM is conducive to cancer cell adhesion.  The 
activation of focal adhesion kinase (FAK) by type 1 collagen and by integrin 
surface receptors on cancer cells leads to PI3K and MAPK cell signaling 
promoting cancer cell survival (Chiarugi and Giannoni 2008). Furthermore, 
FAK also regulates EMT through TGF-β signaling and ECM adhesion 
causing disruption of E-cadherin interactions in CRC (Avizienyte et al. 2002; 
Cicchini et al. 2008).  
 
1.2.3.2 The secreted cytokine milieu of the metastatic niche 
  The induction and maintenance of EMT at the invasive front is 
essential for the progression of metastatic disease (Descot and Oskarsson 
2013). Cytokines such as TGF- β and hepatocyte growth factor (HGF) are 
both strong inducers of EMT, with HGF also promoting stem cell like 
properties in already differentiated cancer cells by strengthening the Wnt 
signaling pathway (Janda et al. 2002; Vermeulen et al. 2010). 
 Inflammatory cytokines have also been implicated in promoting the 
progression of metastasis. In breast cancer, the production of IL-6 by 
osteoblasts promotes outgrowth of bone metastases, while PI3K signaling 
initiated by CXCL12 and IGF1 further stimulate metastatic outgrowth (Sethi 
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et al. 2011; Zhang et al. 2009). Inflammatory cytokines also recruit 
inflammatory monocytes and myeloid progenitors to the site of lung 
metastases from breast cancer through CCL2 and CXCL1/2 chemokines 
(Acharyya et al. 2012; Qian et al. 2011). Furthermore, inflammatory myeloid 
progenitors also maintain a stem cell like state in cancer cells, preventing 
upregulation of differentiated cell markers and therefore immune recognition 
and destruction (Landsberg et al. 2012).   
 Cancer cells as well as the niche parenchyma in lungs can secrete 
the calcium binding S100 proteins (Descot and Oskarsson 2013). During the 
formation of the pre-metastatic niche, TNFα, TGF-β and VEGF-A secretion 
by the primary tumour leads to upregulation of S100A8/9 and recruitment of 
CD11b myeloid cells along the CXCL1/2 axis (Hiratsuka et al. 2006; 
Hiratsuka et al. 2008; Lukanidin and Sleeman 2012).  
 Microvesicles around 30-100nm in diameter known as exosomes 
have also recently been implicated in metastasis (Descot and Oskarsson 
2013). Exosomes released from melanomas have been shown to prime 
BMDCs for a pro-metastatic phenotype through the delivery of Met receptors 
(Peinado et al. 2012). Exosomes have also been shown to induce 
expression of growth factors such as VEGF-A and remodeling enzymes 
such as MMP2 and MMP9 at the pre-metastatic niche (Grange et al. 2011; 
Jung et al. 2009; Peinado et al. 2011). Additionally, exosomes have also 
been implicated in mediating suppression of anti-tumour immune responses 
(Valenti et al. 2007). A study by Clayton and colleagues in 2011 described 
the expression of the ectonucleosidases CD39 and CD73 by cancer derived 
exosomes that led to an increase in extracellular adenosine (Clayton et al. 
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2011). Conversion of 5’AMP to adenosine by exosomes resulted in the 
inhibition of T cell activity in an A2A-receptor dependent manner, similar to 
Treg mediated suppression discussed in Section 1.3.3.2. (Clayton et al. 
2011). 
 
1.2.3.3. The role of MMPs and other remodeling enzymes in the metastatic 
niche 
 MMPs have an important role in the remodeling of the ECM at the 
primary tumour site in order for invasion to occur (Descot and Oskarsson 
2013; Sleeman 2012). Similarly, MMPs as well as other remodeling 
enzymes like cathepsins have an important role at the metastatic niche. 
MMPs cleave domains of ECM components that can subsequently interact 
with integrins and other surface receptors thereby initiating intracellular 
signaling (Descot and Oskarsson 2013). For example, in mammary gland 
involution MMP2 cleaves an EGF-like fragment from the basement 
membrane protein LM-332, which subsequently binds to EGFR and initiates 
MAPK signaling (Schenk et al. 2003). These cleaved domains can also be 
involved in immune cell recruitment. The degradation of collagen by MMPs 
produces tripeptide Pro-Gly-Pro, which initiates CXCR1/2 mediated 
recruitment of neutrophils to the lungs (Weathington et al. 2006). As the 
structure of the ECM allows retention of growth factors, MMP enzymatic 
activity releases these growth factors such as TGF-β thus promoting 
proliferation and survival of cancer cells (Dallas et al. 2002). In mammary 
carcinoma models, MMP2 and MMP9 are able to cleave latent TGF-β in the 
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pre-metastatic niche and hypoxic areas resulting in cancer invasion and 
angiogenesis (Yu and Stamenkovic 2000). 
 The state of hypoxia causes secretion of lysyl oxidase (LOX) enzyme 
in response to hypoxia inducible factor (HIF)-1, which in turn leads to 
stiffening of the matrix by the formation of crosslinks between collagen fibres 
(Erler et al. 2006). This LOX dependent ECM stiffening ultimately promotes 
MAPK and PI3K signaling through focal adhesions. The presence of matrix 
stiffening is often associated with aggressive tumours and a poor prognosis 
(Levental et al. 2009). A hypoxic state in the metastatic niche also recruits 
VEGFR1+ BMDCs and CD11b+ myeloid cells, while also maintaining stem 
cell like properties of cancer cells (Du et al. 2008; Lin and Yun 2010; Lu and 
Kang 2010). It is postulated therefore that the hypoxic state in the metastatic 
niche promotes metastatic outgrowth by encouraging the proliferation of the 
cancer stem cell population (Sleeman 2012). 
 
1.2.4 The role of the immune system in metastasis 
 Cells of the immune system play important roles in the prevention of 
metastasis and destruction of tumour cells, however they have also been 
implicated in aiding the progression of disease (Kitamura et al. 2015). 
 Macrophages have been implicated in both tumour suppression and 
tumour progression. Macrophages are recruited to the tumour site through 
the production of cytokines such as colony stimulating factor 1 (CSF-1), 
VEGF-A, CCL2 and CXCL12 (Cook and Hagemann 2013; Lee et al. 2013). 
Once at the tumour site, these tumour associate macrophages (TAMs) can 
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suppress CD8+ T cell cytotoxic activity through the expression of 
programmed death ligand 1 (PD-L1) and recruitment of Tregs via CCL22 
(Curiel et al. 2004; Kuang et al. 2009). Macrophages have been implicated 
in aiding angiogenesis and have been shown to be associated with new 
blood vessels, aiding dissemination of metastatic cancer cells (Kitamura et 
al. 2015). In a mouse model of breast cancer, the depletion of macrophages 
impaired the onset of angiogenesis thereby leading to suppression of PyMT 
cell metastasis to the lungs (Lin et al. 2006; Lin et al. 2001). TAMs promote 
angiogenesis through the secretion of VEGF-A, and knock out of the Ets2I 
gene in TAMs leads to the upregulation of thrombospondin 1 and 2 
(Zabuawala et al. 2010). TAMs are also involved in invasion and 
intravasation of tumour cells as intravital microscopy exhibits the association 
of disseminating tumour cells and TAMs during intravasation in PyMT 
tumours (Wyckoff et al. 2004; Wyckoff et al. 2007). The secretion of EGF by 
TAMs enhances the invasive qualities of tumour cells through the stimulation 
of invapodium formation (Zhou et al. 2014). TAMs also aid the adhesion of 
tumour cells to the ECM through the secretion of CCL18 and osteonectin 
(Chen et al. 2011; Sangaletti et al. 2008). The production of cathepsin B and 
S by TAMs in a mouse model of pancreatic cancer has also been shown to 
promote angiogenesis and the metastasis of tumour cells (Gocheva et al. 
2010). The induction of TAM-like phenotype in tumour infiltrating 
macrophages have not yet been fully characterized, however recent studies 
have demonstrated the role of CD4+ T cells in this process (Kitamura et al. 
2015). The secretion of IL-4 by CD4+ Tcells increases the production of EGF 
by TAMs, which is associated with invasion of tumour cells (DeNardo et al. 
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2009). Furthermore, the production of IL-4 by tumour cells also increases the 
production of cathepsins by TAMs promoting angiogenesis (Gocheva et al. 
2010). The production of GM-CSF by human breast tissue alters the 
phenotype of macrophages to a TAM-like phenotype, which has been shown 
to be required for the occurrence of metastasis in a xenograft mouse model 
(Su et al. 2014). COX2 inhibition by Etodolac suppresses the expression of 
VEGF-A and MMP9 by TAMs, preventing the metastasis of breast cancer 
cells to the lungs in a mouse model (Na et al. 2013). Interestingly, the 
histidine-rich glycoprotein overexpression in TAMs skews their polarization 
to anti-tumour from pro-tumorigenic through the down-regulation of placental 
growth factor (PGF) thereby inhibiting metastasis by normalizing the 
structure of leaky blood vessels (Rolny et al. 2011). Collectively, these 
suggest that the roles of macrophages in tumour progression or suppression 
are heavily dependent on the tumour microenvironment (Kitamura et al. 
2015).  
 Similarly, neutrophil contribution to tumour immunity is also tumour-
dependent. Neutrophils have been implicated in the promotion of 
angiogenesis and cell migration (Kitamura et al. 2015). A mouse model of 
melanoma demonstrated that UV light stimulation promoted the recruitment 
of neutrophils to the tumour site to enhance angiogenesis leading to an 
increase in metastasis (Bald et al. 2014). Conversely, in a murine model of 
spontaneous breast cancer, the depletion of neutrophils was correlated with 
increased metastatic foci within the lungs (Granot et al. 2011). Moreover, 
neutrophils isolated from tumours in mice were found to kill tumour cells in 
vitro in an H2O2-dependent manner. The adoptive transfer of these anti-
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tumour neutrophils into tumour bearing mice suppressed the development of 
lung metastases (Granot et al. 2011).  
 CD11b+ Gr1+ MDSCs are also recruited to the tumour site through 
CXCL5 or GM-CSF as shown by a mouse model of pancreatic cancer 
(Bayne et al. 2012). At the invasive front, MDSCs can promote invasion of 
tumour cells through expression of MMPs (Yang et al. 2008). MDSCs have 
also been shown to suppress the production of cytokines by T cells in vitro 
and the use of GR1 neutralizing antibody decreases the frequency of 
MDSCs while increasing the presence and function of NK cells in a 
subcutaneous model of lung cancer in mice (Srivastava et al. 2012; Yang et 
al. 2008). This ablation of MDSCs also prevents the metastasis of tumour 
cells from the subcutaneous site to the lungs. However, GR1 neutralizing 
antibodies are not specific to MDSCs and can also suppress monocytes and 
neutrophils (Sawant et al. 2012).  
 The adaptive immune subset also plays a role in metastasis. Tregs 
are recruited to the primary tumour site by CCL22 and CCL5 (Curiel et al. 
2004; Tan et al. 2009; Tan et al. 2011; Yang et al. 2012). The secretion of 
TNF increase lung metastasis in a melanoma mouse model by causing the 
expansion of Tregs (Chopra et al. 2013). Furthermore, the suppression of 
NK cell cytotoxicity in a TGF-β-dependent manner by Tregs further promotes 
metastasis (Smyth et al. 2006b). The role of Tregs in tumour development is 
further discussed in Section 1.3.4.  
 A study in the murine breast cancer model PyMT revealed that the 
loss of TGF-β signaling led to an increase in CXCL1 and CXCL5 thereby 
recruiting MDSCs to the tumour site (Novitskiy et al. 2011). This in turn led to 
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the accumulation of Th17 cells due to the secretion of IL-6, IL-23 and TGF-β 
by MDSCs. In a positive feedback loop, the secretion of IL-17 by Th17 cells 
further recruited MDSCs to the tumour site thereby increasing 
immunosuppression and ultimately leading to increased metastasis to the 
lungs (Novitskiy et al. 2011). Conversely, Th17 cells can also recruit DCs 
and cytotoxic cells to the tumour site, suggesting that the role of Th17 cells 
in tumour immunity is dependent on the tumour environment in the same 
manner as TAMs and neutrophils (Zou and Restifo 2010).  
 Finally, B cells expressing CD25 and B220 known as B-regs also play 
a role in metastasis (Kitamura et al. 2015). In an intravenous 4T1 murine 
breast cancer model, an increase in CD25+ B220+ B-regs was observed. 
The administration of B220 depleting antibody in this model resulted in fewer 
lung metastases (Olkhanud et al. 2011). It has been postulated that B-regs 
act by converting CD4+ T cells to Tregs via the secretion of TGF-β, although 
more investigation is needed (Olkhanud et al. 2011).  
 The recruitment of suppressive cell types to the tumour allows tumour 
cell survival and dissemination into circulation as shown by different tumour 
models. It is also clear that the role of immune cells in cancers is dependent 
on the tumour microenvironment, with a variety of cytokine and chemokine 
expression by tumour cells influencing the type of immune cells recruited. 
Further investigation and understanding of the mechanisms involved in 
recruitment and suppression on different tumour models would pave the way 
for effective immunotherapy treatments in cancer and metastasis. 
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1.3 Regulatory T cells  
1.3.1 Discovery of Tregs 
 Tregs are described as CD4+ CD25+ Foxp3+ T cells and develop in 
the thymus during positive and negative selection. The idea of the thymus as 
the site of a suppressive T cell subset development was first postulated in 
the 1960s, when thymectomy between day 2 and day 4 of life led to 
autoimmune destruction of ovaries in neonatal mice (McIntire Kr Fau - Sell et 
al. 1964; Nishizuka and Sakakura 1969). It was Sakaguchi and colleagues in 
1995 that discovered a suppressive CD25+ subset of CD4+ T cells that 
prevent the onset of autoimmunity in thymectomized mice. It was also 
observed that when CD4+ T cells were adoptively transferred into 
thymectomized mice without the CD25+CD4+ subpopulation, autoimmune 
disease was still present (Sakaguchi et al. 1995).  
 CD25 is not specific to this suppressive subset of T cells and is also 
upregulated on all activated T cells. The forkhead transcription factor 
Forkhead Box Protein 3 (Foxp3), found on the X-chromosome, was 
identified as a specific maker of Tregs (Fontenot et al. 2003; Hori et al. 2003; 
Khattri et al. 2003). A loss-of-function mutation in the foxp3 gene locus was 
discovered to be responsible for the autoimmunity in Scurfy mice and for the 
onset of IPEX (immunodysregulation, polyendocrinopathy, enteropathy, X-
linked syndrome), an inherited autoimmune disorder in humans (Bennett et 
al. 2001; Brunkow et al. 2001; Wildin et al. 2001). Furthermore, while Foxp3 
expression was primarily limited to CD4+CD25+ Tregs, retroviral expression 
of Foxp3 in CD25-CD4+ T cells in vitro and transgene induction of Foxp3 in 
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vivo promoted suppressive activity and expression of Treg associated 
markers such as CD25, GITR and CTLA-4 (Fontenot et al. 2003; Hori et al. 
2003; Khattri et al. 2003). While in mice Foxp3 expression is specific to 
CD4+ Treg cells, activated human T conventional cells also transiently 
upregulate Foxp3 without acquiring suppressive activities or a Treg-like 
phenotype (Fontenot et al. 2005b; Gavin et al. 2006).   
 
1.3.2 Development of Tregs 
1.3.2.1 Thymic Tregs (tTregs) 
 Tregs develop during positive and negative selection in the thymus. T 
cell progenitors migrate from the bone marrow to the subcapsular zone of 
the thymus where they expand as double negative (DN) cells and begin to 
express TCRs (Overgaard et al. 2015). Upon migration back to the medulla 
of the thymus, these early stage lymphocytes begin their double positive 
(DP) stage and express both CD4 and CD8 (Germain 2002). During this 
time, DP cells undergo selection in the thymus determined by the signal 
strength received by thymic APCs. High avidity interactions between TCR 
and peptide MHC (pMHC) complex lead to negative selection of thymocytes, 
whereas low to medium affinity leads to positive selection (Workman et al. 
2009). The DP thymocytes subsequently differentiate into either the CD4 or 
CD8 lineage, depending on the expression of certain transcription factors 
(Overgaard et al. 2015).  
 Of the CD4 single positive (CD4SP) lineage, thymic derived Tregs are 
thought to develop from immature CD24hiCD4+CD8- thymocytes, although a 
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small proportion have been identified as having been developed from DP 
cells (Kitagawa et al. 2017; Lee and Hsieh 2009). These immature CD4SP 
cells undergo strong TCR and CD28 co-stimulation to generate tTreg 
precursor cells with a CD25+GITR+Foxp3-CD4SP phenotype (Lio and Hsieh 
2008). These tTreg precursors undergo further stimulation through TCR 
binding and IL-2 to differentiate into a Foxp3+ tTregs with a stable DNA 
methylation pattern (Kitagawa et al. 2017; Lio and Hsieh 2008). Some 
studies have shown, however, that IL-2 is not necessarily required for tTreg 
cell differentiation, as mice with IL-2 knockdown only experience a 50% 
decrease in numbers of tTregs (D'Cruz and Klein 2005; Fontenot et al. 
2005a). In 2017, Shimon Sakaguchi and colleagues showed that the 
presence of Treg Super Enhancers (SEs) precede the expression of Foxp3 
in tTreg precursors and are associated with Treg genes such as Foxp3, 
Ctla4 and Il2ra. Furthermore, it was also observed that Foxp3 is not require 
for the induction of Treg-associated genes, but enhances an established 
Treg gene expression pattern (Kitagawa et al. 2017).    
 
1.3.2.2 Peripherally derived Tregs (pTregs) 
 Tregs can also be induced outside of the thymus from naïve CD4+ T 
cells. This induction occurs through exposure to stimulatory cytokines, such 
as IL-10 and TGF-β, and strong TCR signaling with suboptimal co-
stimulation (Plitas and Rudensky 2016). The Foxp3 cis-regulatory element 
conserved non-coding sequence (CNS) 1, required for the induction of 
pTregs, contains a retrotransposon normally found in placental mammals 
suggesting a role of pTregs in maternal-neonatal tolerance (Samstein et al. 
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2012). It has also been shown that CNS knock-out mice that do not develop 
pTregs did not develop severe autoimmunity, but instead developed 
spontaneous Th2 responses at mucosal sites and inflammation associated 
with asthma and allergic airways (Josefowicz et al. 2012).  These data 
suggest that while tTregs are involved in self-tolerance, pTregs are involved 
in tolerance to non-self antigens (Plitas and Rudensky 2016). 
 
1.3.3 Function of Tregs 
 Tregs promote self-tolerance and prevent autoimmune responses 
through the suppression of other immune cell subsets. In the presence of 
APCs in vitro, Tregs are functionally capable of suppressing the proliferation 
and cytokine production of naïve Tcells, while in vivo Tregs suppress the 
effector activities of CD8+ and CD4+ Tcells (Sakaguchi et al. 2008; 
Takahashi et al. 1998; Thornton and Shevach 1998). 
 There are four main mechanisms described for Treg-mediated 
suppression, either acting directly on effector cells or APCs or indirectly 
through suppressive cytokines. 
 
1.3.3.1 Suppression through inhibitory cytokines 
 Inhibitory cytokines, such as IL-10, TGF-β, and IL-35 appear to have 
differing suppressive functions in vivo and in vitro. The anti-inflammatory 
cytokine IL-10 in vivo has been shown to be important for control of 
Experimental Autoimmune Encephalomyelitis (EAE), a murine disease 
homologue of human multiple sclerosis, inflammation at mucosal sites and 
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infection (Schmidt et al. 2012).  Conversely a suppressive function of Treg-
generated IL-10 could not be identified through the use of in vitro 
suppression assays (Schmidt et al. 2012).  
 While TGF-β has been shown to be required for induction of pTregs in 
vivo, its suppressive ability remains controversial. Although TGF-β deficient 
Tregs have been shown to suppress conventional T cells in vitro, Treg-
mediated control of colitis in vivo has been shown to require TGF-β (Izcue et 
al. 2009; Read et al. 2000). Surface-bound TGF-β has also been shown to 
play a role in cell-cell contact-mediated suppression (Nakamura et al. 2001). 
In a model of diabetes, Tregs expressing membrane-tethered TGF-β were 
able to control CD8+ T cell infiltration into islet therefore delaying the onset of 
disease (Green et al. 2003).  
 IL-35 is a member of the IL-12 heterodimeric cytokine family formed 
from the Epstein-Barr virus induced gene Ebi3 and p35 (or Il12a). This 
recently described inhibitory cytokine is preferentially expressed by, and 
required for suppressive activity of, Tregs (Collison et al. 2007). Both Ebi3 
and Il12a deficient Tregs not only had reduced regulatory function in vitro but 
also failed to cure IBD in vivo (Collison et al. 2007).  
 
1.3.3.2 Metabolic disruption-mediated suppression 
 The upregulation of IL-2Rα (CD25) is a classic hallmark of Tregs. 
While IL-2 is required for the differentiation of tTregs and for their 
maintenance, Tregs do not secrete IL-2 themselves. An interesting 
hypothesis postulated that high-level expression of CD25 allowed Tregs to 
“scavenge” IL-2 thus depriving local actively proliferating effector T cells 
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leading to cytokine deprivation-mediated apoptosis (de la Rosa et al. 2004; 
Duthoit et al. 2004; Fontenot et al. 2005a; Pandiyan et al. 2007; Thornton 
and Shevach 1998).  Recent studies have shown, however, that depletion of 
IL-2 alone is not sufficient in preventing the suppression of effector T cells by 
Tregs (Oberle et al. 2007).  
 CD39 and CD73 are ectoenzymes expressed on the surface of Tregs 
generating pericellular adenosine and adenosine derivatives that can 
activate the A2A receptor on effector T cells and suppress their function 
(Borsellino et al. 2007; Deaglio et al. 2007; Kobie et al. 2006). Not only does 
the activation of A2A receptors suppress T cell function, it also promotes the 
secretion of TGF-β and inhibits production of IL-6; a cytokine that promotes 
differentiation of naïve CD4 cells into a Th17 rather than a Treg phenotype 
(Oukka 2007; Zarek et al. 2008).  
 
1.3.3.3. Suppression through direct cytotoxicity  
 Human Tregs express granzyme B upon activation and can directly 
kill activated effector cells as part of the perforin/granzyme cell death 
pathway (Grossman et al. 2004; Hoves et al. 2010). While this pathway is a 
principle cytotoxic mechanism performed by NK cells and CTLs upon 
intracellular pathogens, it has also been shown to be a potential mechanism 
of suppression executed by Tregs (Grossman et al. 2004; Hoves et al. 
2010).  
 Murine Foxp3+ Tregs have also been shown to upregulate granzyme 
B upon activation (Shevach 2009). It has been reported that granzyme B-
deficient murine Tregs have decreased suppressive activity in vitro, and the 
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upregulation of granzyme B allows killing of effector cells by Tregs in a 
perforin-independent granzyme B-dependent manner (Gondek et al. 2005). 
In 2010 Boissonnas et al used two-photon microscopy to show the killing of 
DCs by Tregs using perforin-dependent mechanisms in a tumour-draining 
lymph node (Boissonnas et al. 2010). 
 
1.3.3.4 Suppression through dendritic cell targeting 
 Tregs can also suppress through inhibition of APCs therefore 
preventing the activation of effector T cells (Vignali et al. 2008). The cell 
surface protein CTLA-4 is constitutively expressed on both murine and 
human Foxp3+ Tregs and has been shown to play an important role in the 
suppressive effects of Tregs (Read et al. 2000; Takahashi et al. 1998). It has 
been reported that by removing the function of CTLA-4 through either 
blocking antibodies or use of CTLA-4-deficient Tregs, the suppression of 
DCs was reduced (Oderup et al. 2006; Serra et al. 2003). Moreover, 
autoimmunity induced by CLTA-4 deficiency or CTLA-4 blockade can be 
improved by the addition of WT Tregs (Bachmann et al. 1999; Takahashi et 
al. 2000). While CTLA-4 deficiency causes systemic autoimmunity, CTLA-4 
deficient Tregs exhibit suppressive functions both in vitro and in vivo through 
cytokine-mediated mechanisms (Read et al. 2006; Tang et al. 2004).  
 Surface bound CTLA-4 interacts with the co-stimulatory molecules 
CD80/CD86 on DCs and the subsequent ligation of these molecules leads to 
upregulation of indoleamine 2,3-dioxygenase (IDO), a potent regulatory 
enzyme that catabolizes tryptophan into proapoptotic metabolites, ultimately 
leading to cell cycle arrest of effector T cells (Fallarino et al. 2003; Mellor 
	 53	
and Munn 2004). In addition, CTLA-4 has also been shown to remove 
CD80/CD86 from the surface of APCs through trans-endocytosis, thereby 
preventing costimulation to APCs (Qureshi et al. 2011).  
 Finally, surface-expressed lymphocyte-activation gene 3 (LAG-3); a 
CD4 homologue, can bind to MHC II with very high affinity (Huang et al. 
2004; Workman and Vignali 2005). This interaction between LAG-3 and 
MHC II on DCs induces an immunoreceptor tyrosine-based activation motif 
(ITAM)-mediated inhibitory signaling pathway leading to the suppression of 
DCs immunostimulatory functions (Liang et al. 2008).  
 
1.3.4 Role of Tregs in Cancer  
1.3.4.1 Tregs in anti-tumour immunity 
 Robert North first postulated the involvement of suppressive-like cells 
in anti-tumour immunity in the 1980s [reviewed in (Gallimore and Godkin 
2008)]. North and colleagues showed that while an anti-tumour immune 
response was mounted in response to Meth A tumours (an MCA-induced 
tumour cell line); tumour growth could not be fully prohibited due to activity of 
suppressor T cells. Furthermore, through measuring concomitant immunity 
(described as the ability to reject a second inoculum of the original tumour 
cell line) it was observed that anti-tumour immune responses deteriorated 
over time concurrent with increased suppressive T cell activity (Gallimore 
and Godkin 2008; North and Bursuker 1984). Further investigation led to the 
characterization of these suppressor T cells as CD4+ CD8- cells, with the 
use of CD4-depleting antibodies leading to successful tumour regression 
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(Awwad and North 1988). The work by North and colleagues first 
demonstrated the ability of Tregs to suppress an anti-tumour immune 
response, and with subsequent identification of CD25 and a specific Treg 
marker by Sakaguchi in 1995, further investigation into the extent of Treg 
suppression commenced (Gallimore and Godkin 2008; Sakaguchi et al. 
1995).  
 Many studies have shown that depletion of CD25+ cells ultimately 
results in generation of an anti-tumour immune response. CD25 depleting 
monoclonal antibodies were used to induce CD8+ T cell and NK cell anti-
tumour responses not only in the Meth A tumour model, but also in other 
tumour cell line derived models (Onizuka et al. 1999; Shimizu et al. 1999). It 
was also found that concomitant immunity could be induced after depletion 
of CD25+ Tcells (Turk et al. 2004).  While prophylactic depletion of CD25+ T 
cells was able to successfully control tumour growth, CD25 depleting 
antibodies given at the time of tumour challenge were not. As activated T 
cells express CD25, this effect was most likely due to depleting of anti-
tumour CD25+ T cells as well as Tregs (Jones et al. 2002; Li et al. 2003; 
Onizuka et al. 1999; Quezada et al. 2008; Shimizu et al. 1999; Sutmuller et 
al. 2001). However, it was possible to promote tumour regression of an 
established tumour through intra-tumoural injection of CD25-depleting 
antibodies (Yu et al. 2005).  
 The identification of Foxp3 as a specific Treg marker allowed 
exclusive depletion of Tregs without affecting effector T cells. The 
development of diphtheria toxin receptor transgenic mice by Rudensky and 
Sparwasser (discussed in Section 1.5.1) allows the depletion of Foxp3+ cells 
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expressing the Diphtheria Toxin Receptor through administration of 
Diphtheria Toxin (Kim et al. 2007; Lahl et al. 2007). Subsequent studies 
using these transgenic mice have demonstrated that specific depletion of 
Foxp3+ cells not only prevents tumour development but also results in 
regression of an established primary tumour initiated by injection of a tumour 
cell line or the carcinogen MCA (Hindley et al. 2012; Klages et al. 2010; Li et 
al. 2010; Teng et al. 2010).  The progression of these collective studies 
initiated by North and colleagues demonstrate the capability of Tregs to 
suppress anti-tumour immune responses and open doors for potential Treg-
specific cancer therapies.  
 
1.3.4.2 Enrichment of Tregs at the tumour site 
 The enrichment of Tregs in different cancers has been well 
documented for both human and murine tumours. The normal ratio of 
conventional T cells to Treg in homeostatic conditions becomes unbalanced 
in cancer patients, and an increase in Tregs can be observed in both the 
peripheral blood and the tumour microenvironment in cancers like 
pancreatic, lung, breast, liver and colorectal tumours (Betts et al. 2007; 
Hindley et al. 2012; Nishikawa and Sakaguchi 2010; Quezada et al. 2011; 
Scurr et al. 2012; Wilke et al. 2010). The increased presence of Tregs in 
cancer patients can indicate a good or poor prognosis depending on the type 
of cancer. In ovarian carcinomas, breast cancers, and gastric cancer an 
increase in Treg numbers is correlated with poor survival (Bates et al. 2006; 
Curiel et al. 2004; Perrone et al. 2008; Sato et al. 2005). Contrastingly 
however, in inflammation driven cancers the presence of Tregs correlates 
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with a good prognosis, in which Tregs are thought to exert suppression of 
pro-tumour inflammation (Ruffell et al. 2010). Similarly, in Hodgkin’s 
lymphoma the presence of Tregs is also consistent with improved survival 
(Álvaro et al. 2005). In CRC, the presence of tumour-infiltrating Tregs have 
been correlated with an improved outcome, however tumour antigen specific 
Tregs in CRC have been shown to suppress an anti-tumour response 
(Bonertz et al. 2009; Scurr et al. 2012). Importantly, altering the ratio of 
conventional T cells (Tconv) to Tregs is associated with a better prognosis. 
In B16 melanoma challenged mice, treatment with CTLA-4 blockade and 
GVAX vaccine significantly increases Tconv cells in comparison to Tregs, 
resulting in tumour rejection (Quezada et al. 2006). 
 There have been several studies to show chemokine-mediated Treg 
enrichment at the tumour site (Ondondo et al. 2013). Treg surface-
expressed inflammatory cytokine receptors, such as CCR4, CCR5 and 
CXCR3, have been shown to be involved in intra-tumoural infiltration of 
Tregs (Iellem et al. 2001; Sather et al. 2007). Both CCL22 and CCL17, 
which are ligands for CCR4, have been shown to be upregulated in ovarian 
carcinomas and human breast cancers (Curiel et al. 2004). In mouse 
models, the disruption of CCL22/CCL17-CCR4 axis leads to a decrease in 
Treg infiltration and increases anti-tumour immune responses (Ishida et al. 
2006; Pere et al. 2011). Not only do CCL5 levels in tumours correlate with 
dampened CD8+ T cell responses, but CCL5 along with CCL3 and CCL4 
level in mouse lymphomas were increased upon myeloid derived suppressor 
cell (MDSC) infiltration (Schlecker et al. 2012). This in turn led to enhanced 
CCR5+ Treg recruitment into the tumour. Similarly, CXCR3+ Foxp3+ Tregs 
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have also been observed in human ovarian, CRC and hepatocellular 
carcinomas (Redjimi et al. 2012; Yang et al. 2011). However, both CCR5 
and CXCR3 are upregulated on activated T cells. The CXCR3 ligands 
CXCL9, CXCL10, and CXCL11 bind IFN-γ and allow homing of activated 
effector cells (Ondondo et al. 2013).  It is important to note, however, that 
while these chemokine axes described recruit Tregs to the tumour site, they 
also recruit effector T cells and are associated with a good prognosis in 
many cancers (Ondondo et al. 2013). Furthermore, a study conducted in our 
lab showed Treg cells utilized many different overlapping chemokine axes 
during homing to MCA-induced tumours, showing a lack of a specific 
chemokine axis for Treg recruitment (Ondondo et al. 2015).  
 While both pTreg and tTregs can suppress an anti-tumour immune 
response, the extent of each subset’s contribution remains unclear.  A study 
by Valzasina et al showed the adoptive transfer of Thy1.1 CD4+CD25- T 
cells into tumour-bearing mice led to the conversion of these cells into 
functional Foxp3+ CD25+ CD4+ Tregs (Valzasina et al. 2006). Other studies 
have shown that the secretion of TGF-β by tumour cells and other immune 
cells such as DCs can also induce differentiation into pTregs at the tumour 
site (Ghiringhelli et al. 2005; Liu et al. 2007). However, the difficulty in 
identification of pTregs and tTregs arises from the lack of specific markers 
for each subset (Ondondo et al. 2013). While Helios and Nrp1 are expressed 
on tTregs and not pTregs, they are also expressed on activated T cells. 
However, by using Helios and Nrp1 as makers for tTregs, studies have 
shown that Tregs present in both murine and human carcinomas are 
predominantly tTregs (Bui et al. 2006; Curiel et al. 2004; Ghiringhelli et al. 
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2005; Hansen et al. 2012; Teng et al. 2010; Wainwright et al. 2011). 
Furthermore, our own lab has previously shown that Tregs accumulating in 
MCA tumours are Helios expressing tTregs (Colbeck et al. 2015; Hindley et 
al. 2012).  
 
1.3.5 Tregs in metastasis 
 As previously described, the presence of Tregs in some cancers is 
correlated with a poor prognosis. Similarly, the presence of Tregs in primary 
tumours in breast, gastric, prostate, CRC, and lung cancers have also been 
associated with metastasis development (Decker et al. 2012; Fu et al. 2013; 
Huen et al. 2013; Lal et al. 2013; Recchia et al. 2013; Takenaka et al. 2013; 
Zhou et al. 2013). Breast cancer patients exhibit increased Treg enrichment 
with progression from normal breast, to ductal carcinoma in situ (DCIS) to 
invasive ductal carcinoma (IDC), whereas intratumoural infiltration of PD1+ 
Foxp3+ Tregs in patients with clear cell renal cell carcinoma (CCRCC) is 
correlated to metastasis relapse (Kang et al. 2013; Lal et al. 2013; Takenaka 
et al. 2013). Patients with metastatic castration-resistant prostate cancer 
(mCRPC) have been shown to have higher levels of CD4+CD25+CD127low/- 
cells in their peripheral blood in comparison to healthy donors (Huen et al. 
2013). Furthermore, Tregs from mCRPC patient peripheral blood 
mononuclear cells (PBMCs) were compared to healthy donor Tregs from 
PBMCs and were found to have overexpression of C-FOS, C-JUN, DUSP1, 
and RGS-1 involved in T cell proliferation and inhibition of cellular migration 
(Huen et al. 2013). Accumulation of systemic and intratumoural Tregs has 
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therefore been correlated with development of distant site metastases in 
several cancers (Halvorsen et al. 2014).  
 
1.3.5.1 Enrichment of Tregs in metastasis 
 In the same manner as the primary tumours, Treg enrichment 
associated with metastasis is cancer-type dependent (Halvorsen et al. 
2014). Patients with breast, gastric and papillary thyroid cancer (PTC) 
display increased Treg enrichment in lymph nodes from patients with 
metastatic disease in comparison to non-metastatic diseased lymph nodes 
(Faghih et al. 2014; French et al. 2012; Kashimura et al. 2012; Mansfield et 
al. 2009). PTC patients with metastatic disease also exhibit an increase in 
PD-1 expressing T cells, a marker of T cell exhaustion as well as a 
mechanism of suppression by Tregs, and therefore the combined presence 
of Foxp3+ Tregs and PD-1+ T cells is suggested as a biomarker of 
aggressive or recurrent disease (French et al. 2012). In patients with 
previously untreated breast cancer, the accumulation of 
CD4+CD25+CD127low/- Tregs in lymph nodes has been associated with the 
decrease in pro-inflammatory cytokines IL-17 and IFN-γ, leading to the 
hypothesis that in this case Tregs promote an anti-inflammatory pro-
tumorigenic state (Faghih et al. 2014). Contrastingly, the presence of 
CD4+CD25high cells in the peritoneal metastases of ovarian carcinoma 
patients is correlated with a good prognosis, suggesting possibilities for 
Tregs to promote metastasis regression in some tumours (Tsiatas et al. 
2009). 
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 As tissue biopsies and samples are restricted to primary tumours, 
PBMCs and lymph nodes, there is little information about metastases-
harboring organs in human patients (Halvorsen et al. 2014). However, 
mouse models have demonstrated the presence of Tregs at distant sites of 
metastasis in murine breast cancer (4T1 and 4T1.2) and melanoma 
(B16F10) (Abadi et al. 2013; Biragyn et al. 2013; Chopra et al. 2013; 
Dalotto-Moreno et al. 2013; Ghochikyan et al. 2014; Kim et al. 2014; 
Olkhanud et al. 2011).   
 
1.3.5.2 Metastasis-promoting functions of Tregs 
 While the functions by which Tregs can promote the progression of a 
primary tumour have been described, their ability to promote metastasis is 
poorly understood (Halvorsen et al. 2014). In both human and murine 
cancers, the expression of COX2 and PGE2 is associated with metastasis 
progression (Brudvik et al. 2012; Karavitis et al. 2012). In CRC, tumour 
expression of COX2 is much higher than surrounding healthy tissue and 
PGE2 levels in peripheral blood is also elevated (Yaqub et al. 2008). PGE2 
promotes tumour progression by stimulating cell proliferation, angiogenesis, 
and invasion of tissue by tumour cells (Brudvik et al. 2012; Fujino et al. 
2011). In one study, the inhibition of COX2 by indomethacin resulted in the 
prevention of CD4+CD25-CD127dim/- Treg-mediated suppression of cytotoxic 
responses against CEA (a colorectal antigen) (Brudvik et al. 2012). Similarly, 
a study using a murine model of CRC showed that tumour cells expressing 
COX2 were involved in PGE2-mediated Treg recruitment, promoting 
metastasis to bone (Karavitis et al. 2012). 
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 The expression of Nrp1 by Tregs stabilizes their phenotype thereby 
enhancing their anti-tumour immune suppressive abilities (Delgoffe et al. 
2013). In a murine study, the ablation of Nrp1 expressing Tregs slowed 
tumour growth in a number of different tumour models and reduced lung 
metastasis in a B16 melanoma model. Furthermore, developed lung 
metastases in these mice exhibited increased infiltration of IFN-γ and TNF-α 
expressing CD8+ T cells (Delgoffe et al. 2013). Interestingly, both 
CD4+CD25+ cells isolated from stage III and IV ovarian cancer patient 
PBMCs and murine Foxp3+ Tregs isolated from spleens were found to 
secrete VEGF-A in vitro (Facciabene et al. 2011). This study potentially 
suggests a role for Tregs to promote metastasis in addition to their 
immunosuppressive capabilities, however further study is required 
(Halvorsen et al. 2014). 
 The secretion of CCL22 and CCL17 by lung metastases has been 
shown to recruit Tregs resulting in the apoptosis of NK cells in a beta-
galactoside-binding protein (b-GBP)-dependent manner (Olkhanud et al. 
2009). Furthermore, the accumulation of Tregs was observed at metastatic 
sites in the B16F10 murine melanoma model. In this study, while the 
administration of TNF resulted in metastases enriched for TNFR2 
expressing Tregs and less infiltration of CD8+ effector cells, the ablation of 
Foxp3+ cells through administration of DTx reversed this effect (Chopra et al. 
2013). 
 Most studies investigating the migration and accumulation of Tregs in 
metastatic foci have been in pre-clinical models and therefore further study 
is required to understand whether the same is true for Treg enrichment in 
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cancer patients. Nonetheless, collectively these studies suggest a role for 
Tregs in metastasis progression and therefore provide opportunities for 
Treg-targeted treatment of metastasis (Halvorsen et al. 2014).     
While Tregs are generally associated with poor outcome of some 
cancer and therapies targeting Tregs such as checkpoint inhibition currently 
show promising results, there is still little evidence to suggest whether 
depletion of Tregs can promote immune control of metastasis. The 
availability of transgenic mouse models and spontaneously metastasizing 
murine carcinoma cell lines allow us to address this question. 
 
1.4 4T1 Murine Mammary Carcinoma Model 
1.4.1 Development of the 4T1 cell line 
 4T1 is a murine mammary carcinoma that closely mimics stage 4 
triple-negative human breast cancer. It is a subpopulation of the 410.1 cell 
line that was originally derived from a spontaneous tumour that arose in a 
female BALB/C mouse nursed on a C3H parent (BALB/BfC3H) (Dexter Dl 
Fau - Kowalski et al. 1978; Pulaski and Ostrand-Rosenberg 2000). Both of 
the subpopulations derived from the parent line (4T1 and 4T07) are resistant 
to thioguanine (H Heppner et al. 2000). 4T1 tumour cells grow well both in 
culture and in vivo, and spontaneously metastasizes to multiple organs from 
a single primary tumour (Lelekakis et al. 1999; Pulaski and Ostrand-
Rosenberg 1998). 
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1.4.2 Suitability of 4T1 for metastasis investigation 
 Of the two subpopulations derived from 410.1, 4T1 spontaneously 
metastasizes via the haematogenous route to the lungs, liver, bone and 
brain (Aslakson and Miller 1992; H Heppner et al. 2000). The resistance of 
4T1 to thioguanine allows the detection of metastatic colonies by the 
clonogenic assay (Pulaski and Ostrand-Rosenberg 2000). In this method, 
organs thought to be harboring metastatic 4T1 colonies are mechanically 
and enzymatically digested and subsequently incubated with 6-thioguanine-
supplemented growth media (described in Chapter 2). Only 4T1 cells survive 
the incubation period and grow colonies, which can be stained with 
methylene blue and counted. The resistance of 4T1 to 6-thioguanine arises 
from a loss-of-function mutation in the HPRT gene. In normal cells, HPRT 
recycles 6-thioguanine into its nucleotide form, which when incorporated into 
DNA is toxic to cells. Although present in 4T1 cells, HPRT is inactive 
preventing incorporation of 6-thioguanine and therefore cell toxicity (Lepage 
1963).  
 The main advantage of 4T1 over other animal models of metastasis is 
that it spontaneously metastasizes from a primary tumour in a manner 
similar to human breast cancer. In human breast cancer cases, the lungs are 
the first sites of metastasis (up to 77% of cases) after which secondary 
tumours can be found in the liver (Amer 1982; Kamby et al. 1987; Pulaski 
and Ostrand-Rosenberg 1998). Similarly, like some human breast cancers, 
4T1 is also poorly immunogenic and triple negative for common breast 
cancer markers. Combined, these traits of 4T1 make this cell line suitable for 
investigating metastasis in clinically relevant situation. Furthermore, as 4T1 
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cells are normally injected subcutaneously around the mammary fat pads, 
they can easily be surgically excised mimicking the treatment of human 
breast cancer (Pulaski and Ostrand-Rosenberg 2000). As 4T1 was a cell line 
derived from a tumour with other non-metastatic subpopulations, it is also a 
useful model for examination of metastasis-associated genes (Christensen 
et al. 1998). 
 
1.4.3 Growth of 4T1 in vivo 
 Subcutaneous 4T1 tumours grow uniformly in BALB/C mice, even 
after low cell numbers are injected, and continue to grow rapidly (Pulaski 
and Ostrand-Rosenberg 2000). Mice bearing 4T1 tumours have also been 
reported to display splenomegaly due to the increase in MDSC number and 
granulocytic infiltration (duPre and Hunter Jr 2007). It has also been 
observed that 4T1 tumours constitutively express genes associated with 
GM-CSF and G-CSF (duPre and Hunter Jr 2007). The number of 4T1 cells 
injected subcutaneously dictates the growth of primary tumours. If fewer 
cells are injected into the mammary fat pads, for example 7 x 103, tumours 
are not palpable until day 14 to day 21, whereas an inoculation volume of 1 x 
106 cells gives palpable tumours between day 4 and day 7. It is reported that 
even though the primary tumour growth increases with higher inoculation cell 
number, the number of metastatic colonies observed does not significantly 
increase (Pulaski and Ostrand-Rosenberg 2000). 
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 Collectively, the specific traits of 4T1 in comparison to other 
subpopulations of 410.1 create a robust animal model to investigate varying 
aspects of metastasis.  
 
1.5 DEpletion of REGulatory T cell animal model 
1.5.1 Development of DEREG mice 
 DEpletion of REGulatory (DEREG) T cell mice are a strain of BALB/C 
mice that were genetically engineered in the Sparwasser lab to express the 
Diphtheria Toxin Receptor (DTR) on their Tregs (Lahl et al. 2007). The 
DEREG strain was developed using a Bacterial Artificial Chromosome 
(BAC); a large fragment of genomic DNA containing a desired gene and 
their corresponding regulatory sequences. For the generation of these mice, 
a BAC containing the foxp3 locus and a DTR-eGFP fusion protein inserted 
into the first exon of the foxp3 gene was inserted into a fertilized oocyte of 
mice (Lahl et al. 2007). Transgenic mice developed in this manner have 
advantages and disadvantages in comparison to knock-in or knockout mice. 
BAC-transgenes only take 3-6 months to generate, compared to 1-2 years 
for knock-in/out transgenics, and have a medium technical difficulty. 
However, the genomic insertion site is not known with BAC-transgenes as 
the BAC is randomly inserted into the genome (Sparwasser and Eberl 2007). 
Through injection of Diphtheria Toxin (DTx) the Tregs of DEREG mice 
can be ablated. This allows investigation of different homeostatic and 
disease states in the absence of Tregs.  
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1.5.2 Depletion of Tregs through DTx 
 The administration of DTx to DEREG mice has been shown to 
selectively deplete Foxp3+ Tregs (Lahl et al. 2007). As the BAC encodes the 
DTR transgene under the regulation of the foxp3 promoter, only cells with 
endogenous Foxp3 expression express the DTR. The receptor-binding 
domain of DTx binds to the DTR on Foxp3+ cells allowing entry into the cell 
where, in order to become active, the polypeptide is “nicked” at an arginine-
rich site (Li et al. 2013). Once activated, the catalytic domain of DTx 
catalyzes the transfer of adenosine-diphosphate (ADP)-ribose to EF-2, an 
elongation factor that promotes the translocation of ribosomes. This blocks 
protein synthesis and ultimately kills the cell (Sandvig and Olsnes 1981; 
Zovickian et al. 1987).  
 Due to genetic silencing, not all Foxp3+ Tregs express the DTR. As a 
result, there is a remaining baseline level of Tregs after DTx administration 
(approximately 10%) (Lahl et al. 2007). This low-level of Tregs prevents 
mice from the development of severe autoimmunity, which is observed in 
Foxp3-DTR knock-in transgenic mice (Kim et al. 2009a; Kim et al. 2007; 
Mayer et al. 2014a). Recently, it has been observed that continued treatment 
with DTx in DEREG mice causes an anti-DTx antibody response resulting in 
Tregs returning to pre-treatment levels (Wang et al. 2016). 
1.5.3 Examples of documented uses of DEREG mice 
 DEREG mice provide a convenient mouse model for the investigation 
of Tregs in homeostasis and in disease. In 2014, Berod et al used DEREG 
mice to explore the involvement of Tregs in Mycobacterium bovis because of 
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the low-level of remaining Tregs preventing autoimmunity. They observed 
that after Treg depletion in DEREG mice, a niche of DTx-insensitive Tregs 
were able to expand. While these mice had worse pathogen burden in 
comparison to DEREG x Foxp3GFP mice (in which total Treg ablation is 
achieved upon DTx treatment), rapid development of severe autoimmunity 
was prevented (Berod et al. 2014). The GFP reporter gene found under the 
regulation of the Foxp3 promoter in DEREG mice can also be exploited as 
demonstrated by the study conducted by Lahl et al in 2009. In this study, 
DEREG mice were crossed with scurfy-mutant (sf) mice to locate “would-be” 
Tregs in order to investigate the potential self-reactive TCRs on 
nonfunctional Tregs (Lahl et al. 2009).  DEREG mice have also been used to 
investigate the role of Tregs in malarial infection. Abel et al found that after 
ablation of Tregs in Plasmodium yoelii-infected DEREG mice, there was an 
increase in activate T cells and a decrease in parasitic burden (Abel et al. 
2012). The role of Tregs in allergic airways has also been investigated using 
DEREG mice. While the absence of Tregs does not aggravate allergic 
airway inflammation, it was found that Foxp3+ Tregs were required for 
Schistosoma mansoni-mediated suppression of allergic airway inflammation 
(Baru et al. 2012; Layland et al. 2013). Tregs have also been shown to 
suppress Th2 immunity during Cryptococcus neoformans infection. In a 
study performed by Schulze et al in 2014, it was observed that the number 
of Foxp3+ Tregs increased in BALB/C wild type mice after intranasal 
infection with C. neoformans and after Treg depletion in C. neoformans-
infected DEREG mice a stronger allergic inflammation response was 
detected along with increased mucus production, IgE production, fungal 
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burden and GATA-3+ Th2 cell presence (Schulze et al. 2014). These studies 
collectively demonstrate the versatility and durability of the DEREG model 
for the investigation of the varying roles of Tregs.  
 
1.6 PET/CT imaging 
PET/CT imaging has been used to diagnose tumours and metastatic 
lesions for a number of years. Each of the two components were developed 
separately; CT was developed in the early 1970s and PET was developed 
over a number of years between 1969 and 1985 (Gerd and Joel 2006; 
Hounsfield 1973). The dual technique was first developed in 1991 by 
Townsend and colleagues and became a working prototype with help from 
Ron Nutt in 1998 (Kinahan et al. 1998; Townsend et al. 1993). Clinical trials 
performed using the original prototype found that the combination of PET 
and CT allowed more precise identification of tumours, and furthermore was 
able to distinguish malignant lesions from surrounding tissue (Charron et al. 
2000; Kluetz et al. 2000; Meltzer et al. 2000).  
 
1.6.1 Principles of PET/CT imaging 
1.6.1.1 Computed Tomography 
PET/CT imaging combines two separate imaging techniques of 
Positron Emission Tomography (PET) and Computed Tomography (CT). In 
a CT, the subject is placed in the centre of a moving circular rig (gantry) 
consisting of an X-ray emitter and X-ray detector set at 180° to each other. 
With the subject in the middle, the X-ray emitter fires X-rays at the subject 
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creating an image on the detector (Figure 1.3). Different densities of tissues 
within the body absorb X-rays of different energies. As ionizing X-ray beams 
penetrate tissues of lower densities, such as internal organs, small fractions 
of the beams are absorbed while the remaining pass through the tissue to be 
received by the X-ray detector (Ohlerth and Scharf 2007). Conversely, in the 
more dense tissues of the body such as the skeleton, only the highest X-ray 
energies pass through to the detector. The attenuated beams that hit the 
detector after passing through the subject are compared to the original X-ray 
beam intensity giving an attenuation value in Hounsfield Units (HU) (Ohlerth 
and Scharf 2007). All attenuation values are normalized to that of water, 0 
HU, as X-rays can pass through water with very little attenuation. The 
attenuation values of body tissues are plotted relative to water on the HU 
scale ranging from -950 for the air space in the lungs to >250 for compact 
bone (Berry 2002; Kalendar 2005; Ohlerth and Scharf 2007; Wegener 1993). 
The values on the HU scale can be assigned to shades of grey in order to be 
visually displayed on a reconstructed CT image (Ohlerth and Scharf 2007).  
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Figure 1.3| Components of CT scanning. X-rays of varying energies are fired from an X-
ray tube towards a subject. As the X-rays pass through the subject, the X-rays are 
attenuated and are received by the X-ray detector. The gantry completes a 360 rotation of 
the subject taking X-ray images at a set number of projections. The data collected by the X-
ray detector throughout a full scan is then reconstructed to produce a CT image. 
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1.6.1.2 Positron Emission Tomography 
PET imaging uses scintillation crystals to detect β-decay of a 
radioisotope.  An unstable radioisotope, such as Fluorine18 (F18), decays to 
emit a positron that travels a distance between 1-2 mm before coming into 
contact with an electron. These particles annihilate each other, emitting two 
γ-rays along a straight angle to be detected by the scintillation crystals. The 
scintillation crystals are coupled to a photon multiplier tube that amplifies the 
signal in order for computer algorithms to calculate the point of annihilation 
(Figure 1.4) (Vaquero and Kinahan 2015). It is then possible to create a PET 
image detailing the positions of radioactivity in the subject being scanned. 
Using reconstruction and data analysis software, the PET image can be 
mapped onto the corresponding CT image, allowing identification of areas of 
increased radioactivity uptake. PET image data is initially read in Bq, which 
looks at the radioactive decay occurring across the subject. This can be 
converted into the Standardised Uptake Value (SUV), the calculation of 
which can be found in Chapter 2. This measurement takes into account the 
weight of the subject, the amount of radioactivity injected, the time at which 
the radioactivity was injected and the time of the scan. All other 
measurements used in clinical and preclinical scanning are derivatives of the 
SUV. 
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Figure 1.4| Components of PET scanning. A radioactive tracer undergoes β-decay to 
emit a positron. The positron travels until it comes into contact with an electron at which 
point annihilation occurs and photons are emitted as gamma rays along a straight angle. 
These photons are detected by a ring of scintillation crystals, which are coupled to photon 
multiplier tubes that amplifies the signal received. Computer algorithms use the activated 
scintillation crystals to determine the point of radioactive decay and reconstruct the PET 
image. 
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1.6.2 Clinical PET/CT imaging 
The main use of PET/CT imaging in clinical medicine uses a 
radioactive glucose analogue known as F18 Fluoro-deoxyglucose (FDG) to 
detect malignant tumours. This technique exploits the Warburg Principle 
which postulates that cancer cells experience increased glucose metabolism 
(Warburg 1956; Warburg et al. 1924). Therefore, in a PET/CT scan tumour 
cells exhibit an increase uptake of FDG compared to surrounding tissues, 
allowing identification of malignant lesions. F18 is also commonly used in 
clinical PET/CT imaging due to its short half-life of 109.8 minutes. This 
means that 24 hours after administration of FDG, radioactive decay is no 
longer detectable within the patient and therefore poses less of a risk to the 
patient. FDG PET/CT is commonly used to measure different cancers, such 
as prostate, lymphoma, bladder and breast cancers, (Fonager et al. 2016; 
Hu et al. 2015; Hulikal et al. 2015; ÖZtÜRk and Karapolat 2015) as well as 
the detection of metastases (Joshi et al. 2013; Lee et al. 2012; Nogami et al. 
2015). F18 has also been investigated for use as part of Fluoromethylcholine 
(FCH) for lymph node staging of prostate cancer, where limited success was 
observed when analysing lymph nodes but scans were able to detect bone 
metastases (Poulsen et al. 2012). Other radioisotopes have also been used 
in PET/CT scanning. Gallium68 (Ga68) labeled DOTATATE has been used to 
target somatostatin receptor (SSTR), specifically SSTR2, in PET/CT 
scanning in order to detect benign and malignant thyroid tumours, gastro-
entero-pancreatic neuroendocrine tumours, and bone metastases arising 
from pancreatic neuroendocrine tumours (Goel et al. 2014; Nockel et al. 
2016; Sadowski et al. 2016). 
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1.6.3 Preclinical PET/CT imaging 
While clinical PET/CT imaging focuses on detection of malignancies 
within patients, preclinical PET/CT can be used for much wider purposes. 
Lee et al. in 2013 used FDG PET/CT to measure the growth of a 
subcutaneous B16 melanoma xenograft in BALB/C nude mice and found it 
to be a more accurate measurement tool than calipers (Lee et al. 2013). 
FDG PET/CT has also been investigated for use in monitoring the 
progression of pulmonary infections in rabbits and in mice. This study was 
performed for up to 38 weeks in rabbits and up to 14 in mice and it was 
found that FDG PET/CT was useful for longitudinal investigation of 
pulmonary infections (Bagci et al. 2013). F18 has also been used for different 
tracers in order to monitor cell migrations, for example N-[2-
(diethylamino)ethyl]-18F-5-fluoropicolinamide or 18F P3BZA has been used to 
trace retinal pigment epithelial cells in the treatment of Parkinson’s disease 
in rats (Bu et al. 2014). Amino acid based radiotracers have been developed 
for preclinical PET/CT based on their experimental applications, for example 
F18 – fluorothymidine (FLT) can be used to monitor cell proliferation (Rendon 
et al. 2016) and F18 – fluoropropyl-L-glutamate (FSPG) can be used to 
visualise intracranial activity (Mittra et al. 2016). The ability to radiolabel 
monoclonal antibodies (mAbs) allows specific imaging of target tissues and 
thus the study of certain disease progression, such as prostate cancer and 
lymph node metastasis (Hall et al. 2012). 
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1.7 Hypothesis and Aims 
 The hypothesis of this project states that the recruitment of Tregs to 
the site of a primary tumour suppresses an anti-tumour immune response 
and results in the progression of tumour growth and metastasis. I 
hypothesise that the depletion of Tregs promotes an anti-tumour immune 
response and prevents/slows the progression of metastasis.  
 The aims of this PhD thesis were: 
1. To deplete Tregs in a genetically engineered mouse model in 
order to investigate the effect of Treg depletion on metastasis 
2. To develop an in vivo imaging technique in order to visualise 
the progression of metastasis over a period of time in a single 
mouse 
3. To investigate the immune microenvironment of primary 
tumours in order to determine its “association” with metastasis. 
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Chapter 2  
2 Materials and Methods 
2.1 Materials and Reagents 
2.1.1 Mice and Cell Lines 
The murine mammary carcinoma cell line 4T1 was obtained from ATCC 
(CRL-2539). 
DEREG mice were a kind gift from Prof Rick Maizels at The University of 
Edinburgh, originally developed by Prof Tim Sparwasser. 
Wild type (WT) female 6-8 week old Balb/c mice were obtained from Envigo 
Laboratories or Charles River Laboratories. 
  
2.1.2 Cell Culture 
Complete Roswell Park Memorial Institute Medium (RPMI) from Life 
Sciences supplemented with 2 mM L-Glutamine, 1 mM sodium pyruvate, 50 
μg/ml penicillin streptomycin, and 10% foetal calf serum all from Sigma 
Aldrich. 
0.05% Trypsin/EDTA, (1X), from Gibco Life Technologies. 
  
2.1.3 Induction of primary tumour growth 
29G insulin syringes from BD biosciences. 
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Diphtheria toxin diluted to a 5 μg/kg in Phosphate Buffered Saline (PBS) at 
pH7 from Gibco Life Technologies. 
Digital Calipers from Vet Tech. 
Ear Punch from Vet Tech. 
2.1.4 Surgical removal of the primary tumour 
100% isoflurane from Prima Healthcare. 
Metacam from Boehringer Ingelhein. 
Vetbond tissue glue from 3M Animal Care Products. 
Vicryl Rapide undyed braided absorbable suture 4-0 from Ethicon 
Woven Swabs from Premier 
Latex surgical gloves size 7 from Encore 
Hydrex antibacterial scrub from Ecolab 
Industrial Methylated Spirit 70% v/v from Ecolab 
Cotton buds from Universal 
Hair clippers from Contura 
Cardiff Aldasorber Scavenger cartridge from Shirley Aldred and Co. 
29G insulin syringes from BD Biosceinces 
  
2.1.5 PET/CT Scanning 
Fluoro-deoxy-glucose (FDG), containing the radioisotope Fluorine18 was 
made either on site by Cardiff University Positron Emission Tomography 
Imaging Suite (PETIC) or delivered by Alliance Medical Molecular Imaging 
LTD. 
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100% Isoflurane (as above) 
Omnipaque contrast agent from GE Healthcare containing 350mg Iodine/ml, 
injected neat 100 μl intraperitonealy (i.p) and 100 μl intravenously (i.v) 
Saline solution 0.9% w/v for intravenous infusion (B. Braun Melsungen AG) 
Mediso nanoScan® PET/CT scanner 
  
2.1.6 Clonogenic Assay 
Hanks Balanced Salt Solution (HBSS) from Sigma Aldrich  
Collagenase type IV from Sigma Aldrich, 50 mg dissolved in 2 of 1X HBSS 
Collagenase type I from Sigma Aldrich, 50 mg dissolved in 25 ml of 1XHBSS 
Hyaluronidase from Sigma Aldrich, 50 mg, plus Bovine Serum Albumin 
(BSA) from Sigma Aldrich, 25 mg, dissolved in 25 ml of 1X HBSS 
Iscove’s Modified Dulbecco’s Medium (IMDM), supplemented with 10% 
FCS, penicillin/streptomycin, and L-Glutamate as before 
60 mM 6-thioguanine in Sodium Hydroxide stock solution, diluted to 60 μM in 
10% IMDM media 
9 cm diameter Nuclon tissue culture plates, Thermo Fischer Scientific 
 
2.1.7 Immunofluorescence Staining 
OCT from CellPath 
99% Acetone (ice cold) from Fischer Scientific 
1X PBS (made in house) 
ImmEdgeTM PAP-pen from Vector Laboratories 
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Avidin Biotin blocking kit from Vector Laboratories 
2.5% Horse Serum from Vector Laboratories 
2.5% Goat Serum from Vector Laboratories 
1% Bovine Serum Albumin (Sigma Aldrich) in 1X PBS 
1% Paraformaldehyde, made from 8% stock solution (40 g of PFA [Fischer 
Scientific] in 500 ml distilled water) 
0.3M glycine from Sigma Aldrich 
Vectashield containing DAPI nuclear stain from Vector Laboratories 
  
2.1.8 Immunohistochemical Staining 
10% Formalin Solution from Sigma Aldrich 
Xylene 
70%, 90% and 100% Ethanol 
1X Tris-EDTA 
1X PBS 
ImmEdgeTM PAP-pen from Vector Laboratories  
3% H2O2/MeOH made from 30% w/v H2O2 from Fischer Scientific  
2.5% Horse Serum (as above) 
2.5% Goat Serum (as above) 
Rat Impress reagent from Vector Laboratories 
Mouse Impress Reagent from Vector Laboratories 
Rabbit Impress Reagent from Vector Laboratories 
Impress-DAB Chromogen from Vector Laboratories 
Impress-VIP Chromogen from Vector Laboratories 
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Vector-SG Chromogen from Vector Laboratories 
Haematoxylin from Sigma Aldrich 
Scotts Reagent from Thermo Shandon 
DPX from Fischer Scientific 
  
2.1.9 Flow Cytometry 
Microvette Lithium Heparin tubes from Starstedt 
Number 24 Scalpels from Swann Morton 
Red Blood Cell Lysis buffer X10 from Biolegend 
Complete RPMI (as above) 
96-well U-bottomed plates from Nuclon 
PBS (as above) 
FACs buffer made in house 
Fixation/permeabilisation buffer from eBiosciences 
BDCanto 
BDFortessa 
  
2.2 Methods 
2.2.1 Induction of 4T1 primary tumour 
2.2.1.1 4T1 cell culture 
4T1 tumour cells were defrosted in a water bath heated to 37°C for up 
to 90 seconds. Tumour cells were then transferred into a 15 ml Falcon tube 
containing 5 ml RMPI medium supplemented with 10% Foetal Calf Serum 
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(FCS) (R10). The cell suspension was then centrifuged at 1500 rpm for 5 
minutes, and the resulting cell pellet was re-suspended in a further 5 ml R10 
medium. Tumour cells were transferred into a T25 flask containing 10 ml 
R10 medium and were incubated at 37°C 5% CO2 for 24 hours. The 
following day, the supernatant was removed from the flask and cells were 
washed with 1x PBS to remove any excess media before the addition of 3 ml 
Trypsin EDTA. The cells were incubated with the Trypsin for 5-10 minutes, 
after which time 7 ml R10 medium was added to inactivate the enzyme. The 
resulting cell suspension was then centrifuged at 1500 rpm for 5 minutes 
and the cell pellet was re-suspended in 5 ml R10. One milliliter cell 
suspension was added to 30 ml fresh R10 in a T175 flask. Cells were split 
up to 3 times a week, and were left to grow for 3-6 passages before being 
injected into mice. 
 
2.2.1.2 4T1 injection and growth 
 On the day of injection, 4T1 cells were counted using a 
haemocytometer and made up to a concentration of 1x106/ml in PBS. Mice 
were scruffed and injected subcutaneously (s.c) with 1x105 4T1 cells (100 μl 
cell suspension) around the mammary fat pads of the lower left quadrant. At 
day 5, injection was accepted to be successful if a small tumour could be 
palpated. Tumours were measured from day 7 up to 3 times per week until 
the tumour was resected or until the mouse was sacrificed. Two 
perpendicular measurements were taken of the tumour from which the 
volume was calculated.   
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2.2.2 In Vivo Treg depletion 
 Diphtheria toxin (DTx) was injected i.p at a concentration of 5 μg/kg 
every other day. For assessing the effects of Treg depletion on the primary 
tumour, DTx was injected i.p from the day the primary tumour was palpable 
(day 5). For assessing the effects of Treg depletion on metastasis, mice 
were injected with DTx twice before surgery on day 0 (day -4 and day -2). 
 
2.2.3. Surgical removal of primary tumour 
Surgical instruments were all purchased from VetDirect under the 
instruction of the Named Veterinary Surgeon (NVS). Twenty-four hours 
before surgery, surgical instruments were sorted into bags (1 set per mouse) 
and autoclaved. Each surgical set contained the following instruments; 1x 
Strabismus Scissors (straight, blunt/blunt), 1x Mayo Scissors (straight, 
blunt/blunt), 1x Needle Holding Forceps, 1x Rat-toothed Forceps, 1x Iris 
Micro-dissecting Forceps, and 2-3x Bulldog Clamps. Each set was wrapped 
in EcoDrape, placed in an autoclave bag and sealed with autoclave tape. 
Paper towels were also placed in autoclave bags (3x towels per bag) for 
sterilization to dry hands with before donning surgical gloves. Before 
surgery, recovery cages containing Vet Bed were allowed to warm in a 
heating chamber set to 37°C. Tumours on each mouse were measured 
before induction of anaesthesia through isoflurane in an anaesthetic box. 
Once the mouse was unconscious, it was placed on a facemask supplied 
with O2 and isoflurane to maintain anaesthesia while the surgery area was 
prepped. The tumour and the surrounding area were shaved using Wella 
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hair clippers, and the area was swabbed 2x with Hibiscrub antibacterial 
wash and 2x with Surgical Spirit. Each mouse was also injected 
subcutaneously (s.c) with 0.5 mg/mL Metacam, a local anaesthetic to 
prevent pain upon waking. Preparation was performed by a surgical 
assistant while the surgeon scrubbed up following complete aseptic 
techniques. The autoclaved bag containing the surgical instruments was 
tipped out onto the surgical work area, along with a sterile operation cover in 
which a hole was cut to fit around the tumour. Using the rat toothed forceps, 
the subcutaneous tumour was lifted up and small incisions around the base 
of the tumour were made with the strabismus scissors. Any blood vessels 
connected to the tumour were clamped for up to 1 minute (or when no blood 
was seen) using the bulldog clamps. Fatty tissue connecting the tumour to 
the intraperitoneal muscle was teased apart using the blunt ends of the 
strabismus scissors and the tumour was removed and placed in either 
Neutral Buffered Formalin Solution (NBFS) or OCT. The wound was closed 
with horizontal mattress stitches using Vicryl rapide absorbable braided 
sutures, and the mouse was placed in the heated recovery chamber until 
consciousness was regained. Mice were checked on every hour for up to 4 
hours, then every 12 hours to assess the wellbeing of the animals and the 
strength of the sutures. Surgical instruments were soaked in warm water and 
washed with Hibiscrub, then were left to air dry.	
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2.2.4. PET/CT imaging 
2.2.4.1 Scanning 
Tumour bearing mice were transferred into the pre-clinical PETIC 
(PET/CT Imaging Centre) facility up to 3 days before scanning. On the day 
of scanning, the Mediso nanoScan PET/CT scanner was calibrated using 
Na22 point source of 1 MBq. Each mouse was warmed for at least 1 hour 
prior to scanning to deactivate brown fat activity at 37°C, and was injected 
i.p with 100 μl Omnipaque iodine contrast agent before induction of 
anaesthesia with isoflurane. Once unconsciousness had been achieved, 
mice were placed on a warmed mouse bed in the PET/CT scanner upon 
which O2 and isoflurane were supplied via a facemask. Fluorine18-
incorporated fluoro-deoxyglucose (FDG) (made in-house) was made up to 
10-14MBq in an insulin syringe, along with 100 μl Omnipaque, and was then 
injected i.v via the tail vein. Fifteen minutes after the i.p injection of 
Omnipaque, a whole body, semicircular CT scan was performed at 70 KVp 
x-ray energy, with 720 projections and a 300 ms exposure time. Thirty 
minutes after the i.v injection of FDG and Omnipaque, a 60-minute static 
PET scan with respiratory gating was performed. The breathing rate of each 
mouse was recorded using a breathing pad placed underneath the animal, 
allowing a respiratory trace to be calculated. Trigger delays were set using 
MC2B software on the respiratory trace, allowing the NuclineTM program to 
exclude decay data observed within a complete respiratory cycle (inhalation 
and exhalation). Upon completion of the PET scan, the mouse was removed 
from the bed and placed in the heated recovery chamber until waking. All 
scanned mice were kept in a scantainer for 24 hours after scanning until 
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complete radioactive decay of the FDG, when mice were returned to the 
normal housing rooms in the PETIC facility.  
 
2.2.4.2 Analysis of PET/CT imaging 
 Scans performed on the old Gamma Medica Triumph II 
PET/CT/SPECT scanner were co-registered on VIVID software (Gamma 
Media Ideas) and analysed on PMod3.3 software. Later scans acquired on 
the Mediso nanoScan PET/CT scanner were automatically co-registered 
upon scan reconstruction on Nucline software (Mediso). Scans were then 
analysed on VivoquantTM software (Invicro). Regions of Interest (ROIs) were 
drawn in 3D around organs thought to be harboring metastatic 4T1 cells 
using different spline and contour tools. For each ROI, the maximum 
Standardised Uptake Value (SUVmax), Hot Pixel Average (HPA) and Total 
Lesion Glycolysis (TLG) were calculated along the parameters detailed in 
table 2.1.  
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Table 2.1| Parameters used to analyse ROIs in PET/CT scans 
Parameter Calculation Units of measurement 
 
 
SUV 
 
Image derived radioactivity 
concentration at t=0 
(Injected dose at t=0/body 
weight) 
 
 
 
g/ml 
 
 
SUVmax 
 
The pixel with the highest 
value of SUV in a given 
area (ROI) 
 
 
 
g/ml 
 
 
Hot Pixel Average 
 
The mean of the 5 pixels 
with the highest SUV in a 
given area (ROI) 
 
 
g/ml 
 
 
Total Lesion 
Glycolysis 
 
 
Average SUV of the whole 
ROI X ROI volume 
 
 
g/ml*cm3 
 
 
 
 
 
	 87	
2.2.5. Clonogenic assay 
Organs suspected to harbor metastatic 4T1 cells in mice (brain, 
lungs, liver and draining LN) were harvested after animals were culled by 
CO2. Organs were immediately submerged in HBSS and transported on ice 
into a class II Hepa-filtered hood. Each organ (except the draining LN) was 
removed from the HBSS and transferred into a 6-well tissue culture plate 
using a Pasteur pipette, and mashed using the end of a 2 ml syringe. The 
mashed organs were then transferred into a 15 ml Falcon tube containing 
2.5 ml of a specific collagenase cocktail. Brains and lungs were added to a 
collagenase IV cocktail and livers were added to a collagenase I cocktail 
along with 2.5 ml of Hyaluronidase. Each well containing a mashed organ 
was washed with 2.5 ml of HBSS twice and added to the corresponding 15 
ml Falcon. Brains were incubated in a shaking water bath at 37°C for 120 
mins, lungs were incubated on a rotating arm at 4°C for 75 mins, and livers 
were incubated in a shaking water bath at 37°C for 20-30 mins. After the 
incubation period, each sample was passed through a 70 μm nylon cell 
strainer washed with HBSS before centrifugation at 1500 rpm for 5 mins at 
room temperature. The resulting supernatant was discarded and the cell 
pellet was washed 2-3 times depending on its size. Each pellet was then re-
suspended in 10 ml of 6-TG media, then plated on a 9 cm tissue culture 
plate and left to incubate for 14 days at 37°C and 5% CO2. Draining LNs 
were removed from the HBSS like the other organs, but were immediately 
mashed through a 70 μm nylon cell strainer directly into 10 ml of 6-TG media 
in a 9 cm tissue culture plate, and were then left to incubate in accordance 
with the other organs. After the incubation period, the remaining media was 
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removed from each plate and any resulting cell colonies were fixed to the 
plate with 5 ml of methanol for 5 mins. Each plate was then washed with 
sterile water, stained with 5 ml methylene blue dye for 5 mins before a final 
wash with sterile water. The resulting blue colonies were then counted once 
the plate was completely dry, with each colony representing one metastatic 
cell. 	
2.2.6. Immunofluorescence 
2.2.6.1 Staining frozen sections 
Organs expected to harbor 4T1 metastatic cells were placed in OCT 
(optimum cutting temperature compound), frozen on dry ice and then kept at 
-80°C until required. Each sample was cut at 5 μm sections on a Cryostat 
and placed on a frosted glass microscope slide before being left to air-dry for 
1-24 hours. Slides were fixed in ice-cold acetone for 10 minutes before being 
washed 3 x 3 minutes in 1x PBS. To prevent non-specific binding, a blocking 
step was performed in which either 2.5% Normal Horse Serum or 2.5% 
Normal Goat Serum was incubated with each section for 30 minutes at room 
temperature. Primary antibodies were made up to the desired concentrations 
in 1% BSA/PBS, and were incubated with the sections overnight at 4°C. A 
list of primary antibodies used is detailed in table 2.2. The following morning, 
slides were washed 3x 3 minutes in 1x PBS. Secondary antibodies were 
made up to the appropriate concentrations in the same way as the primary 
antibodies and then centrifuged at 13 000 rpm for 10 minutes at 4°C in order 
to remove aggregates. Slides were then incubated with the secondary 
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antibodies for 30-60 minutes at room temperature. Slides then underwent 3 
washes in 1x PBS at 3 minutes each before being fixed in 4% PFA 
(paraformaldehyde) for 10 minutes at room temperature. Any excess PFA 
was then quenched by incubation with 0.3Molar glycine (in PBS) for a further 
10 minutes at room temperature. Slides were washed for a final 3 times in 1x 
PBS as before being mounted in Vectashield containing DAPI (4, 6-
diamidino-2-phenylindole). The coverslips were then sealed to each slide 
with clear nail varnish to prevent movement of the coverslip and the sample 
sections underneath.  
 
2.2.6.2 Immune cell infiltration quantification on frozen sections 
 Frozen tumour sections were stained with fluorescent conjugated 
antibodies targeting CD8+ CD3+, CD4+CD3+, and Foxp3+CD3+ cells. 
Sections were viewed on a fluorescence microscope and positive cells were 
counted by eye per high power field of view. For each section, 10 high power 
fields of view were enumerated and from this an average was calculated.  
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Table 2.2| Antibodies used in Immunohistochemistry and 
Immunofluorescence staining 
Target 
Antigen 
Clone Conjugate Isotype Supplier Final 
concentration 
(μg/ml) 
Primary antibodies 
CD3 - Purified Rabbit 
Poly 
Dako 0.6 
Foxp3 FJK-165 Purified Rat 
IgG2a 
eBioscience 1 
CD4 RM4-5 Purified Rat 
IgG2a 
Biolegend 1 
CD8 53-6.7 Purified Rat 
IgG2a 
eBioscience 1 
B220 RA3-6B2 Purified Rat 
IgG2a 
Biolegend 1 
Secondary antibodies 
Rat IgG - Alexa Fluor 
488 
Donkey 
IgG 
Life 
Technologies 
1 
Rabbit Ig - Alexa Fluor 
568 
- Life 
Technologies 
1 
Streptavidin - FITC - Biolegend 1 
Rat IgM  Alexa Fluor 
594 
- Life 
Technologies 
1 
Rat IgG - Alexa Fluor 
555 
- Life 
Technologies 
1 
Isotype control antibodies 
Rat IgG2a RTK2758 Purified - Biolegend See primary 
Rat IgM RTK2118 Purified - Biolegend See primary 
Rat IgM RTK2118 Biotinylated - Biolegend See primary  
Rabbit Ig  Purified  AbCam See primary 
Mouse 
IgG1 
 Purified  AbCam See primary 
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2.2.7. Immunohistochemistry 
2.2.7.1 Staining paraffin embedded sections 
Tumours, lungs and draining LNs taken from DEREG mice were 
placed in bijoux tubes containing 5 ml 10% formalin solution for up to 1 
month before being embedded in paraffin. Each sample was cut into 5 μm-
thick sections on a Leica Microtome and mounted onto a glass slide, and 
any excess wax was melted off at 60°C. Slides were then completely de-
waxed through 3 x 5 minute washes with xylene and then rehydrated in 
descending alcohol washes (100% MeOH, 90% MeOH, 90% MeOH, and 
70% MeOH) at 3 minutes each. Antigen retrieval was performed by 
microwaving slides in pre-warmed 10 mmol/L Tris, 1 mmol/l EDTA at pH9 for 
8 minutes, after which time slides were left to cool for 30 minutes before 
being equilibrated in 1x PBS. Any endogenous peroxidase activity was 
quenched using 3% H2O2/MeOH for 5 minutes at room temperature before 
slides were washed 3 x 3 minutes in 1x PBS. To prevent non-specific 
binding, slides were incubated with 2.5% Normal Horse Serum for up to 30 
minutes at room temperature. Specific primary antibody solutions were 
made up to the suitable concentration in 1% BSA/PBS solution, and were 
incubated with each slide overnight at 4°C. A list of antibodies used can be 
found in table 2.2. The following day, slides were washed 3 x 3 minutes in 1x 
PBS. Primary antibodies were then detected using an ImmPRESS Horse 
Radish Peroxidase polymer detection kit during a 30-minute incubation with 
each slide, after which time slides were washed a further 3x 3 min in 1x 
PBS. The detected antibodies were then detected using Impact DAB (3, 3’-
diaminobenzidine; brown), Impact VIP (Very Intense Purple; purple) or 
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Vector SG (grey). Slides were rinsed twice in dH2O and then counterstained 
in Haematoxylin for up to 1 minute. Once slides had been rinsed with 
running tap water, they were then dehydrated in ascending alcohols (70% 
MeOH, 90% MeOH, 90% MeOH, 100% MeOH) for 3 minutes each and then 
3 x 5 minute washes with xylene. A coverslip was then mounted onto each 
slide using DPX (distyrene, a plasticiser, and xylene) and slides were left for 
up to 1 hour at 60°C for the DPX to set. Sections were then imaged on Zeiss 
Axio Observer Z1 or scanned on Zeiss Axio Scan.Z1 slide scanner. 
 
2.2.7.2 Quantification of T cell infiltration in paraffin sections 
 Paraffin embedded tumour sections were stained with antibodies 
targeting CD8+, Foxp3+, and CD3+ cells. Slides were scanned on a Zeiss 
Axio Scan.Z1 slide scanner and analysed using Zen software. A grid was 
placed over each section and 10 squares were enumerated and an average 
was calculated.  
 
2.2.8 Flow Cytometry 
2.2.8.1 Phenotyping DEREG mice 
 Mice were ear coded when they reached 4 weeks old, and were 
subsequently tail-tipped under local anaesthetic. Blood from the tail-tip was 
collected in a Microvette lithium heparin-containing tube in order to prevent 
clotting, and tubes were stored on ice for up to 45 minutes. Each blood 
sample was then stained with APC-Cy 780 conjugated anti-mouse CD4 
antibody (eBioscience) and was left to incubate for 1 hour on ice. Samples 
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were then re-suspended in 200 μl 1x Red Blood Cell (RBC) lysis buffer 
(made from 10x stock solution) and run on a BD FACsCanto flow cytometry 
machine. Up to 200 000 events were captured, and DEREG positive mice 
were identified as having GFP+ (FITC) CD4+ cells. The gating strategy is 
shown in figure 2.1. 
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Figure 2.1| Gating strategy for determining the phenotype of DEREG litters. 
Plots were initially gated on GFP versus side scatter area (SSC-A) and then on CD4 versus 
SSC-A. From the CD4+ population, a new plot was created as CD4 versus GFP and a gate 
was drawn around CD4+GFP+ population. (A) Shows the gating strategy for a DEREG 
negative mouse. (B) Shows the gating strategy for a DEREG positive mouse.	
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2.2.8.2 Looking for Tregs in DEREG mice 
 DEREG and WT Balb/c mice were sacrificed and their spleens and 
LNs were harvested. In a multiwell plate, spleens and LNs were 
homogenised using the base of a syringe plunger. The homogenised tissues 
were then re-suspended in complete RPMI medium and passed through a 
70 μm cell strainer. Cell suspension were then centrifuged 1500 rpm for 5 
minutes, the supernatant discarded, and the resulting cell pellet was re-
suspended in complete RPMI and washed through centrifugation as before. 
Red blood cells from the homogenised spleens were lysed using RBC lysis 
buffer, 5 ml of which were added to each cell suspension for 90 seconds. 
After this time, 20 ml of RMPI was added to stop the reaction and cells were 
subsequently centrifuged at 1500 rpm for 5 minutes and the supernatant 
was discarded.  
 The single cell suspensions were plated in a 96-well u-bottomed plate 
at a density of 5x105 – 1x106 cells per well. Cells were washed twice using 
PBS and were subsequently stained for dead cells using a fixable dead cell 
staining kit (LIVE/DEAD Aqua by INVITROGEN). LIVE/DEAD was diluted 
1/10 in PBS and 3 μl were added to each cell-containing well and the plate 
was incubated in the dark at room temperature for 15 minutes. Cells were 
then washed twice in PBS through centrifugation at 1500 rpm for 3 minutes 
before Fc receptors were blocked using diluted anti-CD16/32 antibody. 
Plates were left to incubate in the dark for 10 minutes at 4°C, after which 
time cells were washed a further 2 times in FACS buffer. Antibody master-
mixes of surface stains were made up to the desired concentrations and 
were added at 25-50 μl per well and left to incubate in the dark for up to an 
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hour at 4°C. A list of surface antibodies used can be found in table 2.4. After 
incubation, cells were then permeabilised using fixation/permeabilisation 
buffer (eBioscience) overnight and subsequently stained with intracellular 
antibodies as before. Flow cytometric data was analysed using FlowJo 
software, the gating strategy can be found in figure 2.2.   
 
Table 2.3| Antibodies used for flow cytometry staining 
Target 
Antigen 
Clone Conjugate Supplier Stock 
concentration 
Final 
concentration 
(μg/ml) 
Surface antibodies 
CD4 RM4-5 APC-Cy-
780 
eBioscience 0.2 mg/ml 2  
CD25 PC61 PE BD 
Pharmingen 
0.2 mg/ml 4  
B220 RA3-6B2 PE BD 
Pharmingen 
0.2 mg/ml 4  
CD8 53-6.7 PECy7 eBioscience 0.2 mg/ml 4  
CD3 17A2 APC-Cy-
780 
eBioscience 0.2 mg/ml 2  
Intracellular antibodies 
Foxp3 FJK-16s PECy7 eBioscience 0.2 mg/ml 4 
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Figure 2.2| Gating strategy for Treg analysis. Initially, cells were plotted as forward 
scatter area (FSC-A) versus forward scatter height (FSC-H) in order to gate on single cells 
and exclude doublet cells. From this population, cells were plotted as FSC-A versus SSC-A 
and a gate was drawn around the lymphocyte population. From the lymphocyte population, 
cells were plotted as AmCyan (LIVE/DEAD) versus SSC-A to select living cells. The living 
cell population could then be plotted as Foxp3 versus CD4, GFP versus CD4 and GFP 
versus Foxp3. 
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2.2.9 Statistical Analysis 
 All statistical analysis was performed on GraphPad PrismTM software. 
Details of each statistical test performed are presented in Figure legends.   
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Chapter Three 
3 Results: Optimising preclinical PET/CT imaging to monitor 
progression of 4T1 metastasis in mice. 
3.1 Introduction 
There are two different imaging components that make up PET/CT; 
Positron Emission Tomography (PET) and Computed Tomography (CT). CT 
uses X-rays to build up a 3D image of a scanned subject, while PET uses 
scintillation crystals to detect annihilation positrons emitted from a decaying 
radioactive isotope. In combination, these two components create an image 
detailing different structures and tissues within the human body. 
The most common use of PET/CT exploits the Warburg effect, in 
which tumour cells have increased glycolysis in comparison to surrounding 
tissues (Warburg 1956). In medicine, the radioactive glucose analogue 
fluoro-deoxyglucose (FDG), containing the radioisotope Fluorine18, is 
injected intravenously into patients and is taken up by highly metabolically 
active tissues such as tumours. Scintillation crystals in the PET scanner 
detect the decay of F18 generating a map of radioactivity that, through the 
use of computer algorithms, can be plotted onto the CT of the patient. This 
allows identification of malignant lesions without the use of invasive surgery.  
 The use of PET/CT as a combined imaging technique was conceived 
in 1991 by Townsend and colleagues, and was further developed into a 
working prototype in 1998 with help from Ron Nutt (Kinahan et al. 1998; 
Townsend et al. 1993). Combined PET/CT was created in order to obtain 
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clinically relevant PET and CT images in a single session, and using the 
original prototype, a number of clinical trials were conducted involving the 
scanning of cancer patients (Charron et al. 2000; Kluetz et al. 2000; Meltzer 
et al. 2000). In the case of head and neck cancers, it was found that PET/CT 
was able to distinguish between malignant lesions and the surrounding 
muscle tissue (Kluetz et al. 2000), and the combination of PET and CT 
allowed for more precise localization of tumours for further radiotherapy 
(Charron et al. 2000; Meltzer et al. 2000). 
The use of PET/CT in preclinical models has been described for a 
number of different disease models, such as certain tumours, brain 
abnormalities and respiratory infections, as well as imaging cell recruitment 
and changes in metabolism (Chapter 1) (Bagci et al. 2013; Bu et al. 2014; 
Lee et al. 2013; Mittra et al. 2016; Park et al. 2015; Rendon et al. 2016). 
Figure 3.1 details the process of CT and PET imaging in a preclinical 
scanner. 
It has been shown that solid tumours can be imaged over time in mice 
using FDG PET/CT. While FDG PET/CT imaging in humans has a high rate 
of success when diagnosing metastasis, in mice this has not been quantified 
(Charron et al. 2000; Kluetz et al. 2000; Meltzer et al. 2000). I aimed to 
successfully optimize both PET and CT imaging on the Gamma Medica 
Triumph II PET/CT/SPECT scanner and subsequently, following 
refurbishment and updating of the imaging facility, the Mediso nanoScan 
PET/CT scanner, for assessing the progression of metastatic disease in 
mice. Specifically, metastatic disease was assessed in DEREG mice 
injected with 4T1 murine mammary carcinoma. Mice were injected 
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subcutaneously close to the mammary fat pad with 1x105 4T1 cells and 
tumours were left to grow for 14 days before being surgically resected. After 
tumour removal, the mice undergo a series of PET/CT scans in order to 
monitor metastasis progression. This chapter describes optimisation of both 
Gamma Medica and Medico scanners as well as use of the relevant 
acquisition and data analysis software. 
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Figure 3.1| Diagrams detailing the process of CT and PET scanning. (A) A mouse is 
placed on the animal bed in the centre of the gantry. X-rays are emitted from the x-ray tube 
at the mouse and are detected on the other side of the gantry by the x-ray detector. The 
gantry rotates 360 degrees emitting x-rays towards the mouse until a full rotation has been 
completed. (B) The mouse sits in the centre of the scintillation crystals while the radioactive 
isotope decays emitting gamma rays at 180° to one another. Gamma rays are detected by 
the scintillation crystals, which cause emission of photons that are amplified by a photon 
multiplier tube. The point at which photons are emitted from the scintillation crystals is 
analysed by a computer, which calculates the point the original decay occurred 
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3.2 Results: Altering different parameters of CT scans allows 
definition of soft tissues 
 The ability to differentiate between the soft tissues in a CT scan is 
vital for enabling Regions Of Interest (ROIs) to be drawn around tissues 
predicted to harbor metastatic cells. There are many different parameters of 
CT scans that can be optimized in order to increase the resolution of 
different areas of the scanned subject such as the skeleton, cardiovascular 
architecture or abdominal organs. An overview of the CT parameters 
optimized can be found in Table 3.1. 
CT optimisations were performed on both the Gamma Medica 
Triumph II PET/CT/SPECT scanner and the Mediso nanoScan PET/CT 
scanners. When comparing the scans from Triumph II scanner to the 
nanoScan scanner, it was observed that even without the use of a contrast 
agent, the contrast of the CTs obtained with nanoScan showed definition of 
tissue not visible using the Triumph II (Figure 3.2). Thus, CT parameters 
were optimized using the Mediso nanoScan unless stated otherwise. 
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Table 3.4| CT parameters for optimisation on the Mediso nanoScan. 
CT Parameter Options Available Overall Effect on CT 
 
X-ray energy 
 
 
35KVp, 50KVp, 70KVp 
 
Soft tissue definition 
and contrast 
 
Binning 
 
1:1, 1:4, 1:16 
 
Final resolution of CT 
 
Projection number 
 
360, 480, 720 
 
Final resolution of CT 
 
Contrast agent 
 
Iohexol, AurovistTM 
 
Soft tissue definition 
and contrast 
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Figure 3.2| The Mediso nanoScan PET/CT scanner produces clearer, higher 
resolution CT images with enhanced soft tissue contrast than the Gamma Medica 
Triumph II PET/CT/SPECT scanner. (A) Indicates the orientation of the scanned mice in 
(B). (B) Shows two mice scanned under the optimized protocol for the Gamma Medica 
Triumph II (i) and the Mediso nanoScan (ii). The white box highlights the increased 
resolution of CT acquired on the nanoScan PET/CT scanner. 	 	
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3.2.1 Optimisation of X-ray energy 
The strength of X-rays used in the acquisition of a CT scan 
determines which tissues are most visible in the final image. X-rays of 
different energies (measured in KVp, where KVp is the peak kilovoltage 
applied across the X-ray tube) are differentially absorbed by tissues within 
the body. Low X-ray energy (35 KVp) can be absorbed by soft tissues such 
as the internal organs but cannot penetrate bone, whereas high X-ray 
energy (70 KVp) penetrates most tissues. Different X-ray energies were 
tested in order to ascertain the optimum energy for soft tissue definition. On 
the Gamma Medica Triumph II, a single female BALB/c mouse was 
anaesthetised, placed on a warmed rat bed in the PET/CT scanner and 
subjected to 3 CT scans at X-ray energies: 60KVp, 50KVp and 45KVp. No 
difference was observed in soft tissue definition between the different X-ray 
energies thus the default setting of 60KVp was used for all subsequent 
scans performed using the Gamma Medica Triumph II. 
X-ray energies of 35KVp, 50KVp and 70KVp were subsequently 
tested for the Mediso nanoScan PET/CT scanner. Whilst all X-ray energies 
were absorbed by the soft tissues of the mouse, the lower X-ray energies of 
35KVp and 50KVp were not absorbed by bone and instead were subject to 
beam hardening, creating a “glowing” effect around the bone appearing as 
streaks on the CT image (Figure 3.3). Artifacts, such as these arising from 
the ribcage can obscure the air space within the lungs, hindering accurate 
delineation of the lung. An X-ray energy of 70KVp allowed absorption of X-
rays by the bone as well as the soft tissues, reducing such artifacts (Figure 
3.3). Therefore, 70KVp X-ray energy was used for all subsequent CT scans. 
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3.2.2 Optimising the projection number 
The number of projections refers to the number of image slices taken 
in a full 360 rotation of the gantry. For example, a scan performed with 360 
projections means an image is taken at every degree the gantry is turned. 
Increasing the number of projections increases the final resolution of the 
images obtained. Since the Mediso nanoScan allows projection number to 
be set at 360, 480 or 720, 720 projections were selected to enable clear 
identification of small structures within the chest cavity. 
  
	 108	
 
 
Figure 3.3| Changes in X-ray energy voltages highlight different aspects of a scanned 
subject. Resulting CT scans of the same naïve mouse scanned at different X-ray energy 
voltages for the same period of time on the Mediso nanoScan scanner. The mouse was 
anaesthetised and placed on the animal bed in the scanner and subsequently underwent 3 
consecutive 3-minute scans at the voltages indicated above. On each of the 3 scans, white 
arrows indicate the beam hardening effect seen at lower voltages, where a “glowing” effect 
is seen around bone. The brightness of each image has been artificially increased by 26% 
using Microsoft PowerPointTM in order to fully reveal the extent of artifacts. 
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3.2.3 Optimising the Binning process. 
Using the NuclineTM software, it is also possible to change the 
resolution of the CT image created by altering the binning process. Binning 
is the process of assigning pixels picked up by the X-ray detector to pixels in 
the projections that make up the final reconstructed CT image, where 
acquisition of a CT image at a 1:1 binning means that for every pixel 
detected by the X-ray detector, 1 pixel is finally created in the reconstructed 
CT image (described in Figure 3.4). Images collected at a 1:1 binning are 
most likely to produce the best resolution CT images but also a higher signal 
to noise ratio. In addition, collection of data at a 1:1 binning requires large 
amounts of computer space and has a longer CT reconstruction time, which 
restricts the throughput of mice in an experiment. To explore whether higher 
binning could be used, a CT scan of a naïve BALB/c mouse, performed 
using the Mediso nanoScan, was reconstructed at a 1:4 binning and 1:1 
binning (Figure 3.5).  While more background noise was observed with a 1:1 
binning, definition of some structures within the abdomen and the chest 
cavity were clearly lost as a result of the 1:4 binning, as indicated by the 
white arrows at (i) in the chest cavity and (ii) in the abdominal cavity.  
Consequently, all CT scans were acquired at a 1:1 binning. 
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Figure 3.4| A diagram describing the process of binning during CT acquisition. During 
the acquisition of a CT scan, each pixel or group of pixels can be assigned to a single pixel 
in the reconstructed image. The lower the binning the better the resolution of the final 
reconstructed CT scans.		 
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Figure 3.5| The binning process enhances the resolution of the final reconstructed CT 
image. A CT image acquired at 1:1 binning and subsequently reconstructed at 1:1 binning 
and 1:4 binning. White arrows indicate the difference in contrast between the heart and 
lungs (i) and some soft tissues in the abdominal cavity (ii). Each image has been artificially 
brightened by 26% using Microsoft PowerPointTM to fully highlight the contrast observed in 
binning techniques. 
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3.2.4 Optimising the use of contrast agents for CT 
 In order to distinguish between the soft tissues, it is standard clinical 
practice to use a nonionic iodine contrast agent called Iohexol (trade name 
Omnipaque) (Cacayorin et al. 1983). In patients, Iohexol is injected 
intravenously to highlight the vasculature or taken orally to highlight gastro-
intestinal structures (Wiklund et al. 1994). In the case of preclinical studies, a 
contrast agent named AuroVistTM has been highlighted as a useful tool to 
highlight the vascular system which in the case of the study described here, 
could be particularly useful for increasing the contrast between the heart and 
the lungs in the chest cavity (Darin et al. 2013). Thus, both contrast agents 
were compared. 
 
3.2.4.1 Iohexol 
 In humans, fat surrounds the internal organs offering “natural” 
contrast between soft tissues. This is not the case in mice, therefore 
injection of contrast agent both intraperitonealy and intravenously was 
deemed necessary to differentiate between the soft tissues in the abdominal 
cavity and the chest cavity.  Female mice were untreated or injected i.p with 
100 μl Iohexol before induction of anaesthesia and 100 μl Iohexol i.v 
thereafter. Fifteen minutes later, mice underwent a CT scan using the 
previously described protocol. By comparing the two CT scans with and 
without Iohexol, sharper contrast between the lungs and the heart [Figure 
3.6 (B)(i)], increased detailing of the heart [Figure 3.6 (B)(ii)] and greater soft 
tissue definition within the abdominal cavity [Figure 3.6 (B)(iv)] was observed 
in the Iohexol treated mice. Moreover, use of Iohexol enabled differentiation 
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of the diaphragm and liver and more detailed image of the peritoneal cavity 
[Figure 3.6 (B)(iii)]. No artifacts were observed as a result of Iohexol use. 
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 Figure 3.6| Using the iodine contrast agent Iohexol aids differentiation of soft 
tissues. CT scans of mice taken on Mediso nanoscan PET/CT scanner. Each mouse was 
scanned at 70 KVp for 3 minutes (A) without and (B) with Iohexol contrast agent. The 
notation (i) indicates the chest cavity, where an increased contrast between the air space 
and the cardiovascular system is observed in mouse administered with Iohexol. (ii) Indicates 
the detail of the heart and (iii) shows Iohexol in the contrast achieved within the abdomen 
after i.p administration. The brightness of each image has been artificially increased by 26% 
using Microsoft PowerPointTM in order to fully demonstrate the differences seen in CT 
images after the use of contrast agent. 
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3.2.4.2 Aurovist 
 Use of the gold-nanoparticle contrast agent AuroVistTM, described for 
use as a vascular contrast agent (Darin et al. 2013; Hainfeld et al. 2006), 
was also explored and compared to Iohexol.  
 Three age matched littermate mice were warmed for >1 hour at 37°C 
before being anaesthetised and injected i.v with approximately 10MBq of 
FDG plus 100 μl of AuroVistTM at a concentration of 100 mg/ml. A CT scan 
was then performed using the previously described protocol; followed 15 
mins later with a PET scan.  
 The scans in Figure 3.7 show that AurovistTM increased the contrast 
between the heart and the lungs in comparison to no contrast agent, but the 
level of contrast was not superior to Iohexol. As Iohexol was freely obtained 
in-house, it became the contrast agent of choice for all subsequent scans. 	
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Figure 3.7| Gold nanoparticle contrast agent Aurovist highlights vasculature in mice. 
(A) shows CT scan of a mouse injected i.v with Aurovist in the orientation shown in (B). (C) 
Shows CT scans of a mouse with no contrast administered (i) and with Iohexol contrast 
agent (ii) in the orientation shown in (D). The white arrows show the difference in contrast at 
the heart (number 1) and the abdomen (number 2). 	 	
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3.3 Results: Optimisation of PET imaging shows areas of high 
metabolic activity.  
 Optimal PET/CT imaging of small animals requires warming of the 
animal to body temperature before induction of anaesthesia and injection of 
FDG (Fueger et al. 2006). Mice have a higher proportion of brown fat than 
humans in order to maintain body heat. This is important as mice have a 
small surface area to volume ratio and can lose body heat quickly. The main 
areas rich in brown fat lie around the neck and shoulder blades, and when 
active these areas have a large glycolytic output (Hu et al. 2010; Wang et al. 
2012). Consequently, on a FDG PET scan areas of brown fat appear highly 
radioactive, and can obscure changes in metabolic activity in other organs. 
By warming mice to their natural body temperature, brown fat begins to 
deactivate and therefore does not uptake FDG at the same rate as more 
metabolically active organs (Fueger et al. 2006; Wang et al. 2012). This is 
illustrated in Figure 3.8.   
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Figure 3.8| Warming mice to their natural body temperature prevents the uptake of 
FDG by brown fat. (A) Indicated the orientation of the mice in the scans in (B) and (C).  (B) 
Shows a scan taken on the Gamma Medica Triumph II of a mouse that has not been 
warmed before scanning. A white oval and arrow highlights the area of brown fat around the 
neck and shoulder blades. (C) Shows a scan taken on the Mediso nanoScan of a mouse 
warmed for >1 hour before scanning. The white arrow and oval indicates the area of brown 
fat. 
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3.3.1 Optimisation of FDG administration 
To identify the most appropriate technique for administering FDG, i.v 
versus i.p injection was compared. Mice were warmed for at least 1 hour 
before being anaesthetised and injected i.p with approximately 10MBq of 
FDG and placed on a warmed mouse bed ready for scanning on the Gamma 
Medica Triumph II scanner. A CT scan was performed first as previously 
described, followed by a 15 minute PET scan 1 hour after the initial i.p 
injection in order to allow sufficient uptake of FDG by tissues. An example of 
a reconstructed PET/CT scan after an i.p injection of FDG is shown in Figure 
3.9. The reconstructed image shows a large area of radioactivity around the 
site of injection [Figure 3.9 (A) in pink and (B) in green), which was almost 
indistinguishable from surrounding organs such as the bladder. A second 
method of FDG administration was then tested, where mice were warmed, 
anaesthetised and subsequently injected i.v with approximately 10MBq FDG 
before undergoing CT and PET scan as before. As shown in Figure 3.10, no 
injection site artifacts were observed and therefore, FDG was administered 
via the tail vein for all future scans. 
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Figure 3.9| FDG injected i.p leaves an area of high radioactivity on PET/CT images. (A) 
A 2D PET/CT image taken using Gamma Medica Triumph II of a mouse injected i.p with 10 
MBq of FDG, with the range of radioactivity seen in the PET scan given in Bq/ml on the 
scale bar below. ROIs have been drawn around the heart in red, the bladder in yellow, and 
the injection site in blue. The pink ROI indicates the size of the area of radioactivity from 
both the bladder and the injection site. (B) A 3D image created using Pmod3.3 software of 
the mouse with ROIs from (A). The area in green indicates the pink ROI in (A). 
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Figure 3.10| Administration of FDG via the tail vein gives a cleaner PET/CT scan than 
i.p administration. A 2D PET/CT image taken on the Gamma Medica Triumph II (A) and a 
3D image created using Pmod (B) of a mouse injected i.v with approximately 10 MBq of 
FDG. The range of radioactivity seen in (A) is given in Bq/ml in the scale bar below the 
scan. ROIs are drawn around the bladder in yellow in (A) and solid yellow in (B), and the 
heart in red (A) and solid red (B). 
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3.3.2 Optimisation of respiratory gating 
On the Mediso nanoScan PET/CT scanner, respiratory gating can be 
used to prevent the movement of the chest from obscuring the finer 
structures within the chest cavity. A breathing pad is placed under the 
mouse on the scanning bed that monitors the breathing rate in breaths per 
minute (bpm) and creates a trace as shown in Figure 3.11. The MC2B 
software gates around a complete breathing cycle (inhalation and 
exhalation) indicated by the white box in Figure 3.11 (i) and excludes data 
collected during this time [between points (ii) and (iii)] from the final 
reconstructed PET image, requiring scans to be run for longer. To enable 
use of respiratory gating, FDG uptake time was reduced to 30 minutes and 
PET scan time was increased to 60 minutes. A comparison of a respiratory-
gated scan and a non-gated scan of the same mouse is shown in Figure 
3.12. A reduction in the diameter of radioactivity around the heart was 
observed after respiratory gating, as shown by the measurements in Figure 
3.12 (B). This allows for greater accuracy when drawing ROIs around the 
heart and the lungs. Therefore, respiratory gating was used on all 
subsequent PET scans. 
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Figure 3.11| MC2B software monitors the breathing rate of the subject being scanned 
creating a trace. The blue line indicates the breathing trace picked up by the breathing pad 
placed underneath the subject and the white box at (i) indicates a full breathing cycle. A 
threshold is set by the red line that, when breached, triggers the MC2B software to begin 
measuring inhalation at (ii). A trigger delay can be set manually to signify the end of the 
breathing cycle shown at (iii). 
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Figure 3.12| Respiratory gating creates cleaner images of the heart in PET/CT 
scanning. (A) Shows a PET/CT scan where the PET has been reconstructed with 
respiratory gating (i) and without respiratory gating (ii).  Two perpendicular measurements 
have been taken across the highly radioactive region of the heart, a diagram of which is 
shown in (iii). The table in (B) details the two measurements taken across the heart in both 
the respiratory-gated reconstruction and non-gated reconstruction. 
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3.4 Results: Regions of interest can be drawn around areas 
thought to harbor metastasizing 4T1 tumour cells. 
 The possibility of using PET/CT imaging to monitor progression of 
tumour growth and metastasis was then investigated. In the case of the 
tumour used in this study, i.e. the 4T1 mammary carcinoma cell line that 
metastasizes to the lung, it was important that consistent and reliable ROIs 
could be drawn around the lungs. The possibility of using VivoQuant 
software (InviCro) to achieve this goal was examined. VivoQuant 
automatically imports data from both the PET and the CT images collected 
on the NuclineTM software, then co-registers the reconstructed images and 
pre-processes the PET image data from Bq/ml to Standardised Uptake 
Value (SUV). 
 
3.4.1 Drawing Lung ROIs 
When looking solely at the PET image data the radioactivity is highest 
through the heart, as this organ has a high metabolic expenditure even 
under anaesthesia. Consequently, the lungs appear to have low or 
background radioactivity in comparison, creating difficulty when drawing lung 
ROI from PET data alone. However, there is a large contrast on the CT scan 
between the black empty air space of the lungs and the grey soft tissue of 
the heart. Therefore, the CT scan can be used to draw the lung ROI. This is 
done on VivoQuant by selecting the lightest and darkest points of the lungs 
on the CT to be set as the upper and lower thresholds within which the 3D 
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ROI is drawn. The PET image is then overlaid onto the CT image with the 
lung ROI allowing the SUV data to be calculated as shown in Figure 3.13.  
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Figure 3.13| CT scans can be used to draw regions of interest (ROIs) in areas low in 
radioactivity. A set of example scans taken on the Mediso nanoScan of a mouse showing 
the stages of drawing lung ROIs. (A) Shows the CT scan without ROIs. (B) ROIs of the 
lungs were drawn with the connected thresholding tool on VivoQuant software; shown in 
lilac and indicated by a white arrow (i). (C) The heart ROI can be imported from the PET 
scan and imposed on the CT scan; shown in red and indicated by a white arrow (ii). (D) The 
lung ROI can be seen clearly when the PET is imposed on the CT scan and will measure 
values used in PET. 
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3.4.2 Drawing soft tissue ROIs 
ROIs can also be used to exclude organs of high metabolic activity 
that do not harbor 4T1 metastasis from data analysis, such as the heart. The 
heart ROI is drawn on the PET image data by selecting the highest and 
lowest SUV values to be set as the upper and lower thresholds between 
which the ROI is drawn in 3D (Figure 3.14 and 3.15). 
Excretory organs such as the bladder and the kidneys are also 
observed as areas of high radioactivity. These organs are very good 
indicators of FDG metabolism within the mouse. ROIs can be drawn around 
the kidneys and the bladder using the same technique as the heart and can 
be monitored over different scans. 
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Figure 3.14| ROIs can be drawn on the PET data using the connected thresholding 
tool. Examples of a PET/CT scan taken on the Mediso nanoScan of a tumour-bearing Treg-
replete mouse after drawing of ROIs. (A) Shows the original PET/CT scan with no ROIs 
drawn. (B) Shows the ROIs visible in the plane, all indicated by white arrows. The lungs are 
shown in lilac, the heart in red and the spleen in purple. (C) Shows the addition of the 
kidney ROIs in magenta and cyan. 
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Figure 3.15| VivoQuant software can create 3D renderings of PET/CT data and ROI 
positions. (A) Shows a 3D Maximum Intensity Projection (MIP) image of the PET/CT image 
shown in Figure 3.15. (B) Shows the 3D rendering of the ROIs drawn in Figure 3.5 on a MIP 
image. 
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3.5 Results: PET/CT image data can be quantified in different 
ways 
 All PET/CT image data stems from the SUV, which is calculated using 
the equation detailed in Table 3.2. The SUV takes into account the animal’s 
weight, the injected dose of radioactivity, the time of radioactivity 
administration and the time of the scan. In medicine, it is standard practice to 
use the maximum SUV measured in a ROI (SUVmax) when describing 
levels of radioactivity within a tissue. However, this is an inaccurate way of 
quantifying changes in radioactivity in mice. The resolution of PET images 
are the same in humans and in mice. Due to the obvious size difference 
between humans and mice a pixel in a mouse covers a larger area of tissue 
than in a human, meaning the SUVmax of a ROI has a higher chance of 
being an anomaly in a mouse because of its size. Therefore, SUVmax is a 
suboptimal way of analysing data collected from pre-clinical PET/CT scans.  
 Another method of PET analysis is the Hot Pixel Average (HPA), in 
which an average of the five “hottest” (most radioactive) pixels of a ROI is 
calculated. However, if the hottest pixel is an anomaly then the overall HPA 
increases.  
 Total Lesion Glycolysis (TLG) is the only measurement that takes into 
account the size of the ROI being analysed. A ROI TLG is calculated by 
multiplying the average SUV by the ROI area, showing the radioactivity 
uptake over the entire organ. The calculations and units of each of the three 
described parameters can be found in Table 3.2. Figure 3.16 shows the TLG 
of different ROIs of a tumour-bearing mouse. In this study the development 
of micrometastases in distant organs are being analysed, which as 
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described previously cannot be individually identified in PET/CT imaging. 
Therefore by looking at the changes in the TLG, the average SUV can be 
measured over time within a set area where metastasis is likely to occur. For 
all future scans, TLG was used to investigate metastasis progression. 	 	
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Table 3.5|	The calculations of different parameters for analysing PET data	
Parameter Calculation Units of measurement 
 
 
SUV 
 
Image derived radioactivity 
concentration at t=0 
(Injected dose at t=0/body 
weight) 
 
 
 
g/ml 
 
 
SUVmax 
 
The pixel with the highest 
value of SUV in a given 
area (ROI) 
 
 
 
g/ml 
 
 
Hot Pixel Average 
 
The mean of the 5 pixels 
with the highest SUV in a 
given area (ROI) 
 
 
g/ml 
 
 
Total Lesion 
Glycolysis 
 
 
Average SUV of the whole 
ROI X ROI volume 
 
 
g/ml*cm3 
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Figure 3.16| TLG is used to analyse PET/CT images. The graph shows the TLG of 5 
different ROIs of a tumour-bearing female Balb/c mouse. 
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3.6 Results: Imaging 4T1 tumours and metastasis 
3.6.1 Imaging primary 4T1 tumours 
 The protocols optimized for the Gamma Media Triumph II 
PET/CT/SPECT scanner and the Mediso nanoScan PET/CT scanner where 
subsequently used to image primary and metastasized 4T1 tumours. Mice 
were warmed in a heating box for at least one hour before Iohexol was 
administered both i.p and i.v as previously described. Ten MBq of FDG was 
administered i.v after induction of anaesthesia and a PET/CT scan was 
performed as before.  
 Large primary tumours were observed around the lower left 
abdominal quadrant on the PET/CT images, an example of which is shown 
in Figure 3.17. A 3D model of the mouse shows a lack of radioactivity uptake 
in the centre of the tumour, which is suggestive of necrosis.  
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Figure 3.17| Solid primary tumours can be imaged using PET/CT.  A 2D (A) and 3D (B) 
PET/CT image taken of a solid tumour bearing mouse using the Gamma Medica Triumph II 
scanner and analysed using Pmod software. The range of radioactivity in the scan shown in 
(A) is given in Bq/ml in the scale bar below the scan. ROIs are drawn on both images as an 
outline (A) or a solid volume (B).  Bladder is drawn in yellow, heart in red and the primary 
tumour drawn in blue. A white arrow indicates the area of necrosis within the tumour. 
  
	 137	
3.6.2 Imaging 4T1 metastasis 
In order to keep the area of the lung ROI constant allowing for a direct 
comparison of TLG between scans, the ROI drawn on the initial PET/CT 
scan was reoriented and transposed onto consecutive scans. An example of 
reorientation can be seen in Figure 3.18. 
 Metastasis progression was then monitored in mice after tumour 
resection. Three days after surgery, all mice were scanned following the 
optimized protocol for the nanoScan PET/CT scanner. Mice were scanned 
once a week for 3 weeks in total, with the initial scan taken as baseline. 
Three consecutive scans from a representative mouse are shown in Figure 
3.19 with ROIs drawn around the lungs, heart, kidneys and bladder. The 
TLG of the lungs was measured over all three scans and a progressive 
increase was observed. Upon sacrifice of the mouse there were no large 
tumour nodules, however the clonogenic assay revealed micrometastases 
(examined in more detail in Chapter 4). This suggests that the increase in 
TLG seen over 3 weeks within the lungs could be due to the progression of 
4T1 metastasis. 
In some cases, metastatic nodules form on the lungs and the ribcage 
in the later stages of metastasis, examples of which can be found in Figure 
3.20. These appear in later scans, and using VivoQuant software can be 
reoriented and transposed onto previous scans in the same way as lung 
ROI. Figure 3.20 shows the increase in TLG over time from metastatic 
nodule. 
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Figure 3.18| Baseline lung ROI can be reoriented to fit lung area on proceeding scans. 
Second CT scan of a mouse scanned on the Mediso nanoScan 14 days after the baseline 
scan shown in the sagittal, coronal and axial plane. (A) CT scan with the baseline lung ROI 
(i) imposed onto the image, where the darker air space is shown at (ii). (B) The lung ROI 
shown by a white arrow reoriented to fit the air space of the lungs shown in (A). 
 
	 139	
 Figure 3.19| Changes in TLG can be observed in the lung ROI of a Treg-replete 
metastasis-bearing mouse. A single Treg-replete metastasis-bearing mouse was scanned 
using the Mediso nanoScan on the same day each week for 3 weeks. Each of the scans are 
shown in (A) week 1 (i), week 2 (ii) and week 3 (iii). The lung ROI (drawn in light sea green 
and indicated by a white arrow) was drawn on the scan shown in (A) (i) and then reoriented 
onto images (ii) and (iii). (B) Shows the TLG of the lung ROI in each scan. 
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Figure 3.20| Metastatic nodules appearing on later scans can be retrospectively 
transposed onto previous scans to monitor changes in TLG.  A Treg-replete metastasis 
bearing DEREG mouse was scanned once a week for 3 weeks.  (A) PET/CT data was 
analysed on VivoQuant software and ROIs drawn around nodule 1 (cyan) and nodule 2 
(magenta) on the final scan (iii) were retrospectively transposed onto scans from week 1 
and 2 [(i) and (ii) respectively].  (B) The TLG was calculated for nodule 1 (i) and nodule 2 (ii) 
on each scan. 
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3.7 Discussion 
PET/CT imaging has been used since the 1990’s for clinical diagnosis 
of cancer and metastasis, and therefore had a potential to be applied to 
preclinical metastasis studies (Kinahan et al. 1998; Townsend et al. 1993). 
The changing of PET/CT scanners mid- project hindered the optimisation of 
PET/CT imaging for this purpose in our lab. However, the Mediso nanoScan 
PET/CT scanner was found to be superior to the Gamma Medica Triumph II 
PET/CT/SPECT scanner, along with the upgrade in analysis software.  
 Through altering CT scan parameters, it was possible to achieve a 
high quality CT scan displaying differentiation between soft tissues and 
smaller structures within the chest cavity. In order to achieve this, it was 
shown that CT scans should be performed with 70 KVp X-ray energy, 720 
projections and 1:1 binning. Along with i.p and i.v administration of Iohexol, 
this protocol created CT images with a high resolution and contrast definition 
between soft tissues.  
When using increased X-ray KVp and projection number during a CT 
scan, the subject receives a higher radiation dose of approximately 13.5 
cGy. This raises the possibility of biological effects occurring as a result of 
the increased radiation. It is widely accepted that high doses ionizing 
radiation can create DNA mutations with a potential to cause cancer. 
Interestingly, studies have shown that small doses of ionizing radiation (in 
the region of 1.2-100 mGy) have a conditioning effect on mice, thereby 
reducing the distinct biological effects of high dose radiation (1-2 Gy) on 
DNA (Nenoi et al. 2015). Conversely, targeted high dose radiation can be 
used to treat some tumours. The radiation doses used for radiation therapy 
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are in the region of 20Gy (McGinnis et al. 2016), whereas the radiation dose 
received during a CT scan using the optimized protocol is more than 100 
fold lower. Therefore, the radiation dose received by mice during CT 
scanning is not high enough to cause detrimental effects to DNA. However, 
to further decrease the risk of ionizing radiation, the Field Of View (FOV) of 
the CT is increased to encapsulate the entire subject. This allows the 
radiation to be spread across the subject rather than being focused on a 
single area. 
 The progression of metastasis was measured through drawing ROIs 
around organs potentially harboring 4T1 cells. It was shown that it is 
possible to draw ROIs on the CT scan or the PET scan using different 
contouring tools on VivoQuant software. As the lungs are the first place 4T1 
cells generally seed during metastasis it was important to keep this ROI 
constant throughout scans. By using the lung ROI drawn on the baseline 
scan and reorienting it to fit the subsequent scans, it was therefore possible 
to measure the change in TLG of the same area over time. The opposite 
was done with ROIs that appear in the later scans, in that they could be 
superimposed onto earlier scans and the change in TLG was measured over 
time. This is important for lymphoid organs such as the spleen and the LNs 
as they show an increase in metabolic activity during Treg depletion 
(discussed further in Chapter 4), and in the later stages of metastasis it has 
been shown using the clonogenic assay that 4T1 cell colonies are present in 
inguinal LNs.  
 The best parameter to measure the progression of metastasis is TLG 
in comparison to the SUVmax, a standard clinical practice for measuring 
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ROIs on a PET/CT scan, and the HPA. Both of these parameters have a 
higher risk of anomaly due to the size of the subject being scanned, and 
while the SUVmax and HPA look at the highest level of radioactivity within a 
ROI, only the TLG takes into account its area.  
 Through optimisation of PET/CT scanning and image analysis, it was 
possible to visualise solid primary tumours and large metastatic nodules 
found in the lungs and ribcage. In addition, through utilizing the lung ROI 
from the baseline scan, it was possible to measure the change in TLG over 
time, where an increase in TLG is indicative of metastasis. 
PET/CT imaging is not without its limitations. FDG PET/CT imaging is 
not specific to cancer cells, as shown by the high levels of radioactivity seen 
in organs such as the heart, kidneys and bladder. While the location of large 
solid tumours within a mouse is clear, micro-metastases cannot be identified 
through their increase in glycolytic activity with such clarity. The 
radiolabelling of specific antibodies has proven to be a promising area, with 
human HER2 antibodies being investigated for use in imaging cancer in 
mice (Denis-Bacelar et al. 2016). However, as 4T1 is a triple negative breast 
cancer cell line it is not possible to use 4T1-specific radiolabelled antibodies 
to image metastasis.  
 In conclusion, the techniques described in this chapter have 
demonstrated successful optimisation of PET/CT imaging using both the 
Gamma Medica Triumph II PET/CT/SPECT scanner and the Mediso 
nanoScan PET/CT scanner. This technique was therefore be used to 
measure the progression of metastasis in Treg-depleted and Treg-replete 
mice after primary tumour resection, described in Chapter 4.  
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Chapter Four 
4 Results: Investigating the effects of Treg depletion on the 
growth of a primary tumour and the progression of metastasis 
4.1 Introduction 
 Regulatory T cells (Tregs) are a subset of CD4+ cells that also 
express Foxp3 and CD25 (Sakaguchi et al. 1995). Tregs have a suppressive 
phenotype and play a major role in maintaining peripheral tolerance. Loss of 
Tregs leads to fatal autoimmune and inflammatory disorders in humans and 
in mice (Brunkow et al. 2001; Lahl et al. 2007). While Tregs are important in 
maintaining immune homeostasis, they have also been implicated in 
suppressing anti-tumour immune responses, whereby recruitment of Tregs 
to the tumour site provides an immune-suppressive niche preventing 
immune-mediated clearance of the tumour (Gallimore and Sakaguchi 2002). 
In humans, studies have shown an enrichment of Tregs in certain tumours 
such as ovarian, breast, pancreatic and lung, and their presence is generally 
correlated with a bad prognosis (Cheng et al. 2016; Hanagiri et al. 2013; 
Knutson et al. 2015; Xu et al. 2010). Previously, studies in mice have shown 
that the ablation of Tregs in mice leads to the control of primary tumour 
growth, although this effect has not been investigated in the context of 
metastasis, which remains the main cause of fatality amongst cancer 
patients (North 1982; North and Awwad 1990).  
DEREG mice expressing DTR on their Tregs can be used to 
investigate the depletion of Tregs on the progression of metastasis. The 
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triple negative murine breast cancer model 4T1 metastasizes spontaneously 
from a primary tumour in the same manner as human stage IV breast cancer 
(discussed in Chapter 1 Section 1.5) and is therefore a robust model to 
investigate development of metastasis. The resistance of 4T1 to 6-
thioguanine can be exploited to detect metastatic colonies in distant organs 
as described in Chapter 1. 
 In vivo imaging can also be used to image tumour progression in 4T1-
bearing mice. PET/CT exploits the Warburg principle of increased glycolytic 
activity of tumour cells (Warburg 1956) by measuring the uptake of a 
radioactive glucose analogue F18-Fluorodeoxyglucose (FDG) by different 
tissues. The optimisation of this technique for analysis of metastasis was 
described in Chapter 3. 
 Few studies have examined the effect of Treg depletion on the 
progression of triple negative breast cancer metastasis in a resection model. 
Therefore, experiments described in this Chapter aimed to investigate the 
effect of Treg depletion on the growth of a primary 4T1 tumour and on the 
progression of metastasis. This investigation was undertaken using 2 
methods of metastasis analysis: the clonogenic assay and PET/CT imaging. 
The experiments tested the hypothesis that depletion of Tregs controls the 
growth of a primary tumour and limits the progression of metastasis. 
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4.2 Results: Depletion of Regulatory T cells can be achieved in 
DEREG positive mice through administration of diphtheria toxin 
 In order to determine the efficiency of Treg depletion of DTx in the 
DEREG mice, two doses of DTx were compared. Female naïve DEREG 
mice were left untreated or treated with 10 μg/kg or 5 μg/kg DTx injected i.p 
on day 0. Upon sacrifice on day 2, spleens and LNs were harvested from the 
mice and cells were stained for CD4, Foxp3, CD25 and GFP as shown in 
Figure 4.1. A Wild Type (WT) Balb/c mouse was injected with 100 μl PBS for 
comparison in which no depletion of Tregs was observed as expected. 
Interestingly, only 85% of the CD4+ Foxp3+ cells in untreated DEREG mice 
expressed GFP (Figure 4.2C). This could be explained by gene silencing of 
the BAC, indicating that not all Foxp3+ cells can be depleted via DTR. A 
significant depletion of Tregs is achieved however, using both doses of DTx. 
Therefore, to avoid adverse effects, the lowest effective dose of 5 μg/kg was 
used in all subsequent experiments. 
  The remaining 15% of Foxp3 positive cells that do not express the 
DTR and are therefore refractory to depletion by DTx, expand to eventually 
repopulate the Treg pool (Figure 4.3). This expansion of DTR- Tregs in 
DEREG mice has previously been shown to confer protection against 
systemic autoimmunity that is observed in DTR knock-in mice after 
prolonged DTx treatment (Mayer et al. 2014b). Interestingly, an expansion of 
GFP+ DTR+ Tregs was also observed in mice after 3 weeks of DTx 
treatment, showing development of resistance to DTx by DEREG mice. 
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Figure 4.2|	 Injection of DTx causes successful depletion of Tregs in DEREG mice. 
DEREG mice were left untreated (n=2) or treated with either 5 μg/kg (n=2) or 10 μg/kg (n=2) 
of DTx to deplete Tregs. Two days later, cells from spleens and inguinal LNs stained for 
CD4, Foxp3, and GFP fluorescence was detected on the FITC channel. Lymphocyte 
populations were gated as described in Chapter 2. (A) CD4+Foxp3+ or CD4+GFP+ cells as a 
percentage of the total CD4+ population (top right quadrant), and percentage depletion of 
cells after DTx treatment is shown in brackets. (B) Foxp3+GFP+ cells as a percentage of 
total Foxp3+ population (top right quadrant), with the percentage depletion of cells after DTx 
treatment in brackets.	
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Figure 4.3| Injection of DTx causes successful depletion of Tregs in DEREG mice. All 
data shown are averages of n=2 from figure 4.1 (A) Shows the proportion of Foxp3+ cells as 
a percentage of CD4+ cells in an untreated DEREG mouse and DEREG mice given 5 μg/kg 
or 10 μg/kg DTx. (B) Shows the proportion of GFP+ cells as a percentage of CD4+ cells in 
the same mice and (C) shows the proportion of GFP+ cells as a percentage of Foxp3+ cells. 
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Figure 4.4| Restoration of Tregs after 3 weeks of DTx treatment. WT and DEREG mice 
were sacrificed 2 days [(n=2)(n=2) respectively] or 3 weeks [(n=1)(n=4) respectively] post 
DTx treatment. Cells from spleens and LNs were stained for CD4, Foxp3 and GFP. 
Examples of a WT Balb/c mouse, a DEREG mouse treated with 5 μg/kg DTx, and an 
untreated DEREG mouse are shown above. The top panel shows the Foxp3+CD4+ cell 
populations and the bottom panel shows the GFP+CD4+ cell population of the same mice. 
Percentages show the gated population as a percentage of the CD4 population. 
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4.3 Results: Using the clonogenic assay to quantify 4T1 
metastasis 
 Metastatic colonies were assessed using the clonogenic assay as 
described in Chapter 2 and outlined in Figure 4.4. In order to demonstrate 
the reliability of this technique, mice bearing 4T1 tumours were sacrificed 
and the lungs, liver, draining LN, and brain were harvested for analysis of 
metastases. Once the cell suspensions had been prepared as previously 
described, samples were plated and incubated with 6-TG media for 14 days. 
Metastatic colonies were observed in the lungs and in some of the draining 
LNs, however no metastases were found in the brain or the liver. This was 
not unexpected however, as brain metastases occur in the later stages of 
the disease (Pulaski and Ostrand-Rosenberg 2000). As the lungs are the 
first sites of metastasis in the 4T1 model, clonogenic assay analyses of 
these organs gave the best indication of metastasis control. Therefore, the 
lungs were the main focus for metastasis experiments. In some cases, lungs 
would show metastatic tumour nodules that would result in a densely packed 
clonogenic assay plate. In this circumstance the plate was split into quarters, 
and one quadrant was counted and then multiplied by 4 in order to calculate 
the total number of metastatic colonies on the plate. Examples of positive 
metastasis and negative metastasis plates can be seen in Figure 4.5. 
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Figure 4.4| The clonogenic assay is used to detect micrometastases in distant organs 
of tumour bearing mice. This figure shows the process of the clonogenic assay, resulting 
in blue 4T1 colonies on a tissue culture plate that are subsequently counted. Each blue 
colony represents 1 metastatic cell. 
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Figure 4.5| 4T1 metastatic colonies are stained blue. (A) Shows a positive clonogenic 
assay plate with blue 4T1 colonies. (B) Shows a negative clonogenic assay plate without 
any 4T1 colonies. 
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4.4 Results: Depletion of Tregs cannot control metastasis induced 
through intravenous injection of tumour cells 
 Some studies have investigated control of lung metastasis 
established through i.v administration of tumour cells. Using this method, 
tumour cells locate to the lungs immediately therefore establishing 
metastatic disease independently of a primary tumour. Bos et al. have 
shown the growth of the breast cancer cell line PyMT in the lungs after i.v 
administration can be controlled through depletion of Tregs (Bos et al. 2013).  
To determine whether this was also the case in the 4T1 model, lung 
metastasis after i.v administration of the cells was assessed. Eighteen mice 
were split into 2 groups that received either 5x105 or 1x105 4T1 cells injected 
i.v on day 0 in order to establish the number of cells required for tumour 
take. Three mice from each group were harvested on day 7, day 10 and day 
14, and lungs, liver, and inguinal LNs were harvested for clonogenic assay 
analysis [Figure 4.6 (A)]. The mice that received 5x105 cells became sicker 
in a shorter period of time with only 1 mouse surviving to day 14.  All mice 
receiving 1x105 cells survived. Analysis of lung clonogenic assay plates 
exhibited almost complete covering with 4T1 metastatic colonies, with further 
colonies being found in the liver (Figure 4.7). Histological samples of lungs 
bearing 4T1 metastatic nodules indicated almost complete occlusion of the 
lungs as a result of tumour growth (Figure 4.8).  
In order to prevent development of respiratory distress in mice as a 
result of overloading of lungs with 4T1 metastatic cells, the number of cells 
injected i.v was reduced to 1x104 per mouse. DEREG positive mice and 
DEREG negative littermate controls were injected i.v with the revised 
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number of cells on day 0 and were subsequently treated every other day 
with 5 μg/kg DTx from day 7 until sacrifice on day 17 (Figure 4.6 B) 
Clonogenic assay analysis was performed on the lungs upon 
sacrifice, revealing no significant difference in the number of metastatic 4T1 
colonies observed in Treg-depleted and Treg-replete mice, as shown in 
Figure 4.9. This could be due to the sheer numbers of cells establishing 
metastatic niches in the lungs. Due to the systemic dissemination of 4T1 
tumour cells and their preferential localization to the lung, a potential anti-
tumour immune response may possibly be unable to clear the tumour 
burden before health deterioration of the mouse due to its rapid growth. 
Fewer cells arriving at the lungs via spontaneous metastasis from a primary 
tumour may present different challenges to the immune system than the 
large number of cells arriving in the lungs through i.v administration, and 
may not overwhelm the lungs in the same manner. Therefore, the effect of 
Treg depletion on metastasis was then investigated on spontaneous 
metastasis occurring from a primary tumour. 
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Figure 4.6| Investigating the effect of Treg depletion on a tail vein model of 
metastasis. (A) Shows the experimental timeline used to measure the establishment of 
lung metastasis after tail vein injection of 4T1 cells. (B) Shows the experimental timelines 
investigating the effect of Treg depletion on the development of metastasis from tail vein 
inoculation of 4T1 cells. 
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Figure 4.7 | 4T1 metastases are found in different organs after tail vein administration 
than from a s.c tumour. Examples of clonogenic assay plates showing metastasis in the 
lungs (A), the liver (B), and the inguinal LN (C) from mice with tail vein induced metastasis. 
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Figure 4.8 | Tail vein induced metastasis cause occlusion of the lungs. Examples of 
Haematoxylin and Eosin (H&E) staining of lungs from naïve healthy mice (A) compared to 
lungs of mice that have tail vein induced metastasis after injection of 1x105 4T1 cells (B). 
Tumour areas are identified by purple lines in (B). 
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Figure 4.9| Treg depletion does not control the progression of metastasis of tail vein 
induced metastasis. The number of lung metastases detected using the clonogenic assay 
in Treg-depleted and Treg-replete mice injected i.v with 1x104 4T1 cells. An unpaired t-test 
was performed giving a p value of p=0.4338 
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4.5 Results: Treg depletion causes regression of a primary 
tumour 
In order to analyse the growth of 4T1 tumours, mice were injected 
subcutaneously with 1x105 4T1 cells close to the mammary fat pads. 4T1 
cells were first palpable on day 5 after injection and were large enough to 
begin measuring on day 7. Tumours were measured up to 3 times a week 
using digital calipers, taking two perpendicular measurements across the 
tumour. 4T1 tumours grew in 100% of injected mice, and all tumours grew 
uniformly until sacrifice (Figure 4.10). Due to rapid tumour growth, small 
necrotic areas prone to scabbing and ulceration were often observed in the 
centre of the tumour. Mice were checked every other day for development of 
necrosis and were sacrificed if a crater-like appearance or discharge was 
observed.  
 Previous studies have shown that the immune response induced as a 
result of Treg depletion can control the growth of a primary tumour in mice 
(Hindley et al. 2012). To assess this in the context of the 4T1 model, 6-8 
week-old DEREG positive mice and their negative littermate controls were 
injected s.c with 4T1 cells on day 0. When the tumours were first palpable on 
day 5, mice were injected i.p with 5 μg/kg of DTx every other day until 
sacrifice on day 21; the full experimental timeline can be found in Figure 
4.11 (A). Tumours were measured 3 times a week, at the same time as DTx 
was administered. Tumour growth curves are shown in Figure 4.11 (B). 4T1 
tumours in Treg-replete mice grew uniformly as before, whereas 4T1 
tumours in Treg-depleted mice began to regress after day 10, with some 
tumours demonstrating complete regression. Not only does this recapitulate 
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the findings seen in other studies, but this also shows that the initial 
depletion of Tregs and resulting expansion of effector T cells is enough to 
initiate an anti-tumour immune response even though Tregs begin to expand 
and return to normal levels after 3 weeks of depletion. Therefore, it was 
hypothesised that metastasis occurring spontaneously from a primary 
tumour could be controlled through Treg depletion in the same manner as 
the primary tumour growth. 
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Figure 4.10| 4T1 tumours grow uniformly in WT Balb/c mice. Female 6-8 week old 
female Balb/c mice were injected subcutaneously with 1x105 4T1 cells on day 0 and 
developing primary tumours were measured from day 7 over a 3-week period. The graph 
shows the volume of the 4T1 tumours over time. 
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Figure 4.11| Depletion of Tregs can control the growth of a primary tumour. (A) Shows 
the experimental timeline of the experiment investigating the effect of Treg depletion on a 
primary tumour.  The graphs in (B) show the tumour volume over time of (i) Treg-depleted 
mice and (ii) Treg-replete mice. (C) Shows the average tumour volumes over time of Treg-
depleted and Treg-replete mice. The statistical analysis in (C) is an unpaired two-tailed t test 
at each time point, giving the following values: day 12 p=0.0034, day 13 p=<0.0001, day 16 
p=<0.0001, and day 21 p=0.0002. 
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4.6 Results: Relationship between 4T1 metastasis and the size of 
the primary tumour 
 In clinical cases of mammary carcinoma, it is standard practice to 
resect a primary tumour as long as it is operable. In this study therefore, to 
analyse metastasis in a clinically relevant setting, 4T1-bearing mice 
underwent surgery to resect their primary tumours. This technique also 
serves to improve the welfare of the animals. Resecting the primary tumour 
prevents infection and ulceration of the necrotic area, while also ensuring the 
primary tumour does not become so large as to hinder the movement of the 
mouse.  
In order to successfully analyse the control of metastasis conferred 
through Treg depletion, it was necessary to establish at what point 
metastasis occurred and thus at what point to resect the primary tumour. To 
do this, Balb/c mice were injected s.c with 1x105 4T1 cells as before and 
resulting primary tumours were resected at varying tumour volumes. Mice 
were then left for a maximum of 14 days after resection before sacrifice, at 
which point the lungs were taken for analysis of metastatic burden using the 
clonogenic assay. Whilst primary tumour volume and numbers of lung 
nodules were not significantly associated, replotting the data as shown in 
Figure 4.12 indicates that to achieve metastatic tumours in > 80% of mice, 
primary tumours should be over 125 mm3 in volume or 5 mm in diameter. It 
is important to note that not all tumour-bearing mice go on to develop 
detectable metastatic disease and some mice develop more metastatic 
colonies than others. Therefore, the primary tumours were resected once 
both perpendicular measurements had crossed the lower threshold. This 
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gave a high chance of metastasis at the time of resection, but also meant 
the tumour was small enough to prevent the development of necrotic 
ulceration and to lower the risk of reduced mobility of the mice.  
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Figure 4.12| 4T1 metastasis development and it’s relationship to tumour volume at 
the point of resection. 4T1 tumour-bearing mice underwent surgery to resect primary 
tumours at different volumes, and were sacrificed 10 days later. Lungs were harvested and 
metastatic burden was analysed using the clonogenic assay. (A) Shows the number of lung 
metastases in mice when tumours were resected at different volumes. (B) Shows the 
percentage of mice with ≥1 metastatic colony when tumours were resected at different 
tumour volumes. Linear regression was performed on the data set and the R2 and p values 
are given in the box to the right of the graph. The dotted red line indicates the lower 
threshold for the tumour volume at the time of resection.  
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4.7 Results: Treg depletion can promote control of metastatic 
disease 
 Once the time point of tumour resection had been established, it was 
necessary to investigate the effect of depleting Tregs before and after 
resection on the progression of metastasis. In a pilot experiment, 10 female 
6-10 week old DEREG mice were split into 3 groups and injected s.c with 
1x105 4T1 cells. Each of the 3 groups then underwent a different treatment 
plan described in Figure 4.13. Briefly, mice in group 1 (Treatment before 
surgery – TS) were given 2 rounds of DTx treatment before the primary 
tumour was resected on day 14. Group 2 (Surgery before Treatment - ST) 
and group 3 (No Treatment - NT) were treated with DTx or PBS respectively 
24 hours after tumour resection. Mice in all groups then received treatment 
every other day until sacrifice on day 24, when the lungs were harvested and 
taken for clonogenic assay. Primary tumour growth was measured in each 
treatment group, and the average tumour growth can be found in Figure 
4.14(A). It was observed that in the T-S group tumour growth was slower 
than in the other two groups and did not reach 125 mm3 in volume at the 
time of resection. Upon sacrifice on day 24, lungs were taken for clonogenic 
assay analysis. Significantly fewer metastatic colonies were observed in 
mice treated with DTx before surgery and after surgery than mice that 
received no treatment, however there was not a significant difference 
between mice treated before or after surgery. The data indicates that as a 
pilot experiment conducted with a small number of mice, it was difficult to 
observe significant differences between the S-T and T-S group. For 
	 167	
pragmatic reasons, the protocol of Treg depletion before surgery was 
adopted for all future metastasis experiments.  
In each of these experiments mice were phenotyped and split into 
DEREG positive and DEREG negative littermate controls. All mice in an 
experiment were treated with DTx in order to eliminate the possibility of non-
specific effects of DTx on tumour metastasis. Figure 4.15 shows the 
cumulative data from repeated metastasis experiments, from which 
significantly fewer metastatic lung nodules were observed in Treg-depleted 
mice when compared to Treg-replete mice. Similar control was observed in 
the primary tumour growth of these mice. Figures 4.16 and 4.17 show the 
tumour growth curves and tumour growth rates of both Treg-depleted and 
Treg-replete mice before and after 2 rounds of DTx treatment started on day 
10. Figure 4.16 (B) shows no significant difference in the overall tumour 
growth rates of Treg-replete mice after treatment with DTx. Contrastingly, 
Figure 4.17 shows a significant decrease in tumour growth rate after DTx 
administration in Treg-depleted mice. Interestingly, this difference is also 
observed in Treg-depleted mice that did not develop metastatic disease but 
not in mice that did [Figure 4.17 (F) and (D) respectively], suggesting that 
mice with slowed primary tumour growth rate were also those that controlled 
development of metastasis.  
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Figure 4.13| Depleting Tregs before and after resection of a primary tumour. (A) 
Shows the experimental timeline for the Treatment before Surgery group (TS) and (B) 
shows the experimental timeline for the Surgery before Treatment group (ST) and the No 
Treatment group (NT). 
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Figure 4.14| Depleting Tregs before primary tumour resection results in fewer 
metastatic colonies. (A) Shows the average tumour volume over time of each treatment 
group. (B) Shows the number of lung metastases per group. Statistical analysis performed 
was a t-test. P values are as follows: p=0.4773 for S-T vs. T-S, p=0.0222 for T-S vs. NT and 
p=0.0465 for S-T vs. NT. Post-hoc power analysis calculations were 11.5%, 65.1%, and 
80.1% for S-T vs. T-S, S-T vs. NT, and T-S vs. NT respectively. 
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Figure 4.15| Treg depletion is able to control the progression of metastatic disease in 
Treg-depleted mice. (A) The average primary tumour growth over time of Treg-depleted 
and Treg-replete mice. An unpaired test was performed at each time point giving the p 
values as follows: p=0.6284, p=0.9502, and p=0.0176. (B) The number of metastatic 
colonies observed in the lungs of Treg-depleted and Treg-replete mice using the clonogenic 
assay. A Mann-Whitney test was performed on the data set giving a p value of p=0.0162. 
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Figure 4.16| Treatment with DTx before primary tumour removal does not affect the 
tumour growth rate in DEREG littermate control mice.  (A) Primary tumour growth 
curves of DEREG littermate control mice. The growth rate of primary tumours before and 
after DTx treatment is shown for all mice (B). Paired t tests were performed on the data sets 
in (B) giving a p value of p=0.8879. Coloured lines and data points represent Treg-replete 
mice that did not develop metastasis. Dotted red line indicates first DTx treatment. 
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Figure 4.17| Depletion of Tregs before primary tumour removal slows tumour growth 
rate in mice that do not develop metastasis.  (A) Primary tumour growth curves of 
DEREG mice that developed metastatic disease (C) and those that did not (E). The growth 
rate of primary tumours before and after DTx treatment is shown for all mice (B), mice that 
developed metastasis (D), and mice that did not develop metastasis (F). Paired t tests were 
performed on the data sets in (B), (D), and (F) giving p=0.0017, p=0.0929 and p=0.0022 
respectively. Dotted red lines on (A), (C), and (E) indicate first DTx treatment. 
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4.8 Results: Using PET/CT imaging to quantify 4T1 metastasis 
 The main limitation of the clonogenic assay is information on 
metastasis progression can only be gained at a single time-point. Therefore 
it was hypothesised that through the use of PET/CT as an in vivo imaging 
technique, information could be gathered about the progression of 
metastasis over time in a single mouse. While PET/CT imaging has been 
described for use in imaging of primary tumours and different metabolic 
diseases, little is known about its potential for imaging metastasis. The 
optimisation of this technique can be found in Chapter 3.  
 In order to determine whether PET/CT was suitable for imaging 4T1 
metastasis, the ability to image solid primary 4T1 tumours was examined. 
Briefly, tumour-bearing mice were warmed for one hour at 37°C in a heated 
recovery box and injected i.p with 100 μl Iohexol contrast agent prior to 
induction of anaesthesia. Once anaesthetised, mice were injected i.v with 
approximately 100 MBq of F18-FDG and a further 100 μl Iohexol. Mice were 
placed on a heated mouse bed in the PET/CT scanner and underwent a 15-
minute CT followed by a 60-minute PET scan. PET and CT scans were 
reconstructed and analysed on Pmod 3.3 software.  
 Primary tumours were observed in DEREG mice PET/CT images as 
shown by the 3D model in Figure 4.18(A). Interestingly, the 3D model of a 
primary tumour shows a lack of radioactivity in the centre. This is most likely 
due to tumour necrosis, as dead tissue in the centre of the primary tumour 
will not take up FDG.  
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Figure 4.18| PET/CT scanning can be used to image tumours and metastatic nodules 
in DEREG mice. Tumour-bearing and metastasis-bearing mice were scanned using the 
Gamma Medica Triumph II PET/CT/SPECT scanner and resulting imaged were analysed 
using Pmod3.3 software. (A) Shows a tumour-bearing mouse with 3D ROIs drawn for the 
heart in red, the bladder in yellow and s.c tumour in blue. (B) Shows metastatic nodules in 
(i) the chest cavity in green and in (ii) the skull in blue. 
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In order to detect metastases within the lungs, mice were imaged 
after resection of the primary tumour using the Mediso nanoScanTM PET/CT 
scanner. After being transferred into the PETIC preclinical scanning facility 
24 hours after surgery and 3 days prior to the initial PET/CT scan, mice were 
imaged once a week for up to 3 weeks and sacrificed 24 hours after the final 
scan. Upon sacrifice, lungs were harvested for analysis of metastasis using 
the clonogenic assay. 
PET/CT scans of mice in the later stages of metastatic disease show 
solid tumour nodules within the chest cavity and, in one case, within the skull 
[Figure 4.18 (B)]. However, the development of micrometastases in the 
lungs during the early stages of disease cannot be seen by eye on a 
PET/CT image. It is therefore necessary to draw a ROI around the lungs on 
the first PET/CT scan that can be transposed onto subsequent scans, in 
order to measure changes in different parameters within a constant area.  
In Chapter 3 the different measures of radioactivity uptake were 
discussed. Due to the lack of visualization of micrometastases by eye on a 
PET/CT image, it was hypothesised that any overall change in radioactivity 
uptake over an entire ROI could be measured through the TLG (g/ml*cm3), 
which is calculated by the product of the area of the ROI and the average 
SUV, rather than at specific sites through the SUVmax or HPA, which looks 
at the most radioactive point or the average of the 5 most radioactive points 
respectively. To test this, Treg-depleted mice and Treg-replete mice were 
scanned once after primary tumour removal and once 2 weeks later. Lung 
ROIs were drawn on week 1 scan and transposed onto the week 3 scan, 
and the TLG was calculated for each ROI and compared to naïve mice 
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(Figure 4.19). Interestingly, naïve mice had a higher lung TLG when 
compared to Treg-depleted and Treg-replete mice. This appears 
paradoxical, especially when comparing PET/CT images of a naïve (A) and 
metastasis-bearing Treg-depleted mouse (B) in Figure 4.20 where there 
appears to be less spread of radioactivity in the naïve mouse in comparison 
to the Treg-depleted mouse, with most of the radioactivity being taken up by 
the heart, bladder and kidneys.   
  
	 177	
	
Figure 4.19 | Lung ROI TLG is higher in naïve mice compared to experimental mice. 
Naïve mice, Treg-depleted (TD), and Treg-replete (TR) mice were scanned once or twice 
and lung ROIs were drawn on PET/CT images. TLG was calculated for each lung ROI and 
plotted on the graph above. A one-was ANOVA was performed on the data sets giving the 
following p values: (i) p=0.0032 (ii) p=<0.0001, (iii) p=<0.0001, (iv) p=0.0037, (v) p=0.0018, 
(vi) p=<0.0001, (vii) p=0.0696 and (viii) p=0.0078. Red data points indicate mice found to 
have metastatic colonies using the clonogenic assay. 
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Figure 4.20| FDG distribution appears greater in experimental mice than naïve mice. A 
PET/CT scan of a naïve mouse (A) and a Treg-depleted experimental mouse 1 week after 
primary tumour removal (B). FDG distribution is shown as SUV.  
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In order to investigate why the lung TLG was higher in the naïve mice, 
the parameters of TLG (ROI volume x average SUV) were considered. Its 
boundaries and its density define the ROI volume of a given tissue. Since 
the lung is characterized by the prevalence of air filled spaces and thus a 
lower tissue density than surrounding bone, it is reasonable to conclude that 
the ROI volume would be higher in naïve mice than experimental mice, 
whose lung air space could be occluded by cancer cells. A calculation of 
ROI volume indicated a larger volume in naïve compared to experimental 
mice (Figure 4.21). The ROI values are used to calculate the SUV thus 
impacting on the final TLG values. 
While the equation for the calculation of SUV takes into account the 
weight of the subject, the time at which the radioactivity was injected, the 
amount of radioactivity injected and the time at which the scan was 
performed, it does not account for the distribution of FDG throughout the 
subject. As FDG is excreted from the body in the same manner as glucose, 
the radioactivity of the kidneys is a good indicator of FDG metabolism. 
Therefore, normalizing all ROI TLG by the average TLG of the kidney ROIs 
would remove variability of FDG metabolism. Figure 4.22 shows that after 
normalizing to the kidney ROI TLG, there is no difference between the lung 
ROI TLG in naïve mice and experimental mice in the week 1 scan and the 
week 3 scan. This shows that even though mice had developed metastatic 
disease (indicated by red data points) the increase in radioactivity uptake, 
measured in TLG, could not be detected above background.  
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Figure 4.21| Naïve mice have increased Lung ROI volume compared to experimental 
mice. Lung ROI volumes were compared using a one-way ANOVA was performed to 
compare lung ROI volume of naïve mice to each experimental group giving the following p 
values: (i) p=0.2390, (ii) p=0.2413, (iii) p=0.0258, (iv) p=0.7933, (v) p=0.7184, (vi) p=0.0202, 
(vii) p=0.9999, (viii) p=0.9999  
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Figure 4.22| Normalizing TLG of ROIs to the average kidney ROI TLG allows accurate 
comparison between groups. Changes in lung ROI TLG were compared using a one-way 
ANOVA giving p values as follows: (i) p=>0.9999, (ii) p=0.995, (iii) p=0.7924, (iv) p=0.7325, 
(v) p=0.9441, (vi) p=0.9221, (vii) p=0.6457, (viii) p=0.8707. Red data points indicate mice 
found to have metastatic colonies using the clonogenic assay. 
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Hounsfield Units (HU), described in Chapter 1, are used to 
differentiate between tissues in a CT scan. Low HU corresponds to empty 
airspace, whereas high HU corresponds to dense tissue. As it was not 
possible to detect lung metastases using TLG, it was hypothesised that a 
change in mean HU of a lung ROI would indicate occlusion of the lungs and 
therefore development of metastases. Figure 4.23 shows the mean HU of 
lung ROIs from naïve and experimental mice. Naïve mice had the lowest 
HU, representing more empty airspace in the lungs in comparison to 
experimental mice. In both Treg-depleted and Treg-replete mice, there was 
a significant increase in mean HU between the scans at week 1 and week 3 
indicating a decrease in airspace and an increase in tissue area. The 
decrease in airspace could not however be accounted for by cancer cells as 
some mice with an increase in mean HU above that observed in naïve mice 
were tumour-free upon clonogenic assay analysis. Table 4.1 shows the 
probability that the increase in HU is due to metastasis for Treg-depleted 
and Treg-replete mice. Out of 6 Treg-depleted mice that displayed an 
increase in HU between week 1 and week 3, 50% of mice developed 
metastatic colonies in the lungs shown by clonogenic assay. Comparatively, 
5 out of 6 Treg-replete mice developed metastasis and showed an increase 
in HU, showing an 83% chance that an increase in HU is due to metastasis 
in this treatment group. While the increase observed in HU is a good 
indicator of metastases, it is difficult to determine whether the occlusion of 
the lungs is due to inflammation as a result of an induced immune response 
or the development of metastatic colonies. Figure 4.24 shows the lungs of a 
mouse with an increase in HU and no metastasis at week 1 and week 3 
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compared to a mouse with an increase in HU with metastatic disease. 
Looking by eye at these images, it is not possible to identify tissue 
inflammation or metastases. Treg-depletion in an otherwise naïve DEREG 
mouse leads to a dramatic increase in uptake of FDG by lymphoid organs 
due to systemic inflammation as shown in Figure 4.25. This further 
demonstrates the difficulties faced when determining the causes of lung 
occlusion. This coupled with the lack of information gained by the TLG of the 
lung ROIs, at the time points measured it is difficult to accurately determine 
the cause of lung occlusion without later confirmation from the clonogenic 
assay. However, with increased numbers it might be possible to assign a 
probability of metastatic disease as a cause of lung occlusion.  
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Figure 4.23| HU increase in mice with occluded lungs. The mean HU of lung ROIs of 
naïve mice was compared to experimental mice. A one-way ANOVA was performed to 
compare mean HU of lung ROI of naïve mice to each experimental group giving the 
following p values: (i) p=0.0001, (ii) p=0.5436, (vii) p=0.0196, (iii) p=0.0294, (iv) p=0.0471, 
(v) p=0.9983, (vi) p=0.6451, (viii) p=0.0060. Red data points indicate mice found to have 
metastatic colonies using the clonogenic assay. 
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Table 4.6|Probability of an increase in HU of lung ROI is as a result of metastases. 
Group n Increased 
HU (n=) 
Occurrence 
of 
Metastases 
(n=) 
Percentage 
(%) 
Probability 
of 
metastases 
Treg-
depleted 
8 6 3 50 0.50 
Treg-
replete 
6 6 5 83.33 0.83 
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Figure 4.24| Increase in HU and occlusion of the lung cannot distinguish between 
inflammation and metastases development. Treg-depleted and Treg-replete mice 
underwent a PET/CT scan at week 1 and at week 3. (A) Shows the two scans of Treg-
depleted mouse that did not develop metastasis but had an increase in HU between week 1 
and week 2. (B) Shows the two scans of a Treg-replete mouse that developed metastases 
and had an increase in HU between week 1 and week 2. 
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Figure 4.25| Depletion of Tregs in a DEREG mouse leads to increased uptake of FDG 
by lymphoid organs. A naïve DEREG (A) and a Treg-depleted DEREG mouse (B) 
underwent a PET/CT scan on the Mediso nanoScanTM PET/CT scanner. Scans were 
reconstructed using NuclineTM software and analysed on VivoQuantTM software. The 
Maximum Intensity Projection (MIP), coronal plane, and a 3D rendering with ROIs are 
shown for each mouse. ROIs are indicated by white arrows and labeled as follows: (i) heart, 
(ii) kidneys, (iii) bladder, (iv) lungs, (v) spleen, and (vi) lymph nodes.  
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4.9 Discussion 
The aims of the experiments in this chapter were to examine the 
effect of Treg depletion on the growth of a 4T1 tumour and the progression 
of its metastasis using both in vitro and in vivo techniques. 
Initial experiments showed that Treg depletion did not result in better 
control of metastasis induced through intravenous injection of tumour cells 
even when low doses of tumour cells were used. It was not possible to 
reduce the dose further as this would have resulted in variable tumour-take 
in control animals. 
The effect of Treg depletion on spontaneous metastasis was 
therefore investigated. Not only did this allow for a more clinically relevant 
experimental set-up, this metastasis model also prevented the overloading 
of lungs with 4T1 cells leading to occlusion and respiratory difficulties. It was 
hypothesised that as primary tumour control was promoted through Treg 
depletion, metastasis progression could be controlled in the same mouse.  
In clinical cases, metastasis arises from a primary tumour where 
small numbers of cells detach and migrate to distant sites. The 4T1 tumour 
cell line is highly metastatic and from the experiments described in this 
Chapter has been shown to spontaneously metastasize from a primary 
tumour >125 mm3 in diameter. In each metastasis experiment, all primary 
tumours were resected once a volume of >125 mm3 had been reached as 
preliminary experiments indicated that metastasis would have occurred in 
>80% of animals bearing such tumours.   
Using this experimental model, significantly less metastatic colonies 
were observed in Treg-depleted mice than Treg-replete mice with many 
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Treg-depleted mice developing very few or no metastatic colonies. Out of 18 
Treg-depleted mice only 8 developed metastasis, 7 of which had a colony 
count of <1000 (ranging from 1-579). Conversely, 15 out of 17 Treg-replete 
mice developed metastasis, 6 of which had >1000 colonies with a maximum 
colony count of 1388 (Figure 4.26). I went on to evaluate whether there was 
a link between the ability of the mice to control primary tumour growth and 
metastases. When the Treg-depleted group was split into mice that did and 
did not develop metastasis, it was observed that there was no significant 
difference in the overall growth rate of primary tumours in mice that 
developed metastatic colonies whereas a significant decrease in primary 
tumour growth rate was observed in those which did not develop metastatic 
colonies. When the same analysis was performed on Treg-replete mice no 
significant difference was found in the tumour growth rates before and after 
DTx treatment and no relationship was observed between primary tumour 
growth rates and development of metastases. This indicates that the control 
observed over primary tumour growth and metastasis progression occurs as 
an effect of DTx mediated Treg depletion and suggests a difference in the 
anti-tumour immune response generated in individual mice as a result of 
Treg-depletion (explored further in Chapter 5).  
  
	 190	
	
Figure 4.26| Significantly fewer metastatic colonies are observed in the lungs of Treg 
depleted mice compared to Treg replete mice. The number of Treg-depleted and Treg-
replete mice that did and did not develop metastasis was compared using a Fischer’s exact 
test. Treg-depleted vs. Treg-replete mice that developed more than 1000 metastatic 
colonies gave a significant p value of p=0.0063, while mice that developed between 1-999 
colonies gave a p value of p=0.0540. 
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While the clonogenic assay gives a good representation of metastatic 
colonies in the lungs of DEREG mice, this method is not without limitations. 
The method described by Pulaski et al. in 2000 states that one colony 
represents one metastatic cell. However while all tissues are homogenised 
in the same way for the same length of time, there is no way to determine 
how many cells initially form a colony. For example, a cluster of metastatic 
cells from a single niche could be broken up during the homogenizing 
process to form small clusters or single cells that will each form an individual 
colonies on the clonogenic assay plate, giving the impression of more 
metastatic colonies in the lungs of DEREG mice. A further limitation of the 
clonogenic assay is metastasis progression is only measured at a single 
time point. Therefore mice must be sacrificed at multiple time points in order 
to monitor metastasis progression over time. Not only does this increase the 
number of mice required for an experiment, it also means progression of the 
disease is not measured in a single mouse. In order to address these 
limitations, PET/CT was investigated for use as an in vivo imaging technique 
to measure metastasis over time.  
PET/CT imaging was successful in visualizing solid primary tumours 
and large metastatic nodules within the chest cavity. Mice were scanned up 
to 3 times over a 3-week period, with the initial scan taken after primary 
tumour resection. In order to accurately measure changes in FDG uptake 
between scans, the lung ROI was drawn on the initial scan and transposed 
onto subsequent PET/CT images, as discussed in Chapter 3, allowing the 
ROI volume to remain constant throughout analysis. It was originally 
hypothesised that an increase in FDG uptake by the lungs could be detected 
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through changes observed in the TLG. In human patient scans, the SUVmax 
is used to identify malignant metastatic nodules. However, these metastatic 
nodules can be identified on a CT image, which is not possible for the micro-
metastatic colonies observed in this mouse model. Therefore it is necessary 
to identify an increase in FDG uptake over an entire ROI using the TLG. 
Initially it was observed that naïve mice had higher TLG than experimental 
mice. Further investigation found that the ROI volume and average SUV 
were also both higher in naïve mice than experimental mice. As described in 
Results 4.8, I concluded that as the lung ROI is defined by the tissue 
density, which in turn is defined by the empty airspace within the lungs, 
problems arise in the case of identifying mouse lung micrometastases. At 
the time of the initial scan, experimental mice have already had treatment 
and have begun to develop micrometastases. Therefore mice will have less 
empty air space and a higher tissue density resulting in lower ROI volumes 
used to detect changes in SUV. Thus, whilst PET can be used to identify 
large lesions in experimental mice, the technique is not sensitive enough to 
detect micrometastases. It was hypothesised that the CT could be used to 
detect changes in tissue structure within the lungs over time. The mean HU 
of lung ROIs of naïve mice were significantly lower than Treg-depleted mice 
at week 3 and Treg-replete mice at both time points, confirming naïve mice 
have larger empty air space than experimental mice. There was also a 
significant increase in mean HU between scans at week 1 and week 3 in 
both treatment groups, indicating an increase in tissue area within the lungs. 
While all but one mouse developed metastatic colonies in the Treg-replete 
group, this was not the case with Treg-depleted mice even though a 
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significant increase in HU was observed. It is reasonable to speculate that 
this increase in tissue area could be due to inflammation arising from Treg 
depletion although currently it is not possible to distinguish between 
inflammation and metastases using HU alone. Differences between 
increases in HU due to inflammation and development of metastases might 
become apparent after repeated scanning. Such an approach is however 
unfeasible due to high costs and animal welfare issues. 
In conclusion PET/CT scanning can successfully image solid primary 
tumours and large metastatic nodules, but through PET imaging alone it is 
not possible to detect micrometastases. Changes in HU of lung ROI show 
potential for detecting micrometastases, as both Treg-replete and Treg-
depleted mice show increases in HU over time. While only 50% of Treg-
depleted mice with an increase in HU were confirmed to have 
micrometastases, this extended to over 80% in Treg-replete mice. If it was 
possible to take an absolute baseline scan before tumour induction or Treg-
depletion, and continue scanning past week 3, it is possible that increases in 
HU due to inflammation would plateau whereas micrometastases would 
continue to increase in HU. Nonetheless, the increases observed in these 
two experimental groups further confirm the results concluded from the 
clonogenic assay. 
The experiments conducted in this chapter have shown that Treg depletion 
can induce the control of metastasis progression in mice. The metastasis 
experiments were conducted after a pilot experiment suggested that 
commencing Treg depletion before primary tumour resection was able to 
promote control over 4T1 metastasis. However, as small numbers of mice 
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were used in this experiment and no significant difference was observed 
between the number of metastatic colonies between Treg-depleted groups, 
further investigation is required to analyse the effect of Treg depletion post-
resection in comparison to pre-resection. Current clinical practice for breast 
cancer patients in most cases is to remove the primary tumour before 
administering adjuvant chemo- and immunotherapies for treatment of 
potential metastasis. Neo-adjuvant chemotherapies are currently being 
investigated for use in resectable liver metastases, osteosarcomas, 
adenoneuroendocrine carcinomas and some breast cancers (discussed in 
Chapter 1) (Ayez et al. 2015; Gu et al. 2015; Kim et al. 2009b; Song et al. 
2012), although neo-adjuvant immunotherapies have not been extensively 
examined in patients. Therefore it is important to further investigate the 
efficacies of neo-adjuvant and adjuvant Treg depletion on the development 
of metastases in murine breast cancer in order for translation into a clinical 
setting. 
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Chapter 5 
5 Results: Investigating the levels of immune cell infiltration into 
primary tumours after Treg depletion 
5.1 Introduction 
 As the data presented in Chapter 4 demonstrated that depletion of 
Tregs was able to promote the control of 4T1 metastasis, the infiltration of T 
cells into the primary tumour was subsequently investigated under the 
hypothesis of mice that went on to develop metastasis had a lower immune 
cell infiltration in the primary tumour in comparison to mice able to promote 
control of metastasis after Treg depletion. 
 In cancer patients, the presence of effector T cells within the tumour 
microenvironment is generally associated with a good prognosis and better 
patient outcome. In a mouse model of MCA induced tumours in our lab, the 
rejection of a primary tumour has been associated with increased infiltration 
of T cells after Treg depletion (Hindley et al. 2012). In line with this, the 
presence of Tregs at the tumour site has been associated with a poor 
prognosis in most cancers apart from those induced through inflammation 
(Bates et al. 2006; Curiel et al. 2004; Perrone et al. 2008; Ruffell et al. 2010; 
Sato et al. 2005). The ratio of Tregs:T cells has been shown to be important 
in promoting tumour rejection as demonstrated by the inhibition of immune 
checkpoints as discussed in Chapter 1 (Quezada et al. 2006).  
 In this Chapter, primary tumours resected from Treg-depleted and 
Treg-replete mice were analysed for the presence of T cells and Tregs. 
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Lymphocyte infiltration was compared between treatment groups and 
between mice that did and did not develop metastases within each treatment 
group. 
5.2 Results: Prolonged Treg depletion leads to an increase in T 
cell infiltration in the primary tumour 
 In order to analyse the lymphocyte infiltration into primary tumours in 
response to Treg depletion, 6-8 week old female DEREG mice were injected 
s.c with 1x105 4T1 cells on day 0. Mice were treated with DTx every other 
day as previously described from day 5 until sacrifice on day 21. Frozen 
sections were cut at 5 μm thickness and subsequently stained for CD8, CD4, 
CD3, and Foxp3 as described in Chapter 2. Examples of 
immunofluorescence staining are shown in the Appendix Figure C. 
 Figure 5.1 shows the number of infiltrating CD8+CD3+, CD4+CD3+ and 
Foxp3+CD3+ cells per high power field of view (HPFOV). It was observed 
that there was a significant increase in both CD8+CD3+ and CD4+CD3+ 
infiltrating cells in Treg-depleted mice in comparison to Treg-replete, which is 
consistent with overall slowed growth and regression of the primary tumour 
as shown in Chapter 4. Interestingly however, there was no significant 
difference between the number of Foxp3+CD3+ cells in the primary tumour 
between Treg-depleted and Treg-replete mice. At the time of tumour harvest 
mice had received 8 DTx doses over a 2-week period, which as described in 
Chapter 4 could be enough time to allow Treg cells to recover.  
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Figure 5.1| Prolonged Treg-depletion leads to increase infiltration of CD8+ and CD4+ 
cells.  4T1 tumours were induced in mice on day 0. Mice were treated every other day from 
day 5 with DTx until sacrifice on day 21. Primary tumours were frozen in OCT and sections 
were stained for CD8, CD4, CD3 and Foxp3. (A) The number of CD8+CD3+ cells per High 
Power Field Of View (HPFOV) in Treg-depleted and Treg-replete tumours. (B) The number 
of CD4+CD3+ cells per HPFOV. (C) The number of Foxp3+CD3+ cells per HPFOV. A Mann-
Whitney test was performed on all the data giving p value of p=0.0009 (A), p=0.0226 (B), 
and p=0.5752 (C). 
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 5.3 Results: Two doses of DTx are not enough to alter T cell 
infiltration in primary tumours 
 As a significant increase was observed in primary tumour T cell 
infiltration after Treg depletion, the immune cell infiltration of primary tumour 
removed during surgery was investigated. Mice were injected with 4T1 cells 
as before and resulting tumours were measured from day 7. DTx treatment 
commenced on day 10 and primary tumours were resected on day 14 after 2 
doses of DTx. Tumours were fixed in 10% formalin solution and 
subsequently embedded in paraffin wax for cutting and staining, following 
the protocol outlined in Chapter 2.  
 Two serial sections were stained as follows: section 1 stained for 
CD8+ cells, and CD3+ cells and section 2 was stained for Foxp3+ cells, CD3+ 
cells blood vessels. Slides were subsequently scanned using a high-
resolution digital Zeiss Axio Scan.Z1 slide scanner and immune cell 
infiltration was analysed as depicted in Figures 5.2 and 5.3. Figures 5.4-5.7 
show examples of primary tumours from a Treg-replete metastasis-bearing 
mouse, Treg-replete metastasis-free mouse, Treg-depleted metastasis-
bearing mouse, and a Treg-depleted metastasis-free mouse respectively.  
 Firstly, the number of CD8+ cells, Foxp3+ cells and CD8-Foxp3-CD3+ 
cells observed per HPFOV were compared between Treg-depleted and 
Treg-replete mice (Figure 5.8). CD3+ cells that were negative for both Foxp3 
and CD8 were used as an indicator of CD4+ T cell numbers. No significant 
difference was observed between the treatment groups for any immune 
subset, including Foxp3+ cells. Each treatment group was further divided into 
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mice that went on to develop metastases and those that did not, the results 
of which are shown in Figures 5.9 and 5.10. 
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Figure 5.2| Quantifying immune cell infiltration in paraffin sections of primary 
tumours. (A) A low power image of a primary 4T1 tumour removed at day 14 from a 
mouse. The total area of tissue is drawn around in blue, the peritumoural tissue is drawn 
around in green and any holes in the tissue are drawn around in purple. A grid is placed 
over the image as shown in (B) and 10 squares are used to count immune cell infiltration. 
The black square indicates the area used in Figure 5.3. 
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Figure 5.3| Quantifying immune cell infiltration in paraffin sections of primary 
tumours. (A) And (B) show the enlarged section depicted by the black box in Figure 5.2(B). 
(B) Foxp3+ cells are counted in green and CD3+ cells counted in purple.  
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Figure 5.4| Immune cell infiltration in Treg-replete tumours. Immunohistochemistry 
images of an example primary tumour from a Treg-replete metastasis-bearing mouse. (A) A 
low power image of a primary tumour stained for CD8 and CD3. (B) A zoomed image of the 
tumour in (A). (C) And (D) show the same tumour stained for Foxp3 and CD3.  
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Figure 5.5| Immune cell infiltration in Treg-replete tumours. Immunohistochemistry 
images of an example primary tumour from a Treg-replete mouse without metastasis. (A) A 
low power image of a primary tumour stained for CD8 and CD3. (B) A zoomed image of the 
tumour in (A). (C) And (D) show the same tumour stained for Foxp3 and CD3.	
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Figure 5.6| Immune cell infiltration in Treg-depleted tumours. Immunohistochemistry 
images of an example primary tumour from a Treg-depleted metastasis-bearing mouse. (A) 
A low power image of a primary tumour stained for CD8 and CD3. (B) A zoomed image of 
the tumour in (A). (C) And (D) show the same tumour stained for Foxp3 and CD3	
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Figure 5.7| Immune cell infiltration in Treg-depleted tumours. Immunohistochemistry 
images of an example primary tumour from a Treg-depleted mouse without metastasis. (A) 
A low power image of the primary tumour stained for CD8 and CD3. (B) A zoomed image of 
the tumour in (A). (C) And (D) show the same tumour stained for Foxp3 and CD3. 
  
	 206	
 
There was no difference observed in CD8+, Foxp3+ or CD8-Foxp3-
CD3+ cell infiltration between Treg-depleted mice that did and did not 
develop metastases (Figure 5.9). However, while there is a large spread of 
CD8-Foxp3-CD3+ cell infiltration in Treg-depleted mice that developed 
metastases, there is a trend to suggest that mice that do not develop 
metastases have a consistently higher infiltration of these immune cells. 
There was no significant difference in the immune cell infiltration between 
Treg-replete mice that did and did not develop metastases as shown in 
Figure 5.10. However, there were too few numbers of mice analysed to draw 
accurate conclusions from and T cell quantification in this manner is not as 
accurate as other methods such as flow cytometry.  
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Figure 5.8| Immune cell infiltration into the primary tumour does not change after 2 
rounds of DTx. Mice were injected with 4T1 cells on day 0 and treated with DTx every 
other day from day 10. Primary tumours were resected on day 14, embedded in paraffin and 
subsequently stained for CD8, CD3, and Foxp3. (A) The average number of CD8+ cells per 
HPFOV in Treg-depleted and Treg-replete mice, where an unpaired t test gave the p value 
p=0.2435. (B) The average number of Foxp3+ cells per HPFOV in Treg-depleted and Treg-
replete, where an unpaired t test gave a p value of p=0.8314. (C) The average number of 
CD8-Foxp3-CD3+ cells per HPFOV in Treg-depleted and Treg-replete mice, where an 
unpaired t test gave a p value of p=0.6305. 
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Figure 5.9| There is no difference in immune cells infiltration in Treg-depleted mice 
that did and did not go on to develop metastases. Data from Treg-depleted mice in 
Figure 5.8 was split into mice that did develop metastases and those that did not. (A) The 
average number of CD8+ cells per HPFOV in primary tumours of Treg-depleted mice that 
did and did not develop metastasis, where an unpaired t test gave p=0.9083. (B) The 
average number of Foxp3+ cells per HPFOV in primary tumours of mice in (A), where an 
unpaired t test gave p=0.3498. (C) The average number of CD8-Foxp3-CD3+ cells in primary 
tumours of mice in (A), where an unpaired t test gave p=0.1294.  
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Figure 5.10|	 There is no difference in immune cells infiltration in Treg-replete mice 
that did and did not go on to develop metastases. Data from Treg-replete mice in Figure 
5.8 was split into mice that did develop metastases and those that did not. (A) The average 
number of CD8+ cells per HPFOV in primary tumours of Treg-replete mice that did and did 
not develop metastases, where an unpaired t test gave p=0.5241. (B) The average number 
of Foxp3+ cells per HPFOV in primary tumours in mice from (A), where an unpaired t test 
gave p=0.1010. (C) The average number of CD8-Foxp3-CD3+ cells per HPFOV in tumours 
of mice from (A), where an unpaired t test gave p=0.7089.  
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5.4 Discussion 
 While increased T cell infiltration into the primary tumour after 
prolonged Treg depletion is associated with tumour control and rejection, 
this does not appear to be an immediate effect as demonstrated by the data 
shown in this chapter. In Chapter 4, not only was it shown that Treg 
depletion can promote control of metastasis, but tumour growth rate was 
also observed to slow after 2 doses of DTx treatment. In the same 
experiment however, the primary tumours that demonstrate slowed tumour 
growth rate do not have a higher T cell infiltration than tumours with no 
change in tumour growth rate.  
 As previously discussed in Chapter 1, the ratio of Tregs:T cells is an 
important factor in determining tumour rejection. Tumours with a lower 
Treg:T cell ratio have a better outcome than those with a higher ratio, which 
is recapitulated in this chapter. After continued DTx treatment, Treg-depleted 
mice had significantly higher infiltration of CD8+ cells and CD4+ cells in 
comparison to their Treg-replete counterparts, while levels of Foxp3+ cell 
infiltration remained unchanged. Conversely, the method of quantification of 
immune cells used in this Chapter indicates that after two doses of DTx the 
ratio of Treg:T cells remains unchanged, although low numbers and 
limitations to the quantification mean full conclusions cannot be drawn.  
 Quantification of immune cells does not shed light on the functionality 
of the tumour-infiltrating T cells. It is possible that while an increase in T cells 
is not observed in primary tumours after Treg depletion, the infiltrating T cells 
might display increased activation in comparison to Treg-replete mice. 
Furthermore, in this Chapter only T cell infiltration has been quantified. It is 
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possible that there is an increase in NK cell, neutrophil, and macrophage 
infiltration into the tumour as a result of Treg depletion, all of which play a 
role in tumour control.  
 Another limitation to this method of T cell quantification is only part of 
the tumour is analysed. In a section, 10 HPFOV are counted and an average 
is taken. While the 10 sections are selected at random to avoid bias, this 
does not necessarily represent the whole 3D tumour. T cells appear to 
cluster around the edge of the tumour with very few reaching the centre, and 
can also appear clustered in pockets like that seen in Figure 5.5. Therefore, 
the infiltration in the 3D tumour might vary from the snapshot observed in a 
single section. The optimal way to analyse total immune cell infiltration into 
tumours would be through flow cytometry.  
 In conclusion, the experiments in this chapter demonstrate that 
prolonged DTx treatment to deplete Tregs alters the ratio of Tregs:T cells in 
a primary tumour and is associated with tumour regression. However, using 
the limited approach of quantification the data suggests that the initial 
numbers of infiltrating T cells after Treg depletion is not necessarily the 
limiting factor of metastasis control. Further investigation is required to 
determine the functional capacity of infiltrating T cells after Treg depletion as 
well as to determine the extent of infiltration of other immune cell subsets 
into the primary tumour. 
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Chapter Six 
6 Final discussion 
6.1 The role of Tregs in controlling metastasis 
 Foxp3+ Tregs are frequently enriched in tumours and are often 
associated with poor prognosis and patient outcome. The presence of Tregs 
within primary tumours creates a suppressive environment preventing an 
anti-tumour immune response (Betts et al. 2007; Nishikawa and Sakaguchi 
2010; Quezada et al. 2011; Scurr et al. 2012). Presence of Tregs has also 
been associated with progression of metastasis in certain cancer types, and 
enrichment of Tregs has been observed not only at the primary tumour but 
also in peripheral blood of patients with metastatic disease (Huen et al. 
2013).  
 The data displayed in this thesis has shown that in a mouse model 
not only does the depletion of Tregs stimulate control of the growth of a 
primary tumour, but neo-adjuvant Treg depletion also promotes the control 
of metastasis. The model of 4T1 murine breast cancer is a good 
representation of human stage IV breast cancer, particularly in its manner of 
spontaneous haematogenous metastasis. Tumours can be easily excised, 
and data presented in Chapter 4 demonstrated metastasis can arise from 
tumours >125 mm3. Therefore, 4T1 is a good model to investigate the effect 
of Treg depletion on metastasis.  
 In the experiments performed to investigate the effect of Treg 
depletion on metastasis, DTx treatment commenced before primary tumour 
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removal (neo-adjuvant treatment). This was based on a pilot study that had 
low numbers but suggested a difference in metastasis control between mice 
receiving neo-adjuvant Treg depletion or not, when no difference was 
observed between adjuvant Treg depletion and Treg-replete mice. In clinical 
cases, treatment is usually given after primary tumour removal to promote 
control over metastasis disease progression. It is therefore important that the 
initial pilot experiment is repeated in order to investigate whether neo-
adjuvant Treg depletion has a greater effect on metastasis control over 
adjuvant therapy, as this could have clinical implications when treating 
breast cancer. In order to address this issue, an experiment will be 
conducted in which tumours will be induced in DEREG positive and DEREG 
negative littermate controls on day 0 and tumours will be resected on day 14 
as described in this thesis. Mice will be treated with DTx twenty-four hours 
after surgical resection and every other day thereafter until sacrifice on day 
28. The clonogenic assay will then be used to investigate the extent of 
metastasis in the lungs of the mice. The hypothesis of this experiment is that 
the presence of a primary tumour is required to induce an anti-tumour 
immune response after Treg depletion and therefore there will be no 
difference in the number of metastatic colonies observed between the 
treatment groups. 
 Interestingly, data displayed in Chapter 4 showed some DEREG 
positive mice demonstrated no response after DTx treatment. Furthermore, 
mice that displayed slowed tumour growth after Treg depletion still went on 
to develop metastases in the lungs. This could be due to suppressive 
immune cell subsets other than Tregs acting to prevent an anti-tumour 
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immune response to metastasis. For example, MDSCs are enriched in 4T1 
tumour-bearing mice and regulatory B cells have also been postulated to 
play a role in suppressing anti-tumour immune responses (duPre and Hunter 
Jr 2007; Olkhanud et al. 2011; Sinha et al. 2012). As the 4T1 tumour 
stimulates expansion of poly-morphonuclear (PMN)-MDSCs, there could be 
a potential to use anti-Gr1 antibodies (Sinha et al. 2012). The caveat with 
using this antibody is that it is not specific to PMN-MDSCs and will have off-
target effects on other granulocytic myeloid cells (Sawant et al. 2012). A 
combination of Treg depletion and Gr1+ cell depletion could have synergistic 
effects on metastasis control in the 4T1 model. CD25+ B220+ B-regs have 
also been identified in an intravenous model of 4T1 (Olkhanud et al. 2011). 
While the activity of these cells has yet to be fully determined, there is also a 
potential to use anti-B220 or anti-CD19 antibody to depleted B-regs numbers 
in the 4T1 model. Further study is needed in the Treg-depleted mice that 
developed metastases to ascertain whether either of these other 
suppressive subsets were at play.   
 The ability of Treg depletion to promote control of metastasis as well 
as a primary tumour highlights Tregs as a potential target for cancer 
therapies. Checkpoint blockade therapies, such as anti-CTLA4 and anti-PD-
1 have been shown to not only reduce intratumoural infiltration of Tregs but 
also to facilitate the recruitment of anti-tumour effector cells in mice and 
humans (Chen et al. 2009; Curran and Allison 2009; Liakou et al. 2008; 
Quezada et al. 2006). Similarly, anti-CD25 antibodies and tyrosine kinase 
inhibitors have also been shown to reduce numbers of Tregs, although the 
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off-target effects of these therapies prove difficult to overcome (Byrne et al. 
2011; von Boehmer and Daniel 2013). 
 Cyclophosphamide (CY) is a nitrogen mustard alkylating agent that is 
often used in high doses in chemotherapy (Martin-Suarez et al. 1997). 
However, low dose CY treatment has been shown to have immune-
modulating effects specific to Tregs (Ghiringhelli et al. 2004; Lutsiak et al. 
2005). A study by Zhao et al postulated that the Treg-specific effect 
observed with low dose CY treatment is due to low levels of intracellular ATP 
(Zhao et al. 2012). CY as a pro-drug is administered and subsequently 
catalysed and converted into its cytotoxic form aldophosphamide in the liver 
before being transported via the circulation (Gamcsik et al. 1999; Rooney et 
al. 2004). Cells detoxify aldophosphamide and other CY derivatives through 
conjugation with glutathione, the production of which is ATP dependent 
(Dirven et al. 1994; Gamcsik et al. 1999). Tregs have notably low levels of 
the microRNA miR-142-3p resulting in high levels of adenylyl cyclase 9, and 
enzyme that converts ATP to AMP (Bopp et al. 2007; Huang et al. 2009). 
This reduction of intratumoural ATP results in lower levels of glutathione 
thereby leaving Tregs susceptible to the toxic effects of CY (Zhao et al. 
2012). A phase II clinical trial has utilized the capacity of low-dose CY to 
specifically deplete Tregs in order to boost anti-tumour immune responses 
induced by vaccination, resulting in increased overall survival of CCRCC 
patients (Walter et al. 2012). While initial studies of Treg depletion in cancer 
patients are promising, further investigation is needed to understand and 
overcome off-target effects from current Treg-targeted therapies (Halvorsen 
et al. 2014). 
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6.2 T cell infiltration  
 After prolonged Treg depletion, the data presented in Chapter 5 
shows an increase in T cell infiltration in the primary tumour in comparison to 
Treg-replete mice.  This is consistent with data shown in Chapter 4 where 
depletion of Tregs led to regression of primary tumours.  
 The method of analysis used in Chapter 5 for investigation of T cell 
infiltration is not necessarily representative of the whole tumour. However, 
the data is suggestive that two doses of DTx do not lead to an increase in T 
cell infiltration into the primary tumour even though metastasis is controlled. 
Immunohistochemistry does not give any information about the function of 
the infiltrating immune cells, which could give a better indication of anti-
tumour responses. Furthermore, infiltration of other immune cell subsets has 
not been quantified in this model, such as NK cell, neutrophils, and 
macrophages, which could better our understanding of the mechanisms of 
metastasis-control after the depletion of Tregs. Tumours were originally 
analysed in this manner in order to preserve their structure to identify HEVs, 
although the data suggests that these blood vessels do not play as a big a 
role in tumour control in this model as the MCA model investigated in our lab 
(Colbeck et al. 2015; Hindley et al. 2012). 
 Further investigation is required to fully understand the infiltration of 
immune cells into the primary tumour and the effect on metastasis. This 
could be done through flow cytometry analysis not only to identify subsets of 
immune cells present within the tumour but also to also sort and isolate T 
cells for further functional analysis.  
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6.3 Using PET/CT imaging to monitor metastasis development 
 In this thesis I have successfully optimized PET/CT imaging for 
visualizing solid primary tumours and large metastatic nodules. While the 
PET component of the imaging system was not able to detect 
micrometastases, the use of HUs to measure the tissue density within the 
lungs showed promise in identifying areas of occlusion due to development 
of metastases. However, while over 80% of increased HU was due to 
metastasis in Treg-replete mice, only 50% was metastasis related in Treg-
depleted mice. The remaining 50% Treg-depleted mice that displayed an 
increase in HU could be due to inflammation in the lungs induced by Treg 
depletion. In order to distinguish between lung occlusion occurring as a 
result of inflammation or metastases, it would be beneficial to perform an 
absolute baseline scan of each mouse to determine individual lung capacity 
and to continue scans past week 3. In this case, occlusion due to 
inflammation would remain constant while occlusion by metastases would 
continue to increase. 
 FDG PET/CT allows identification of cancers due to their increase in 
metabolic activity compared to surrounding tissue. However, this is not 
specific to cancers as demonstrated in Chapter 4. Studies in both humans 
and in mice have radiolabelled different tracers to measure the progression 
of different diseases. In humans, F18 as part of Fluoromethylcholine has 
been used to detect lymph node malignancies and bone metastases, and 
Ga68 labeled DOTATATE has been used to image thyroid cancers (Goel et 
al. 2014; Nockel et al. 2016; Poulsen et al. 2012; Sadowski et al. 2016). In 
preclinical studies, amino acid based radiotracers have been used to monitor 
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cell proliferation, while others such as F18 P3BZA have been used to monitor 
cell migration in Parkinson’s disease in rats (Bu et al. 2014; Rendon et al. 
2016). More recently, human HER2 antibodies have been radiolabelled for 
use in imaging human breast cancer xenografts in mice (Denis-Bacelar et al. 
2016). While there are currently no specific antibodies available for 4T1 
tumours, the above studies show promise in developing a specific 
radiotracer for 4T1 PET/CT imaging. This would allow the metastasis of 4T1 
cells to be imaged over time and could therefore be accurately measured on 
a PET/CT image. Currently, there are no preclinical PET/CT studies that use 
FDG or other specific tracers to image metastasis or the effect of 
metastasis-treatment, therefore it is important to develop a mechanism by 
which it is possible.  
 
6.4 Final conclusions 
 In this thesis I have demonstrated that PET/CT imaging can be used 
to visualise solid tumours and large metastatic nodules and also has the 
potential to be used to measure the development of micrometastases in 
preclinical models. I have also shown that neo-adjuvant Treg depletion 
promotes the control of a murine mammary carcinoma growth and 
metastasis. The prolonged depletion of Tregs allows expansion and 
infiltration of effector T cells into the primary tumour leading to primary 
tumour regression even after levels of Foxp3+ cells return to normal. The 
method of quantification used suggests that the number of T cells in the 
primary tumour at the point of resection does not increase in Treg-depleted 
mice in comparison to Treg-replete, even though better control of metastasis 
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was demonstrated. Therefore, further investigation is required into the 
function of the T cell present in the primary tumour at the point of resection, 
as well as the identification of other effector immune cell subsets present.   
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Appendix 
 
Fluorescence Minus One (FMOs) for detecting levels of Treg 
depletion 
 
	
Figure A| Flow cytometry plots showing Fluorescence Minus One (FMOs) for Treg 
depletion detection. FMOs were prepared on spleen single cell suspensions from Treg-
replete DEREG negative mice. Cells are gated on the lymphocyte population as shown in 
Chapter 2. Numbers represent the proportion of cells in each quadrant.  
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Isotype controls for Chapter 5 
 
 
Figure B| Isotype controls for CD8 (Rat IgG2a VIP), Foxp3 (Rat IgG2a DAB), and CD3 
(Rabbit polyclonal SG) in Treg-replete (A and B) and Treg-depleted (C and D) tumours. 
Scale bars represent 200 μm. 
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Figure C| Examples of immunofluorescence staining on Treg-depleted and Treg-replete 
tumours that were frozen after surgical resection.  Tumour samples were sectioned as 
describe in Chapter 2 and serial sections were stained with CD4 CD3, CD8 CD3, and Foxp3 
CD3 before subsequent staining with the nuclear stain DAPI. White arrows indicate double 
positive cells in each circumstance, which were quantified as number of double positive 
cells per high power field of view. 	 	
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